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Traditional chemotherapy has two major drawbacks: non-specificity and resistance. 
Nanocarrier formulation is to date the most promising formulation strategy which enables 
sustained, controlled, and targeted delivery of therapeutic agents. Ligand conjugation is a 
strategy to reduce non-specificity by selectively interacting with the tumor cells which have an 
overexpression of the receptors. The benefits of using ligand for nanomedicine are well 
recognized, however, there are still areas to improve for it to be a mature technology. The issues 
include: (1) No established guidelines for receptor selection and conjugation; (2) lack of 
experimental investigations on the parameters which may have significant impact on the 
efficacy of the ligand mediated nanomedicine; (3) lack of methods to precisely control and 
quantify the parameters (e.g. size, ligand density, multivalent affinity, etc). Hence in Chapter 3 
and 4, we developed methods for the control and quantification of two important yet largely 
ignored parameters of ligand mediated nanomedicine: the ligand density and the tethering chain 
length (the length of the linker which connects ligand to the nanocarrier). The targeting effects 
of the Herceptin conjugated PLA-TPGS/TPGS-COOH polymeric nanoparticles were evaluated 
in vitro when the parameter of interest was varied. In chapter 3, two methods are used to control 
the particle surface Herceptin content: one is to adjust the PLA-TPGS:TPGS-COOH 
copolymer blending ratio, and another is to control the feeding concentration of the ligand. The 
results suggest that the increase in the number of NP surface functional groups and the increase 
in ligand feeding concentration can increase the NP surface ligand content; which can improve 
cellular uptake and cytotoxicity of the formulation on receptor overexpressed cells. In Chapter 
10 
 
4, tethering chain lengths of the Herceptin conjugated PLA-TPGS/TPGS-COOH nanoparticles 
were adjusted by varying the PEG molecular weight from 1000 to 5000. The results show that 
the shortest tethering chain length (PEG 1000) leads to the highest cellular uptake and 
cytotoxicity of the Herceptin conjugated NPs on receptor overexpressed cell line. Drug 
resistance is another barrier of effective chemotherapy. SiRNA mediated nanomedicine, the 
co-delivery of anticancer drug and the siRNA which silences the gene responsible for 
resistance, can be a strategy to alleviate drug resistance. In chapter 5, anticancer drug docetaxel 
and Polo-like kinase 1 siRNA (siPLK1) are formulated in Herceptin conjugated TPGS micelles 
for enhanced docetaxel treatment of breast cancer. The results show that introducing siPLK1 to 
the micelle formulation of docetaxel reduces the IC50 by 79%. In Chapter 6, anticancer drug 
cisplatin and siPLK1 are co-formulated in cisplatin prodrug crosslinked TPGS-PLL nanogel for 
the enhanced cisplatin treatment of breast cancer. Cytotoxicity tests on multiple breast cancer 
cell lines show that including siPLK1 as part of the formulation reduces IC50 by 70% to 80%. 
Chapter 1 is an introduction of the thesis which covers background information, research 
objective and a thesis outline. Chapter 2 is a literature review on current progress in the ligand 
and siRNA mediated nanomedicine. Chapter 7 summarizes the findings in the experimental 
investigations and proposed recommendations for future work. 
 
Keyword: Biodegradable polymers; Cancer nanotechnology; Drug targeting; Molecular 
biomaterials; Multidrug resistance; Pharmaceutical nanotechnology;  
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SE standard error 
SPDP 3-(2-Pyridyldithio)propionic acid N-hydroxysuccinimide ester 
SLNs solid lipid nanoparticles 
TEA triethylamine 
THF tetrahydrofuran 
TPGS D--tocopheryl polyethylene glycol 1000 succinate 
TPGS-COOH carboxyl group-terminated TPGS 
XPS X-ray photoelectron spectroscopy 
TOS d-α-Tocopheryl succinate 
TEAA triethylammonium acetate buffer 




Chapter 1. Introduction 
1.1. Background 
Cancer is a worldwide healthcare problem. It has high occurrence and mortality rate.  The 
GLOBOCAN project in 2008 identified 12.7 million cancer cases and 7.6 million deaths (13% 
of all deaths) worldwide, and the cancer incidences were expected to increase to 22.2 million by 
2030. With the heavy investments and enormous efforts, available data in the past ten years 
(1999-2008) showed a 1% per year decline of cancer death rate in the USA [1]. The 
improvement was attributed to the modern technologies of diagnosis and therapy. Among them, 
nanomedicine such as nanocarrier formulations of chemotherapy drugs, Doxil® and Abraxane 
®, have made important contributions. Nanocarrier formulation is to date the most promising 
formulation strategy which enables sustained, controlled, and targeted delivery of therapeutic 
agents.  
Nevertheless, patients who are diagnosed with late stage cancers have low 5-year survival (e.g. 
23.3% for breast cancer, 11.7% for colon cancer and only 3.6% for lung cancer) [2]. Cancer is 
still the second most common cause of deaths in the USA, and the No.1 killer in many Asian 
countries such as Singapore. In the past few decades, the standard treatments of cancer have 
been surgery, radiotherapy and chemotherapy. If all of them fail, the patients usually have less 
than 10% chance to survive. New therapy methods which include targeted therapy, 
antiangiogenesis therapy, immunotherapy, photodynamic therapy, hyperthermia therapy, and 
gene therapy have been approved or entered clinical trials for the treatment of cancer. But none 
of them have revolutionized cancer therapeutics or replaced the position of the three standard 
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therapies. The reasons include the lack of potency and specificity, fast developed resistance, 
and unfamiliar side effects. Traditional chemotherapy is potent and effective; however, it is 
usually associated with severe side effects and gradually developed resistance.  
Nanocarrier formulations of anticancer agents have the following advantages: (1) protection of 
agents from metabolism, degradation, and clearance; (2) passive tissue targeting by enhanced 
permeability and retention (EPR) effect; (3) delivery of drug into cells in a bulky way by 
endocytosis to achieve high transportation efficiency; (4) active tumor cell targeting via surface 
decorated ligands; (5) sustained and controlled release at dosage within the therapeutic window; 
and (6) capability to co-deliver multiple agents at fixed ratio and release sequence to achieve 
additive or synergistic effects.  
Lack of selectivity is one barrier for effective chemotherapy. Decoration of nanocarrier 
surfaces with ligands to actively target receptor expressing tumor cells (ligand mediated 
nanomedicine) is a trend in nanomedicine due to the selective interaction with tumor cells. 
Ligand mediated nanomedicine can increase efficacy and reduce the side effects of anticancer 
agents. Currently, six ligand mediated drug delivery systems have entered clinical trials, and 
five of them are for the treatment of cancer [3]. The benefits of using ligand for nanomedicine 
are well recognized, however, there are still areas to improve for it to be a mature technology. 
These issues include: (1) No established guidelines for receptor selection and conjugation; (2) 
lack of experimental investigations on the important parameters which may have significant 
impact on the efficacy of the ligand mediated nanomedicine; (3) lack of methods to precisely 
control and quantify the parameters (e.g. size, ligand density, multivalent affinity, etc).  
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Drug resistance is another barrier of effective chemotherapy. Chemotherapeutic resistance can 
be pharmacokinetic resistance such as fast drug metabolism, clearance, and inefficient 
intracellular accumulation, or genetic resistance such as the development of drug efflux pumps 
and the up-regulation of compensatory pathways. Formulation of anticancer drugs in ligand 
modified nanocarriers alleviates the pharmacokinetic resistance by enabling passive tumor 
tissue targeting and active cancer cell targeting [4]. SiRNA mediated nanomedicine, the 
co-delivery of anticancer drug and the siRNA which silences the gene responsible for 
resistance, can be a strategy to solve the genetic resistance. The advantages of siRNA are the 
convenience in design and synthesis, and the high potency. SiRNAs which target the resistance 
mechanisms have been shown to significantly enhance the efficacy of the corresponding 
therapy agents on preclinical models. However, the application of therapeutic siRNA is 
hindered by the “off-target effect”, the sensitivity to enzymatic degradation, fast renal clearance, 
immunogenicity, and inability to efficiently penetrate cell membrane. These issues can be 
resolved by nanocarrier formulation of siRNA which can protect siRNA from enzymatic 
degradation and immune recognition, deliver siRNA into cells by endocytosis or receptor 
mediated endocytosis if the nanocarrier is modified with targeting ligand, and can facilitate 
sustained release of siRNA for prolonged gene knockdown. Nanocarrier formulations of 
siRNA have entered clinical trials [5]. Not only chemotherapy, for all cancer therapeutic 
methods, therapy resistances exist. Delivery of nanocarrier formulated siRNAs which target the 
resistance mechanisms can be a general strategy to reverse the resistance and make the therapy 
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more effective. In addition, siRNA which target the resistance can reduce the dosage of the 
therapy agents and thus reduce the side effects.  
1.2. Research objective 
The objective of the PhD work aims at developing ligand and siRNA mediated nanocarriers 
based on TPGS polymers for enhanced chemotherapy. The more specific objectives are listed 
below: 
 Develop methods to precisely control and quantify the targeting ligand density and tether 
chain length of Herceptin modified PLA-TPGS/TPGS-COOH polymeric nanoparticles 
(NPs), and to investigate how these parameters can affect the targeting effects.  
 
 Design and synthesize TPGS based micelle for ligand mediated co-delivery of small 
molecule hydrophobic drug docetaxel and PLK1 siRNA (siPLK1) which target the genetic 
resistance of docetaxel. 
 
 Design and synthesize TPGS based nanogel for co-delivery of small molecule hydrophilic 
drug cisplatin and siPLK1 which target the genetic resistance of cisplatin. 
1.3. Thesis outline 
This thesis consists of seven chapters. Chapter 1 is an introduction on the concepts and benefits 
of ligand and siRNA mediated nanomedicine. Chapter 2 is a literature review which covers the 
following topics: cancer characteristics, cancer therapy methods, ligand mediated 
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nanomedicine, and siRNA mediated nanomedicine. Chapter 3 to Chapter 6 are experimental 
investigations. Chapter 3 proposes a strategy to precisely control and quantify the Herceptin 
density on the docetaxel loaded PLA-TPGS/TPGS-COOH NPs and examines on HER2 
overexpressed cell lines how the change in ligand density can affect the targeting effects of the 
NPs. The strategy is to blend two polymers, PLA-TPGS and TPGS-COOH, at designated ratios 
in NP preparation; in the blends, TPGS-COOH serves as surfactant which presented the 
functional groups at controlled density on NP surface for herceptin conjugation. Chapter 4 
shows the investigation on how the variation in tethering chain length which links the ligand 
with the NP could affect the targeting effects at fixed surface ligand density. More specifically, 
in the study, TPGS-COOHs with different PEG molecular weights were synthesized and mixed 
with PLA-TPGS for the conjugation of Herceptin. The targeting effects of these nanoparticles 
were evaluated on HER2 overexpressed SK-BR-3 cell line. Chapter 5 describes the formulation 
of small molecule hydrophobic drug docetaxel and siPLK1 with precisely controlled ratio and 
release sequence in Herceptin conjugated TPGS micelles for enhanced docetaxel treatment of 
breast cancer. Chapter 6 expatiates on the formulation of small molecule hydrophilic drug 
cisplatin and siPLK1 in cisplatin prodrug crosslinked PLL-TPGS nanogel to co-deliver 
cisplatin and siPLK1 for the enhanced cisplatin treatment of breast cancer. Chapter 7 
summarized the findings in the experimental investigations and proposed recommendations for 





Chapter 2. Literature review 
2.1. Cancer  
Cancer is a leading cause of death worldwide. The GLOBOCAN project identified that in the 
year 2008, 12.7 million cancer cases and 7.6 million deaths (13% of all deaths) occurred 
globally; and the cancer incidences were expected to increase to 22.2 million by 2030. The 
5-year survival rates for patients who are diagnosed with late stage cancers are very low (e.g. 
23.3% for breast cancer, 11.7% for colon cancer, and 3.6% for lung cancer). Cancer is a 
heterogeneous disease with some shared traits such as uncontrollable proliferation, inducing 
angiogenesis, activating invasion and metastasis, developing of multidrug resistance (MDR), 
and the abnormal tumor microenvironment. The development of these characteristics attributes 
to the genomic instability and mutations, and the tumor-promoting inflammation [6].  
2.2. Cancer models 
Models have been proposed to describe the nature of malignant tumors, and to identify which 
type of cancer cells is responsible for tumor progression. Traditionally, it was believed that all 
cancer cells have the potential to gain the ability to proliferate extensively and metastasize. The 
gain of therapy-resistance at the time of cancer relapse is due to clone evolution and is 
completely stochastic [7]. Based on this model, traditional cancer therapies intend to remove as 
many cancer cells as possible. In contrary, cancer stem cell (CSC) model has been proposed 
and gained its popularity in recent decades. In this model, cancer cells organize themselves 
hierarchically in much the same manner as normal tissues. The cancer stem cells, just like 
normal stem cells, have intrinsic ability of self-renewal, differentiation, and multidrug 
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resistance. Therefore, cancer relapses and gain-of-therapy-resistances are due to the existence 
of cancer stem cells. Hence, cancer can be cured if we manage to eliminate all cancer stem cells 
selectively. The cancer stem cell model has the potential to revolutionize cancer treatment. 
However, this model gained support as much as disputation. This is because the identified CSC 
frequency depends strongly on experimental conditions and tumor types [8]. At the current 
stage, the CSC model provides little guidance for cancer treatment due to a substantial 
patient-to-patient variability of CSC properties and frequencies for any particular type of 
cancer; lack reliable CSC markers; and the need for a deeper understanding of 
epithelial-to-mesenchymal transition. Despite the differences, there is a consensus among all 
models that at least a subpopulation of cancer cells has stem cell traits; they are more aggressive 
and well protected from cell death, regardless of whether they are originally existed or the 
consequence of evolution. These cells share a number of common characteristics which make 
cancer difficult to cure. These characteristics give rise to two most intractable problems of 
cancer:  metastasis and multidrug resistance.  
2.3. Cancer characteristics 
2.3.1. Uncontrollable growth and proliferation 
Cancer cells achieve uncontrollable growth and proliferation through many different 
mechanisms such as inducing and sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, and enabling replicative immortalities [6]. Growth and 
proliferation signals are unregulated in many cancers by excessive production of growth factors, 
elevated level of growth factor receptors, constitutive activation of downstream signaling, and 
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suppression of negative-feedback mechanism, etc. For example, the human epidermal growth 
factor receptor 2 (HER2) overexpression is associated with aggressiveness and poor prognosis 
due to the high level and sustained growth signaling through HER2 without relying on the 
binding of growth factors [9]. In addition, around 40% human melanomas have activating 
mutations of B-Raf protein, leading to constitutive activation of the mitogen activated protein 
(MAP)-kinase pathway [10]. In addition, many cancer cells grow uncontrollably by mutations 
in tumor suppressor genes such as RB (retinoblastoma-associated) and TP53. These tumor 
suppressor genes are usually checkpoints in interconnected signaling pathways; they can stop 
cell proliferation and trigger apoptosis when the cells are under stress. Alternative to the 
mutation of cell damage sensors such as RB and TP53, cancer cells can resist apoptosis by 
upregulating antiapoptotic factors (Bcl-2, Bcl-xL), and downregulating of proapototic factors 
(Bax, Bim, Puma). Cell immortality is also associated with the malfunctioned telomerase 
activity [11]. The shortening of telomere gradually leads to senescence, an irreversible 
non-proliferative but viable state. Cells that circumventing this proliferative stop will have 
critically shortened telomere and subsequent DNA translocation and trigger of cell apoptosis. It 
was found that in breast cancer cells, telomerase help to reconstruct a longer telomere after 
telomere failure (i.e. the occurrence of DNA translocation and gene mutation). The delayed 
telomerase function suggested an encouragement of generation of gene mutations, and the 






Metastasis is responsible for 90% of cancer-associated deaths. Metastasis is a series of events 
during which cancer cells invade local tissue and vessels, move through the circulation, exit 
from the vessels, and establish colonies at distance sites [12]. For metastasis to occur, first, 
cancer cells need to accumulate sufficient genetic and epigenetic mutations that disrupt the 
adhesive mechanisms which normally tether cells to their neighbors and to the extracellular 
matrix. However, although tens of thousands of cancer cells can be shed into the circulation 
every day, less than 0.01% of them can survive to produce metastasis [13]. It is suggested by 
current data that the initial survival of tumor cells and their subsequent growth at the distant 
sites are the rate-limiting step [14]. After the cancer cells enter the blood vessel, they will need 
to survive and circulate in this hostile environment characterized by shear stress, immune 
surveillance, and the lack of survival cues. Current researches suggest an important role of 
platelet in protecting circulating tumor cells and assisting their lodge in distant sites [15]. 
Administrations of anti-coagulant agent suppress the rate of tumor metastasis [16]. It has been 
observed that for each type of cancer, metastasis occurs for a specific spectrum of organs and 
with a different period of latency [17]. The period of latency is the time between the lodge of 
cancer cells from primary tumor in distant sites, and the time for clinically relevant metastasis 
to occur. For example, metastasis occurs for breast cancer several years after malignant cells 
can be detected in bone marrow specimen [18]. In contrary, metastasis of pancreatic cancer 
does not have such dormancy, it occurs shortly after the primary tumor is diagnosed [19]. It has 
been suggested that both the organ microenvironment and the oncogenetic background play 
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important roles in determining metastatic latency [17]. In addition, it is still not clear whether 
the existence of primary tumors promotes or suppresses tumor metastasis due to contradictory 
experimental results [20-22].  
2.3.3. Multidrug resistance 
Another intractable problem in cancer is the development of multidrug resistance (MDR). 
Cancer cells are genetically unstable and may evolve resistance to therapies over time. MDR is 
a phenomenon that cancer cells can develop resistance to multiple types of drugs. In the cancer 
stem cell model, the CSCs are intrinsically drug resistant, and can evolve gradually after 
treatment of anti-cancer drug. These survived CSCs can give rise to cancer cells that share this 
drug resistant traits and cause relapse of cancer. Cancer cells can gain drug resistance by a 
range of mechanisms such as mutation or overexpression of drug targets, inactivation or 
elimination of the drug through metabolism, overexpression of drug efflux pumps, etc [23]. The 
overexpression of drug efflux pumps has been observed in various cancer types and is found to 
be the leading cause of MDR. These drug efflux pumps belong to a family of energy-dependent 
transporters, known as ATP-binding cassette (ABC). The extensively studied ones include 
ABCB1 (also known as P-glycoprotein, Pgp), ABCC1 (also known as MRP1), and ABCG2 
(also known as BCRP or MXR) due to their broad range of substrates [24].  
2.3.4. Abnormal tumor microenvironment  
Cancer cells organize themselves in a way that is different from that of normal cells [25-27]. 
Normal cells in human tissue are within a few cell diameters of a blood vessel so that they could 
get sufficient oxygen and nutrients, and prevent the accumulation of metabolic wastes. 
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However, tumor cells proliferate more rapidly than the cells forming blood capillaries. As a 
result, some of the cancer cells reside distant (>100 μm) from blood vessels, causing hypoxia, 
and accumulation of metabolic wastes which lower the extracellular PH. In addition, solid 
tumors and their metastases, when grow beyond a microscopic size, can stimulate pathological 
angiogenesis, generating poorly organized and leaky vasculature. Moreover, due to the 
disorganization of tumor vasculature and absence of functional lymphatic, tumor has increased 
interstitial fluid pressure, which imposes a barrier for drug delivery.  
Another important component of the tumor microenvironment is the immune inflammatory 
cells. Immunological monitoring can suppress the occurrence of cancer by destroying 
immunogenic cancer cells. However, based on the clone evolution model, cancer cells which 
evade immune recognition survive and expend to colonies which only elicit weak immune 
response [6]. This is a process called “immunoediting”. Recent discoveries revealed the 
existence of tumor-promoting inflammatory cells, which include macrophage subtypes, mast 
cells, neutrophils, and T and B lymphocytes. These cells produce signaling molecules to 
promote proliferation, angiogenesis, and matrix-remodeling in a process which shear 
similarities with wound healing. In addition, cancer cells could remodel its immune 
microenvironment by secreting immunosuppressive factors (e.g. TGF-β) to directly paralyze 
infiltrating cytotoxic T lymphocytes (CTLs) or indirectly recruit immunosuppressive 
inflammatory cells (e.g. regulatory T cells, myeloid-derived suppressor cells) to suppress the 




2.4. Cancer therapies 
2.4.1. Traditional therapeutic methods  
2.4.1.1. Surgery 
The most commonly used cancer treatment methods are surgery, radiation therapy and 
chemotherapy. One or the combination of them are selected by doctors based on the type, 
location, stage of cancer, the patient’s age, general health and other factors. The purpose of 
surgery is to remove tumor locally. It is normally used in combination with radiotherapy or 
chemotherapy to fully eradicate cancer. Surgery is not indicated for lymphomas and is 
insufficient for advanced solid tumors.  
2.4.1.2. Radiotherapy 
Radiotherapy (i.e. radiation therapy), also a local treatment, kills cancer cells and causes 
shrinkage of tumor by high energy radiations such as x-rays, γ-rays, and charged particles. The 
rationale behind radiotherapy is that radiation damages the DNA integrity of cells; cancer cells 
usually have impaired DNA repair machineries, hence they are more likely to undergo cell 
death. Despite the effectiveness, radiotherapy has the risk of causing second cancers for 
long-time survivors [28].  
2.4.1.3. Chemotherapy 
Chemotherapy is the use of anticancer drugs to kill the fast growing the dividing cancer cells. 
The use of small molecule drugs for the treatment of cancer can be traced back to 1942, when 
administration of nitrogen mustard was shown to cause regression of lymphoid tumor. Decades 
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of heavy investment in money and manpower resulted in the establishment of a library of 
medicines for cancer treatment. Most of them interfere with DNA replication or the process of 
mitosis to halt the cell division and cause cell death. However, chemotherapy has many 
drawbacks. Firstly, chemotherapy causes severe side effects. The drugs are usually given via 
intravenous (i.v.) injection and circulated to all parts of the body; it could cause damage to fast 
dividing cells other than cancer cells in organs such as heart, bone marrow, and hair follicles. 
Hence, chemotherapy can only be given in cycles with rest periods between treatment periods 
for normal tissues to repair themselves. In addition, most chemotherapy drugs have poor 
solubility, narrow therapeutic window and short efficacious time, hence, repeated 
administration at an optimal schedule is important, and is the focus of many clinical trials. 
Another important issue for chemotherapy is the development of MDR. Patients can develop 
resistance to multiple types of anticancer drugs with distinct mechanisms of action. If all 
surgery, radiotherapy and chemotherapy fail to control the progress of cancer, the patients have 
less than 10% chance to survive.  
2.4.2. New therapeutic methods 
2.4.2.1. Targeted therapy 
Targeted therapies rely on agents for blocking the “molecular targets” which are identified to 
play an important role in tumor growth and progression [29, 30]. Side effects can be reduced if 
the malfunctioned molecules or pathways specific for cancer cells are blocked. A successful 
targeted therapy requires the two components: a good “target” and an effective and specific 
blocking agent. The first targeted therapy was developed to interfere with estrogen binding to 
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estrogen receptor (ER) and has been approved for the treatment of ER positive breast cancer. 
Numerous other targeted therapies have been developed for the treatment of cancer. The 
benefits of targeted therapy include clear mechanism of action, more selective to cancer cells 
(i.e. lower side effects), and holding promise for personalized medicine. However, a major 
limitation for targeted therapy is the fast development of therapeutic resistance, due to the 
redundancy of signaling pathways and the genetic instability which permits production of 
mutated molecular targets.   
2.4.2.2. Antiangiogenesis therapy 
Antiangiogenesis therapies rely on angiogenesis inhibitors (i.e. small molecule inhibitors or 
antibodies) to block angiogenesis which is turned on in tumor development and progression to 
promote the growth of new blood vessels, providing tumor with oxygen and nutrients [31, 32]. 
The first approved angiogenesis inhibitor is the bevacizumab, a monoclonal antibody which 
specifically binds to vascular endothelial growth factor (VEGF), blocking it from binding and 
activating VEGF receptor, and thus inhibit the formation of new blood vessels. Bevacizumab 
has been shown to reduce tumor growth rate and prolong overall survival time of cancer 
patients.  
2.4.2.3. Biological therapy (immunotherapy) 
Biological therapy (i.e. immunotherapy) is to boost, direct or restore the body’s own immune 
system to treat cancer as a single agent or in combination with other treatments [33, 34]. 
Biological therapy agents include interleukins (ILs), interferons (IFNs), monoclonal antibodies, 
colony-stimulating factors, cancer vaccines, and genes. The functions of biological therapy are 
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multidimensional which include the following: making the cells more recognizable by the 
immune system; boost the killing power of the innate immunity; use together with high dose 
chemotherapy or radiation to enable faster repair or replacement of normal cells; and prevent 
cancer metastasis. Agents such as IFN-α, IL-2, and antibodies such as rituxan® and herceptin® 
have been approved for the treatment of cancer. Many more are in clinical trials. A major 
breakthrough is the recent approval of Ipilimumab for the treatment of metastatic melanoma 
[35]. Ipilimumab is a monoclonal antibody which binds to cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA4), which is an important negative regulator of CTL activation, to attenuate 
immune suppression and boost the immunity. This strategy suggests a new possibility in 
biological therapy: to manipulate T-cell activity by blockage of immune checkpoints.  
2.4.2.4. Hyperthermia therapy 
Hyperthermia therapy (i.e. thermotherapy) exposes tumor to high temperature to kill cancer 
cells [36, 37]. The rationale behind hyperthermia therapy is that cancer cells can be killed by 
high temperature which causes minimal injury to normal tissue. Hyperthermia therapy can be 
local, regional and whole-body hyperthermia. For local and regional hyperthermia, heat can be 
generated by different types of energy such as microwave, radiofrequency, and ultrasound. 
Whole-body hyperthermia is indicated for the treatment of metastatic cancer by raising the 
body temperature to 107-108 
o
F using a thermal chamber or hot water blankets. Although 
hyperthermia therapy is not widely available, it is studied in many clinical trials. Hyperthermia 
therapies hold great promise because they usually cause tolerable toxicity; especially local 
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hyperthermia which seems only causes temporary side effects such as burns, blisters, 
discomfort, pain, swelling, and bleeding.     
2.4.2.5. Photodynamic therapy 
Photodynamic therapy (PDT) activates photosensitizing agents (usually small molecule agent) 
by light at specific wavelength to kill cancer cells [38, 39]. Upon illumination by laser, the 
photosensitizing agent can produce reactive oxygen which kills the surrounding cancer cells, 
damages blood vessel to prevent the supply of oxygen and nutrients to tumor, and may activate 
the immune system to attack cancer cells. PDT using porfimer sodium (Photofrin®) has been 
approved by the US FDA for treatment or relief of symptoms of certain cancers. The major 
limitation of PDT is the inability of the laser to pass through more than 1 cm of tissue; hence 
PDT can only be used for the treatment of tumors on skin, or on the lining of internal organs and 
cavities. Beside, PDT is a local treatment which cannot be used to treat metastatic cancer. In 
addition, the approved porfimer sodium can make skin and eye sensitive to light for nearly 6 
weeks after treatment, impairing the patients’ quality of life after treatment.  
2.4.2.5. Gene therapy 
Gene therapy involves delivering of genetic materials such as DNA or RNA into a patient’s 
cells for the treatment cancer [40, 41]. Many different approaches and genetic materials have 
been investigated. Healthy cells can be genetically engineered with enhanced ability to fight 
cancer. Cancer cells can be genetically engineered to be more sensitive to other treatments. The 
genetic modification can be achieved by direct insertion of genes into the genome or by 
delivery of functional plasmids which can express the target proteins. Gene therapy is still at the 
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experimental stage with strictly controlled clinical trials, because of the associated risks. 
Harmful mutations can be produced if the gene is inserted into wrong locations. In addition, if 
the gene is accidentally inserted into the reproductive cells, the change can be passed on from 
parents to children after treatment. Furthermore, the viral vectors for gene delivery could cause 
undesirable inflammations, and the infection can be possibly transmitted from patients to other 
people or to the environment.  
2.4.3. Nanomedicine 
2.4.3.1. Introduction to nanomedicine 
Nanomedicine is the application of nanotechnology in the field of medicine. The term 
nanotechnology is defined in a variety of ways in literature. It was defined in year 2000 by the 
US National Nanotechnology Initiative as “Nanotechnology is concerned with materials and 
systems whose structures and components exhibit novel and significantly improved physical, 
chemical and biological properties, phenomena and processes due to their nanoscale size” [42]. 
The reduction in size leads to different and qualitatively new properties. For example, 
nanomaterials have surface to volume ratio orders of magnitude larger than that of macroscopic 
materials. In addition, all electrons in iron oxide NPs could spin in the same direction, leading 
to large magnetic field, which could improve the contrast for magnetic resonance imaging 
(MRI) [43]. Also, for cadmium selenide (CdSe) quantum dots, the color of emitted fluorescent 
light can be adjusted by fine-tuning the size of the nanostructure [44]. Specific properties of the 
nanosized materials open a new paradigm for better diagnosis and therapy in medicine.  
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2.4.3.2. Nanomedicine for cancer treatment 
Nanomedicine for cancer treatment is emerging as a new treatment paradigm which can be 
integrated with all other treatment methods to improve efficacy and to reduce side effects. For 
radiotherapy, gold NP has recently been used as a therapy enhancer, based on the discovery that 
gold is an excellent x-ray absorber; and the accumulation of gold NPs in tumor by passive 
targeting leads to the a higher dose of radiation energy to malignant tissue compared with the 
dose received by normal tissue [45]. Experiments on EMT-6 xenograft mice model 
demonstrated more than 200% dose enhancement in tumor tissue and 86% cure in more than 
one year for gold NP enhanced radiotherapy, in contrast, only 20% cure was achieved for 
radiotherapy alone. Hyperthermia can also be realized by loading tumor with 
supraparamagnetic iron oxides (SPIOs) NPs which can generate heat under alternating 
magnetic field. This process is also called magnetic hyperthermia. Poly(lactic 
acid)-D-α-tocopherol polyethylene glycol 1000 succinate (PLA-TPGS) copolymer coated 
SPIOs has been shown to achieve cancer cell penetration, tumor accumulation and efficient 
liver clearance 24 h after injection [46]. Under magnetic field, PLA-TPGS NP encapsulated 
SPIOs efficient kill cancer cells, in contrast, the NPs or the magnetic field alone has negligible 
toxicity [47]. Photodynamic therapy with improved laser penetration depth has been realized 
by activating photosensitizing agent which was loaded into the pores of mesoporous-silica–
coated NaYF4:Yb,Er upconversion fluorescent nanoparticles (UCN) by near-infrared light [48]. 
Intratumoral injection of UCN into C57BL/6 melanoma tumor bearing mice and subsequent 
activation with 980-nm laser suppressed tumor growth to a higher extend compared to UCN or 
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laser irradiation alone.  
More importantly, formulations of therapy agents such as small molecules, proteins and nucleic 
acids in the form of prodrugs or in nanocarriers lead to numerous benefits, including (1) 
protection of agent from metabolism, degradation, and clearance; (2) passive tissue targeting by 
enhanced permeability and retention (EPR) effect; (3) delivery of agents into cells in a bulky 
way by endocytosis to achieve high transportation efficiency; (4) active tumor cell targeting via 
surface decorated ligands; (5) sustained and controlled release at dosage within the therapeutic 
window; and (6) capability to co-deliver multiple agents at fixed ratio and release sequence to 
achieve additive or synergistic effects.  
Anticancer agents are subjected to metabolism, degradation, and clearance after administration 
into the body. Drugs are primarily eliminated from the body through kidney and liver. Kidney 
is efficient at eliminating drugs with size smaller than 10 nm. Nanocarriers increase the size of 
therapy agents from usually less than 1 nm to tenth or hundreds of nanometers, which will 
effectively escape from renal clearance. Modification of nanocarrier surface with polyethylene 
glycol or polysaccharides can increase the colloidal stability and reduce surface adsorption of 
serum proteins by steric hindrance, result in less immune clearance of the nanocarrier. Besides, 
therapy agents are shielded from degradation in the blood and metabolism in the liver or other 
organs such as lungs, kidneys, and intestine. Hence the circulation time of the therapy agents is 
prolonged. One of the characteristics of solid tumors is the abnormal vasculature which has a 
larger fenestration (100 nm to 600 nm) than majority of the normal tissues, and the ineffective 
lymphatic drainage, as a result, nanocarriers tends to accumulate in tumor tissue, especially 
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under the condition of prolonged circulation. This is a phenomenon called EPR effect which is 
also called passive targeting; meaning that nanocarrier with appropriate size and surface 
properties tends to target the tumor tissue regardless of the loaded therapy agents. The above 
properties of nanocarriers lead to a variation in pharmacokinetics and biodistribution of the 
loaded therapy agents.  
Nanocarriers can deliver the bioactive molecules in a bulky way (as a reservoir) by endocytosis. 
The nanocarriers sacrifice their surface energy to detach a small piece of the cell membrane and 
be enveloped, so that they can easily get into the cells. The delivery efficiency is much higher 
than the single molecules to across the cell membrane by various mechanisms such as 
facilitated diffusion transport, active transport, receptor mediated transport, etc. The pathway 
depends largely on nanocarrier size, material, and surface properties and cell types [49]. For 
example, it has been shown that PLGA NP (diameter=300 nm; polydispersity index=0.2; 
negative surface charge) entered vascular smooth muscle cells predominantly through 
clathrin-mediated endocytosis (CME); while the same particles entered rat corneal epithelial 
cells by clathrin- and caveolae-independent pathways. When the PLGA NP surfaces were 
modified with a cationic polymer, poly(L-lysine), the NP-cell interaction force was increased 
by 5-fold, and the modified particles were internalized rapidly through CME.  
Active targeting can be achieved by modifying nanocarrier surface with ligands which interact 
with specific cell surface receptors. Ligand modification usually enhances nanocarrier 
internalization into the receptor-expressed cells more rapidly than its bear counterparts though 
a distinct route. Active targeting is a useful strategy to improve selective tumor cell 
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accumulation of the nanocarrier formulation of anticancer agents. It was shown that 
introvenous administration of photosensitizing agent loaded mesoporous silica UCNs and the 
subsequent laser activation showed no tumor shrinking effects on melanoma xenograft mice, 
however, when the UCNs were decorated with folic acid, the receptor of which is 
overexpressed in B16-F0 melanoma cells, significant tumor inhibition was observed compared 
with control groups, suggesting an pivotal role of targeting ligand [48]. The details of targeted 
drug delivery will be discussed in section 2.5. 
Nanocarrier enable sustained and controlled release of encapsulated, conjugated, or adsorbed 
therapeutic agents by diffusion of the agents or the swelling, erosion, hydrolysis, and 
degradation of the nanocarrier materials, or the cleaving of chemical bound by PH, temperature, 
or reduction stimuli. The release rate and the overall release percentage depend on the materials 
and structures of the nanocarrier matrix, as well as the loading methods of the therapeutic 
agents. Sustained release of therapeutic agents can keep the drug concentration within the 
therapeutic window for days or even weeks, eliminating the need for repeated administration, 
reducing side effects, and minimizing cost. For example, Feng et al., encapsulated hydrophobic 
small molecule anticancer drug paclitaxel into the PLA-TPGS copolymer NP by single 
emulsion solvent evaporation method, and demonstrated an initial burst release of 30% (w/w) 
and subsequent sustained release of up to 80% (w/w) in 700 h [50]. After i.v. injection into SD 
rats, the paclitaxel concentration dropped below the minimal effective level in 24 h when 
formulated in Cremophor EL; in comparison, the paclitaxel concentration remain within the 
therapeutic window for 240 h when formulated in PLA-TPGS NPs.  
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Last but not least, nanocarrier formulation of anticancer agents has the flexibility of 
co-delivering multiple agents to achieve combination therapy. Co-delivery can potentially 
resolve the complexity of variation in pharmacokinetics of different agents, and facilitate 
precise control of loading ratio and release sequence. It has been shown by Lim et al. that 
co-delivery of two anticancer agents cytarabine and daunorubicin at fixed ratio of 5:1 in 
liposome (CPX-351) achieved better efficacy than free-drug cocktail delivered at the same ratio 
on CCRF-CEM xenograft model [51]. In addition, co-delivery of two anticancer agents from 
the same polymeric nanocarrier with sequential release had better tumor suppression effect than 
when the two agents were separately loaded in the nanocarrier and delivered simultaneously. 
Sengupta et al. constructed a PLGA core lipid shell NP, which was loaded with doxorubicin in 
the core by conjugation and combretastatin-A4 in the shell by adsorption. Tumor bearing mice 
treated with the NPs loaded with both agents with sequential release had significantly lower 
tumor volume and higher survival rate than the ones treated with simultaneously delivered 
single agent loaded NPs [52, 53]. 
2.5. Ligand mediated nanomedicine (active targeting) 
2.5.1. Benefits of ligand mediated nanomedicine 
Ligand mediated nanomedicine (i.e. active targeting; molecular targeted nanocarrier) is the 
modification of the surface of nanodevices with affinity ligands with selectivity to targeted 
tissues or cells. Two major benefits of ligand modification are (1) enhanced tissue or cell 
interaction with the nanodevices for improved efficacy; and (2) enhanced tissue or cell 
selectivity for reduced side effects. The feasibility and aforementioned benefits have been 
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proven in numerous preclinical researches. So far there are still no clinically validated ligand 
modified nanocarriers (LMNs) for drug delivery on the market, but there are five LMNs which 
entered phase I clinical trials for cancer treatment (Table 2.1) [54]. These LMNs are ligand 
modified liposomes or polymeric NPs formulations of small molecular drugs (docetaxel, 
doxorubicin, and oxaliplatin), nucleic acid (RRM2 siRNA and P53 gene). Three of them 
(MBP-426, CALAA-01, and SGT53-01) use transferrin as targeting ligand. Tansferrin receptor 
is important for iron uptake through its interaction with transferrin, and is unregulated in many 
cancer types. The surface of BIND-014, the PEG-PLA polymeric NP formulation of docetaxel, 
is conjugated with S,S-2-[3-[5-amino-1-carboxypentyl]-ureido]-pentanedioic acid (ACUPA), a 
prostate-specific membrane antigen (PSMA) substrate analog. PSMA is a cell surface protein 
which is heavily expressed on certain cancer cells and newly formed blood vessels in tumor. 
ACUPA modification was shown to have better anti-tumor efficacy on mice models, in 
comparison with unmodified NP. The completed phase I clinical trial showed anti-tumor 
activity in 9 out of 28 heavily-retreated patients with advanced or metastatic solid tumors. 
MCC-465, a liposome formulation of doxorubicin, was modified on the surface with dimmers 
of antibody fragments (F(ab’)2) GAH which has shown affinity for majority of human stomach 
cancer cells. Treatment with MCC-465 led to up to 80% reduction in tumor growth compared 
with controls in GAH-positive xenograft mice model. In clinical trials in metastatic or recurrent 
stomach cancer patients, MCC-465 was shown to be well tolerated and have a 




Table 2.1. Targeted NPs in clinical development. Reprint from [54]. 
 
 
2.5.2. Types of targeting ligands 
2.5.2.1. Antibody and antibody fragments 
Nowadays, over 200 delivery systems using antibody and antibody fragments as targeting 
ligands are in preclinical research and clinical trials [4]. Some of the antibodies themselves are 
targeted cancer therapeutic agents. For example, rituximab (Rituxan®), trastuzumab 
(Herceptin®), and cetuxumab (Erbitux®) are approved by FDA for the treatment of B-cell 
lymphoma, breast cancer, and colorectal cancer, respectively. The advantages of using 
monoclonal antibodies (mABs) include clinically proven efficacy, high binding affinity (two 
epitopes), capable of inducing antibody-dependent cellular toxicity to kill receptor 
over-expressed cells, ability to maintain stability during long-term storage. However, there are 
also some concerns regarding the use of mABs, such as unspecific binding, large 
hydrodynamic size (~20 nm), and high manufacturing cost relative to small-molecule drugs. 
These lead to the development of antibody fragments including antigen binding fragments 
(Fab), dimers of antigen-binding fragments (F(ab’)2), single chain fragment variables (scFV), 
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small polypeptides derived from antibody binding domain (affibody), and heavy chain 
antibodies engineered to one tenth of the size of an intact antibody with a missing light chain 
(nanobodies).  
2.5.2.2. Nucleic acids 
Another class of targeting ligand is aptamer. Aptamers are single-stranded DNA or RNA 
oligonucleotides, which can recognize molecules such as proteins, phospholipids, sugars and 
nucleic acids, with high affinity and specificity [55].  Their size ranges from 20 to 80 bases (6 
to 26 kDa). Aptamer binding to specific targets could be selected by the ‘systematic evolution 
of ligands by exponential enrichment’ (SELEX) method [56]. For example, A10 
2-fluoropyrimidine RNA aptamer that recognizes the extracellular domain of the PSMA has 
been conjugated to docetaxel loaded PLGA-PEG NPs for treatment of prostate cancer [57]. The 
system was shown to have high selectivity and efficacy in vivo. However, there are only few 
aptamers available for cancer cell targeting. The development process is laborious and costly.  
2.5.2.3. Other targeting ligands: growth factors, vitamins and peptides 
Growth factors and vitamins also can be used as targeting ligands, as cancer cells often 
over-express the receptors for nutrition to maintain growth and proliferation. Some of the 
examples are vitamin folic acid (folate) targeting folate receptors (FR), and transferrin (Tf) 
interacting with Tf receptors (TfRs). Decorating nanocarriers with folate or Tf improves 
intracellular delivery and therapeutic outcomes in mouse models [58, 59]. However, one 
drawback of using folate and Tf is that the receptors are also expressed in fast-growing healthy 
cells such as fibroblast, epithelial, and endothelial cells, leading to on-specific targeting and 
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subsequent decrease in drug effectiveness and increase in side effects.  
Peptide targeting attracts attention in recent years. The first example is TAT, which is derived 
from the trans-activating transcriptional activator of human immunodeficiency virus. It was 
also named as ‘cell penetrating peptide’ (CPP) due to its ability to enter cells. Nowadays, many 
other peptides have been developed for targeted drug delivery (drug delivery via active 
targeting) to tumor cells or tumor supporting structures, including neovasculature and tumor 
stroma (i.e. tumor ECM). The most widely used peptide for tumor neovasculature targeting is 
RGD (arginine-glycine-aspartic acid) which binds integrin αvβ3 on endothelial cells. The 
selectivity and efficacy of RGD conjugated single wall carbon nanotubes, PLGA nanoparticles, 
and liposomes have been demonstrated in vitro and in vivo [60-62]. However, since RGD can 
also bind to some non-cancer-cell-specific integrins such as α5β1 and α4β1, the clinical relevance 
of RGD need to be further assessed. Some other tumor targeting peptides include bombesin 
targeting gastrin-releasing peptide receptors; somatostatin targeting somatostatin receptors; 
and LyP-1 targeting cells carrying p32 proteins [63].  
2.5.3. Important parameters for ligand mediated nanomedicine 
Several issues need to be addressed in nanomedicine to achieve commercialization, including: 
(1) the toxicity and fate of injected nanocarriers, which includes the absorption, distribution, 
degradation, and elimination; (2) scale-up of the production of nanocarriers with 
reproducibility and quality control; (3) guidelines for design of nanocarriers based on the 
understanding of the design parameters and their role in nano-bio interactions. The following 




Size is an important parameter for both passive tissue targeting and active cancer cell targeting. 
The role of nanocarrier size in passive targeting in the aspect of clearance and tumor tissue 
penetration has been emphasized in many articles and become a principle for nanomedicine. 
The role of nanocarrier size in active targeting has recently been studied by simulations and 
experiments. Nanocarrier size and surface ligand density were considered to be the two most 
important factors for active targeting effect. In the investigation of size, ligand density is 
usually assumed or made constant.  
In a seminal paper published in 2005 by Gao et al., based on the understanding of the process 
of receptor-mediated endocytosis and the mathematical framework developed for an initially 
curved membrane spreading on a flat substrate, the researchers established a model for the 
internalization of NP into receptor expressing cells [64]. The starting point is the contact 
between the NP and the cell membrane, and the end point is when the total area of contact 
between the cell and the NP reaches the surface area of the particle. The assumptions of this 
research include (1) immobile ligand and rapid diffusive receptors; (2) the number of ligands 
is fixed and uniformly distributed on the NP; (3) NP encountered cell membrane is an initially 
flat membrane; (4) clathrin-indepenent process; (5) all ligands on NPs are bound to the 
receptors in the wrapping zone; (6) receptor-ligand binding leads to membrane wrapping 
around the NP; the generated binding energy is consumed by the increase in local curvature 
and reduction in configurational entropy due to receptor immobilization. Based on energy and 
mass balance, equations are established to describe this dynamic process. Several implications 
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were deduced from the equations for spherical particles: (1) there exists a minimal receptor 
density and a maximal particle radius for endocytosis to be possible; (2) an optimal radius 
exists for smallest wrapping time (i.e. internalization time); (3) receptor density affects the 
optimal radius. To better guide the design of NPs, in 2010, Li and Xing made two more 
assumptions (1) constant receptor density; (2) the density of receptor is much smaller than the 
density of ligands, and deduced the relationship between optimal size and receptor density 
(constant ligand-receptor affinity); and between optimal size and ligand-receptor binding 
affinity (constant receptor density) [65]. By substituting both the receptor density and 
ligand-receptor affinity, the optimal size can be calculated. 
Chan’s group prepared Her-GNPs by physically absorbing Herceptin® (Her) on 2-100 nm 
diameter gold NPs (GNP) [66]. The extend of Her-GNP internalization into receptor 
over-expressed SK-BR-3 cells after 30 min incubation was tested, and the results show that 
40 nm and 50 nm Her-GNPs have the highest level of particle internalization, and greatest 
effect on altering the signaling processes essential for basic cell function (including cell 
death). However, in this investigation, surface herceptin density increased linearly with the 
increasing of GNP diameters. Although the author emphasized on the size effect, the ligand 
density could also play an important role; which is not included into the discussion. Proper 
match of the two parameters could be the reason for best targeting effect instead of size alone. 
2.5.3.2. Shape and mechanical strength 
Nanocarrier shape and mechanical strength also plan an important role in determining 
pharmacokinetics, biodistributions, and nanocarrier-cell interactions. It has been shown that 
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filomicelles (micelles of filament shape) with micrometer length and 20-60 nm diameter have 
higher blood retention time and slower cellular uptake efficiency than their spherical 
counterparts under flow conditions [67]. In addition, red blood cell mimicking deformable 
hydrogel microparticles was shown to have 30-fold longer circulation time than their rigid 
counterparts [68].  
2.5.3.3. Surface charge and modifications 
Surface charge significantly affects the interaction between nanocarrier and proteins, and 
nanocarrier and cells. Positively charged nanocarriers adsorb more serum proteins than neutral 
and negatively charged nanocarriers, leading to a higher level of clearance and immune 
activation. Besides, positively charged nanocarriers can be internalized into cells more rapidly 
than neutral and negatively charged nanocarriers due to higher interaction force. Surface 
modification with PEG (PEGylation) improves nanocarrier colloidal stability, reduce serum 
protein adsorption and decrease cell internalization; due to increased surface hydrophilicity, 
steric hindrance, and the shielding of surface charge. PEGylation is a widely used strategy to 
improve the circulation time of nanocarriers, in order to achieve higher level of passive 
targeting. However, PEGylaiton has been shown to reduce the level of cell internalization of 
nanocarriers, leading to a reduction in drug dosage inside tumor cells, despite the high level of 
tumor tissue accumulation. It has been shown on C-26 syngeneic xenograft tumor BALB/c 
mice model that although 6mol-% PEG2K modified liposome (PEG-lipo) has plasma AUC 
(area under the curve) twice that of liposome without PEG modification (lipo), the actual 
tumor accumulation efficiency (AUC(tumor)/AUC(plasma)) of PEG-lipo (0.31) is lower than 
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lipo (0.87); and the two formulations of doxorubicin have equal toxicity, tumor shrinkage and 
survival [69]. Therefore, PEG sheddable nanocarrier was designed to explore the long 
circulation property of PEG and minimize it blocking effect on cell internalization. 
Nevertheless, PEG is still an important component in many nanocarrier delivery systems to 
improve the stability and circulation time.  
2.5.3.4. Ligand type 
For ligand mediated nanocarriers, ligand type, ligand density, and tethering chain length are 
important parameters identified in literature. Ligand is chosen based on cell or tissue of 
interest. Selectivity and affinity are the key criteria for the selection of targeting ligand. 
Selectivity is determined by the relative receptor expression level on the cell of interest (i.e. 
cancer cell) compared with normal cells. Another dimension of selectivity is the selective 
binding of ligand to its target receptor compared with unspecific binding (i.e. off-target 
binding). High affinity for target cell or tissue and low affinity for healthy tissue is an 
important contributor to the second dimension of selectivity, and thus preferred. High-affinity 
vehicles were shown to have greater accumulation at tumor tissue compared with normal 
tissue. However, the ideal situation of specificity is difficult to achieve; off-target binding is 
usually associated with high affinity, especially for receptor expressing health tissues. 
Recently, it was found that the overall affinity of ligand modified nanocarrier with 
low-affinity ligand can be increased by multivalency (i.e. modification of nanocarrier surface 
with multiple targeting ligand). In this case, the affinity of ligand modified nanocarriers not 
only depends on ligand type but also ligand density. Tassa et al. demonstrated that multivalent 
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interactions significantly improved binding affinity of even weak small molecule targeting 
ligands by up to 4 orders of magnitude; by performing direct quantitative study using surface 
plasmon resonance [70]. Simnick et al. showed that thermal triggered micellation of ligand 
conjugated copolymers greatly improved the receptor-mediated binding and cellular uptake 
compared with free ligand conjugated copolymers using an in vitro cell binding assay [71]. It 
is commonly believed that higher binding affinity between targeting ligands and its 
corresponding receptors correlates high selectivity. However, when the analysis is expended 
to 3D tumor, the situation is more complicated. It has been suggested that if the binding 
affinity is too high, the extravasated nanocarriers could binds quickly and strongly to nearest 
cells forming a ‘binding site barrier’, slowing down particle diffusion in solid tumors [72].  
2.5.3.5. Ligand density 
Ligand density significantly affects the interaction between nanocarriers and the biological 
systems; especially the cell uptake efficiency. Researchers try to use computation and 
computer simulation to mimic the complex process of cell internalization of nanoparticles to 
find principles which can guide design of a ligand modified nanocarrier system for medical 
applications. Based on the computational model established by Gao et al. (details in section 
2.5.3.1), and in order to make a more thorough understanding of the design parameters which 
can extend beyond size and receptor density, Yuan and Zhang abandoned the assumption that 
all ligands on the particle are bound to the receptors in the wrapping zone, instead they 
assumed that the receptors in the wrapping boundary can be neglected compared with the 
receptors in the wrapping zone [73]. With the assumption and the previous framework, a few 
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conclusions are deduced from the thermodynamic analysis: (1) at a given ligand density a 
minimal size of particle exists; (2) at a given size, a minimal ligand density exists; (3) 
wrapping of nanoparticles can proceed with many ligands unbound; (4) an optimal particle 
size and surface ligand density exist to minimize endocytotic time.  
Experiments have also been conducted to examine how ligand density affects the interaction 
between cells and the nanocarriers at a given particle size. Gu et al. synthesized aptamer (Apt) 
conjugated PLGA-PEG triblock copolymer (PLGA-b-PEG-b-Apt; TCP) and formed micelles 
together with PLGA-PEG diblock copolymer (DCP) at precisely controlled ratio to control 
the surface Apt concentration. The size of the nanoparticle is primarily determined by the 
matrix material (i.e. PLGA-PEG) and was fixed in the experiments. When examined on 
receptor overexpressed monolayer cell line, the cellular uptake of nanocarriers increased with 
the increase of surface Apt (i.e. TCP/DCP ratio). However, when examined in receptor 
overexpressed xenograft tumor mice model, i.v. injection of docetaxel loaded nanoparticles 
with 5% TCP led to the maximum tumor accumulation of docetaxel; further increase in TCP 
to 10% caused a reduction in tumor accumulation. The reason suggested by the author is the 
compromise of the stealth effect due to excessive shielding of PEG by Apt. The result implies 
that there are discrepancies between current computational model and monolayer cell model 
for evaluation and screening of nanocarrier formulations for cancer therapy. The 
establishment of design principles needs more cooperative effort to come up with better 




2.5.3.6. Tethering chain length 
Targeting ligand can be attached to the surface of nanocarriers by physical adsorption via 
electrostatic interactions or chemical conjugation. The advantages of chemical conjugations 
include (1) more stable attachment compared with physical adsorption which can easily detach 
or be replaced; (2) precise control of surface ligand density; (3) possible control of ligand 
orientation on the surface. Modifying nanocarrier surface with functional groups are necessary 
for ligand conjugation. In many designs, PEG is the tethering chain which harbors the 
functional groups for ligand conjugation. The number and length of the tethering chains and its 
flexibility are important parameters which affect the interaction between nanocarriers and cells. 
Wang and Dormidontova established a nanocarrier model which had a hard core and a shell 
consisting of flexible polymers, the end of which was attached with a monomeric ligand for 
targeting. Using Monte Carlo simulation, design parameters such as nanoparticle core size, 
ligand-receptor binding energy, ligand density, tethering chain length and density were 
examined by evaluating the interaction between the nanocarrier and flat surface containing 
mobile receptors at a fixed initial distance from the nanocarrier (the system is brought to 
equilibrium after 8 million Monte Carlo time steps) [74]. The simulation and discussion on the 
number and length of tethering chains provide additional design considerations. It was found 
that in close proximity of cell surface, increasing the number of tethering chains or increasing 
the tethering chain length without increasing the number of ligands increased the 
conformational penalty (entropy) due to the stretching or compression of the flexible polymer 
chains, and hence led to a decrease in targeting effects. However, larger number or longer tether 
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chains increase the probability of ligand-receptor interaction at far distance over a larger cell 
surface area. Kawano and Maitani evaluated the targeting effects of folic acid modified 
PEGylated liposome at different PEG (the tether chain) molecular weight of 2000, 3400, and 
5000 on KB cells which have an overexpression of folate receptor. Folic acid modification was 
achieved through post-insertion of folic acid conjugated 
PEG-distearoylphosphatidylethanolamine (FA-PEG-DSPE) into the liposome. The flow 
cytometer results showed that at low surface ligand density (0.01 to 0.3 mol% Folic 
acid-PEG-DSPE), the highest cell uptake occurs at long PEG chain length (Mw 5000).  
2.6. SiRNA mediated nanomedicine 
An important reason that leads to the ineffectiveness of cancer treatments is the intrinsically 
possessed or gradually developed therapy resistance. Small molecule inhibitors which target 
MDR proteins sensitized cancer cell lines and xenograft tumor mice models to chemotherapy 
[75]. However, these inhibitors achieved limited success in clinical trials owning to the lack of 
potency or specificity. Small interfering RNA (siRNA) is a double strand RNA with 21-23 
nucleotides which functions as a post-transcriptional regulator to cleave its target mRNA, 
leading to a reduction in mRNA and corresponding protein levels. SiRNA can be easily 
designed based on target gene sequence and synthesized by commercially available solid-phase 
techniques. SiRNA silencing is expected to have high potency and selectivity. Proper design of 
siRNA which does not contain immune stimulation sequence or complementary sequences for 
irrelevant genes could minimize toxicity and “off-target” effects [76]. However, the clinical 
success of siRNA is hindered by its sensitivity to enzymatic degradation, fast clearance, 
54 
 
immunogenicity, and incapability of entering cells. All these issues can be addressed by using a 
nanocarrier siRNA delivery system. Co-delivery of an anticancer agent and siRNA that target 
the resistance mechanism of this agent has been shown to have better efficacy than a mixture of 
two types of carriers, each of which is loaded with a single agent; probably because co-delivery 
could resolve the complexity of variation in pharmacokinetics, and ensure co-localization of the 
two agents to maximize the additive or synergistic effect.  
2.6.1. Cancer resistance to therapies 
The treatments of cancer in the past few decades are surgery, radiotherapy and chemotherapy. 
Surgery is usually accompanied with radiotherapy or chemotherapy as a preventive measure for 
non-metastasized patients. For metastasized cancer, chemotherapy becomes an essential part of 
the treatment. When these methods fail, the patients have less than 10% chance of survival. 
New treatment methods such as targeted therapy, antiangiogenesis therapy, hyperthermia 
therapy, immunotherapy and gene therapy have been developed in assistance to the standard 
methods, which have not significantly changed the current practice of cancer treatment. One 
major cause of the treatment failure is the intrinsically possessed or gradually developed 
resistance. Clinical trials and preclinical experiments have suggested a significant correlation 
between tumor hypoxia and radiotherapy resistance, due to the disturbance of 
radiation-induced reactive species and the activation of hypoxia-inducible factor 1 (HIF-1) [77]. 
Hypoxia is shown to cause 2-3 fold reduction in therapeutic efficacy. Methods have been 
developed to overcome the hypoxia barrier. It has been demonstrated on mouse xenograft 
model of glioma that the single administration of anti-VEGF antibody, bevacizumab, 48 h 
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before radiotherapy led to synergistic effect due to transient normalization of tumor vasculature, 
which resulted in temporary tumor re-oxygenation and improvement of radiotherapy sensitivity 
[78].  
Chemotherapy resistance is due to diverse reasons. One important reason is the innately 
possessed or gradually acquired MDR. For example, more than 90% of ovarian cancer patients 
who initially respond to standard regimen of chemotherapy with platinum-based drug and 
taxane are believed to relapse after a median period of 18 months due to the emergence of MDR 
[79]. Similarly, MDR is believed to account for treatment failure in more than 90% of 
metastatic breast cancer patients [80]. The most common mechanism of MDR is the 
overexpression of active drug efflux pumps. Among them, P-glycoprotein (Pgp) transports 
drugs that are crucial to most chemotherapeutic regimens, such as anthracyclines, taxanes, 
vinca alkaloids, etc [75]. Inhibiting Pgp by small molecule inhibitor Verapamil has been shown 
to improve the overall survival and response rate of the combination regimen of vindesine and 
5-FU for 99 antracycline-resistant metastatic breast cancer patients in a phase III clinical trial 
[81]. MDR could also be attributed to the up-regulation of molecules that strengthen the 
surviving pathways, making the drug less effective. Inhibition of these molecules could 
sensitize anti-cancer drugs. In a phase II clinical trial, it was demonstrated that the addition of 
iniparib, a poly(ADP-ribose)polymerase (PARP) inhibitor, to DNA damaging agents 
gemcitabine and carboplatin improved overall survival and response of 123 metastatic 
triple-negative breast cancer patients[82]. 
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Drug resistance also causes treatment failure of the newly developed agents for targeted 
therapy, immunotherapy, hyperthermia therapy, and gene therapy. Majority of HER2 positive 
metastatic breast cancer patients develop resistance to Herceptin (trastuzumab) monotherapy 
within one year [83]. It is believed that the loss of phosphatase and tensin homolog (PTEN) 
leads to persistent activation of phosphatidylinositol 3-kinase (PI3K)/Akt pathway which is a 
potential cause of Herceptin resistance. Addition of Everolimus, an inhibitor of mammalian 
target of rapamycin (mTOR) which is the downstream of PI3K/Akt, to Herceptin monotherapy 
resulted in clinical benefits and disease response in a phase I/II clinical trial, that involved 47 
patients with trastuzumab-resistant HER2-overexpressing metastatic breast cancer [84]. Most 
immunotherapy attempts in recent decades are proven elusive due to the lack of clinical 
efficacy. One important reason that leads to the ineffectiveness of immunization is the immune 
suppressive tumor microenvironment. A recent phase III clinical trial on relapsed-refractory 
metastatic melanoma patients demonstrated that ipilimumab, a monoclonical antibody inhibitor 
of cytotoxic T-lymphocyte antigen 4 (CTLA4) which is a key negative regulator of immune 
activation, when used alone or in combination with a short peptide (gp100) for a melanoma 
differentiation antigen resulted in a twofold survival benefit at 12-15 months which was still 
durable after 2.5 years, compared to the control arm which received the short peptide alone [85]. 
Although not tested in clinic yet, this kind of inhibitors holds great promise in combination with 
other immunotherapeutic regimens to lower the resistance of immunotherapy.  
Targeting therapeutic resistance of cancer improves the efficacy of current treatment. Small 
molecule inhibitors are the main focus of research and commercialization. The development 
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could start from a naturally existing small molecule which is biologically active, followed by 
structurally guided design and synthesis. However, the natural compound is not always 
available. Alternatively, the development could start by identifying a biological target, 
followed by strategical design and intensive screening of molecules that could modulate the 
target. However, many of these molecules failed at phase II or phase III clinical trials due to 
lack of potency or specificity, making enormous investment delivery few outcomes. SiRNA 
could serve the function as inhibitors for therapeutic resistance with high potency and standard 
and relatively simple design and synthesis methods.  
2.6.2. Small interfering RNA (siRNA)  
SiRNA is a double strand RNA with 21-23 nucleotides. It functions by guiding the 
ribonucleoprotein complex RNA-induced silencing complex (RISC) to target mRNA, cleaving 
it at specific sites, which leads to fast degradation of the mRNA and a reduction of the 
corresponding protein level. SiRNA can be designed based on the sequence of the target gene 
with consideration of a few criteria, such as the G/C content, 5’ end stability of the antisense 
strand, etc [86]. When most of the design criteria are satisfied, the siRNA will have a high 
efficiency in silencing the target gene. The sense and anti-sense strands of the siRNA could be 
synthesized separately by the well established solid-phase synthesis of oligoneucleotide, 
followed by an annealing step [87]. The siRNA could also be synthesized directly from short 
hairpin RNA (shRNA) with is transcribed from a single-strand synthetic DNA template using 
T7 RNA polymerase [88]. Compared to the design and synthesis of small molecule inhibitors, 
that of siRNA is more straightforward and standardized. Besides, theoretically, siRNA could be 
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designed to silence any gene of known sequence with potency that small amount of siRNA 
could induce a robust response. In addition to siRNA, posttranscriptional gene silencing can 
also be achieved by antisense oligonucleotide and shRNA. Compared to antisense 
oligoneucleotide, siRNA appears to be quantitatively more efficient; and the silencing effect 
lasts for a longer time [89]. Compared to shRNA, which need to be produced in the nuclei by 
plasmid or viral vector and transported to the cytoplasm, siRNA relies less on the cell 
machinery whose variation in level is shown to greatly affect the efficacy of shRNA 
[90].Furthermore, compared to shRNA, siRNA is easier to be chemically modified.  
SiRNA therapy develops very fast and realized bench to bedside in a short period. The term 
‘RNA interference’ (RNAi) was born around a decade ago to represent a phenomenon when a 
double-stranded RNA can trigger silencing of its complementary mRNA [91]. Another 
breakthrough came just one year later; Baulcombe’s group discovered ~25 nucleotides RNA 
molecules which could be a “specific determinant” of RNAi. The RNA molecules were later 
known as siRNA [92]. In the year 2001, Thomas Tuschi and colleagues chemically synthesized 
siRNA and demonstrated on cultured mammalian cells that the sequence-specific RNAi 
response lasting days [93]. Afterwards, siRNA silencing of therapeutic siRNA was quickly 
proven in mammals [94, 95]. In 2004, only 6 years after the discovery of RNAi, the first 
siRNA-based therapy entered phase I clinical trial for the treatment of wet age-related macular 
degeneration. In recent years, siRNA therapeutics has been developed for the treatment of 
cancer, the most intractable disease usually lacking effective treatment. Multiple phase I 
clinical trials are ongoing to demonstrate the safety and efficacy of siRNA as a therapeutic 
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option for cancer [96]. Existing clinical trials result from stable nucleic-acid-lipid particle 
(SNALP), cationic liposome, and cyclodextrin-based polymer formulations of siRNA proved 
RNAi mechanism in human and demonstrated tolerability of chronic dosing [97]. 
Although current clinical trials are focused on siRNA monotherapy, preclincal experiments 
have demonstrated the benefits by rationally adding siRNA to existing therapeutic regimens to 
enhance the efficacy. Zheng et al. screened a library of siRNA targing all protein kinases and 
E3 ubiquitin ligases and identified tumor necrosis factor receptor-associated factor 2 as the 
target, which when being inhibited caused the most significant radiosensitization of multiple 
radiotherapy resistant cell lines [98]. Spankuch et al. demonstrated on multiple breast cancer 
cell lines that the cells were a hundred times more sensitive to chemotherapeutic agent 
paclitaxel, if the cells had been transfected with as little as 0.056 nM of polo-like kinase 1 
siRNA using the standard oligofactamine
TM
 protocol 4 h before the addition of the drug [99]. 
Kortylewski and colleagues chemically linked signal transducer and activator of transcription 3 
(STAT3) siRNA and CpG oligonucleotide agonist of toll-like receptor (TLR) 9, and 
administered the conjugates locally or intravenously to tumor-bearing mice [100]. CpG 
oligonucleotides, an immunotherapy agent in clinical trials for melanoma, can initiate a cascade 
of innate and adaptive immune responses when bind to TLR9 [100]. STAT3 plays a pivotal role 
in immune suppression at tumor microenvironment. Inhibiting STAT3 by siRNA could 
potentially magnify the elicited immune response. Co-administration of them in a conjugate 
format results in a better control of tumor volume compared to CpG oligonucleotide alone.  
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However, the application of siRNA in vivo is hindered by the ‘off-target effect’, sensitivity to 
enzymatic degradation, fast renal clearance, immunogenicity, and inability to efficiently 
penetrate cell membrane [101]. Safe and efficient delivery method is of paramount importance 
for the success of siRNA therapeutics. The main reason that led to the retrieval of large 
pharmaceutical companies such as Roche from investing in siRNA therapeutics was the failure 
of developing sound strategies to solve important technical challenges such as delivery [5]. 
SiRNA could be delivered by physical methods such as electroporation and hydrodynamic 
injection. Electroporation, a technique that transiently disturbs the cell membrane by electric 
field leading to uptake of extracellular materials, has been used in phase I and phase II clinical 
trials to delivery furin bifunctional shRNA ex vivo to autologous tumor cells to inhibit immune 
suppressor transforming growth factor beta (TGFβ) [102]. However, this method is difficult to 
apply in vivo, and has raised safety concerns of the application of powerful electric pulses [103]. 
Hydrodynamic method has been used for intravenous (i.v) administration of naked siRNA in 
mice models with satisfactory transfection efficiency, however, it requires high volume and fast 
speed i.v injection which limits its clinical usage [104]. SiRNA conjugates have also been 
developed for the delivery of siRNA. Soutschek et al. chemically linked apolipoprotein B 
(apoB) siRNA and cholesterol via a pyrrolidine linker (chol-siRNA) by solid-phase synthesis, 
and tested the conjugates on mice model. The results clearly indicated an around 50% reduction 
in apoB mRNA level in liver and jenjenum 24 h after tail vein injection of 0.2 mL of 50 mg/kg 
chol-siRNAs solution. Radioactive labeling revealed that the elimination half life of 
chol-siRNAs was 95 min, while that of unconjugated siRNAs was only 6 min. Besides, 24 h 
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after injection, significant level of chol-siRNAs were detectable in liver, heart, kidney, adipose, 
and lung tissue samples, in comparison, no detectable amounts of unconjugated siRNAs were 
observed in the tissue of these organs [105]. However, later, Wolfrum et al. found that the 
improvement in pharmacological properties of cholesterol conjugation is mainly due to the 
association of chol-siRNA with the nanosized lipoprotein particles in the blood stream. It was 
shown in mice model that lipoprotein bound chol-siRNA which target apoB is 8 to 15 times 
more effective in reducing apoB protein levels in the liver, gut and blood than equal amount of 
unbound chol-siRNA, which do not readily associated with lipoprotein particles and therefore 
cannot be taken up by cells [106]. The CpG-siRNA conjugate which do not have the ability to 
associate with lipoprotein was shown to have limited half-life and stability in serum [100].  
2.6.3. Nanocarrier for siRNA delivery  
Nanocarrier formulation of siRNA for sustained, controlled and targeted delivery is an 
attractive strategy to overcome the limitations in exploring the great potential of siRNA as 
inhibitors for therapeutic resistances. SiRNA based nanomedicine, i.e. nanocarrier formulation 
of siRNA, could solve the delivery problem of siRNA and provide a platform for co-delivery of 
siRNA and other therapeutic agents. Early clinical developments are focused on local delivery 
of siRNA, however, half of the siRNA therapeutic candidates that entered clinical trials after 
2008 are systemically delivered by nanocarriers [5]. The paradigm shift towards the use of 
nanocarrier for siRNA delivery attributes to the benefits that no other delivery strategies could 
provide. (1) The nanocarrier could protect siRNA from enzymatic degradation and immune 
recognition. It has been shown by Musacchio et al that when incubated in a RNase containing 
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buffer solution at 37
o
C, naked siRNA completely degraded in 0.5 h, phosphothioethanol (PE) 
conjugated siRNA (siRNA-S-S-PE) degraded after 6 h, and siRNA-S-S-PE/PEG-PE micelles 
formulation of siRNA showed no sign of degradation after 24 h [107]. Besides, immune 
stimulation is one of the main reasons that lead to the “off-target” effect of siRNA, which not 
only may cause misinterpretation of the therapeutic effect but also has negative impact on the 
health of the recipient. In an anti-influenza study, it was found that the anti-viral activity of 
siRNA was primarily due to immune stimulation [108]. In addition, it was shown on mice 
model that siRNA that contains immune stimulatory motif induces the production of interferon 
and proinflammatory cytokines, causing systemic toxicity [109]. However, no immune 
stimulation was observed when such siRNA was encapsulated in cyclodextrin polycation 
nanoparticles, probability due to the endosomal buffering and lack of uptake by specific 
immune competent cells [110]. (2) Nanocarriers can deliver the bioactive molecules in a bulky 
way (as a reservoir) by endocytosis. The nanocarriers sacrifice their surface energy to detach a 
small piece of the cell membrane and be enveloped, so that they can easily get into the cells. 
The delivery efficiency is much higher than the single molecules to across the cell membrane 
by various mechanisms such as facilitated diffusion transport, active transport, receptor 
mediated transport, etc. It was shown by Morrissey et al that siRNAs when formulated in 
liposomes could enter cell cytoplasm and being released to serve their function [111]. 
Moreover, the endocytosis pathway (e.g. clathrin-dependent, Caveolae-mediated, 
macropinocytosis) and the destination of the bioactive molecule can be controlled by 
elaborative design of the nanocarrier [49]. (3) The nanocarrier surface can be modified with 
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ligands which target biomarkers on the cell membrane. The ligands may improve the selectivity 
and efficacy of the nanocarriers. For examples, Sato et al incorporated vitamin A onto the 
HSP47 loaded cationic liposome by physical mixing to target liver hepatic stellate (HS) cells 
for the treatment of liver fibrosis [112]. The selective internalization of vitamin A decorated 
liposome into HS cells instead of other types of cells was shown in monolayer cell culture and 
rat model. (4) The nanocarriers of appropriate size and surface coatings could escape excretion 
by the reticuloendothelial system (RES) and thus realize sustained delivery to the target tissue. 
This is manifested by prolonged half-life in blood and change in biodistribution. Morrissey et al 
showed in mice model that the circulation half-life for unmodified siRNA was only 0.03 h, for 
siRNA with 2’-OMe substitution was 0.8 h, and for siRNA formulated in SNALP was 6.5 h. (5) 
The sustained release of siRNA from the nanocarriers facilitate continuous supply of siRNA at 
therapeutic dosage without causing dose-related off-target effects. Zhou et al observed a 
sustained release of siRNA in 168h from siRNA loaded poly(lactic-co-glycolic 
acid)-poly-L-lysine-polyethyleneglycol (PLGA-PLL-PEG) copolymer nanoparticles, leading 
to persistent silencing of the target gene [113]. Last but not least, nanocarrier formulation of 
siRNA has the advantage to co-deliver siRNA and other therapeutic agents to overcome 
therapeutic resistance. Co-delivery could potentially resolve the complexity of variation in 
pharmacokinetics of different drugs, and facilitate precise control of loading ratio and release 
sequence [114]. The spacial and temperal co-localizaiton of the loaded agents confers the 
system advantages, compared to free drug cocktails. It will be shown by many of the examples 
in the following part of the review.    
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2.6.4. Co-delivery nanocarriers for siRNA and cancer therapeutic agents 
2.6.4.1. Lipid  
Liposome 
The liposome SNALP is the first type of nanocarrier that entered clinical trials for the systemic 
delivery of siRNA, attributing to the improved transfection efficiency and pharmacokinetics, 
tolerable toxicity, and the scalable production method. The physical and chemical properties of 
a liposome are largely decided by the constituent phospholipids. For the delivery of siRNA, 
cationic lipid is an essential component to enhance siRNA encapsulation efficiency by 
charge-charge interaction and to tightly pack siRNA to reduce size. The cationic lipid can be 
designed to destabilize endosome and accelerate endosomal escape. In addition to the cationic 
lipids, the system usually also comprises neutral helper lipids to improve stability and 
PEG-lipids to increase circulation time and to facilitate formation of smaller liposome during 
production [115]. However, highly positively charged surface interact extensively with plasma 
proteins and the complement system, leading to immune activation and fast clearance. SNALP 
overcomes this drawback by containing an ionizable cationic lipid with is positively charged at 
low PH for siRNA loading and become almost neutral at PH 7.4 to minimize charge in 
circulation [116]. Another strategy developed by Huang’s group incorporate high level of PEG 
on liposome surface to increase steric hindrance and to prevent clearance by RES [117]. The 
formed liposome is named liposome-polycation-DNA (LPD).  
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The structure of liposome enables loading of hydrophilic agents in the aqueous core and on 
surface, and hydrophobic agents inside the lipid bilayer for co-delivery of siRNA and other 
cancer therapeutic agents. Chen et al developed a targeting peptide decorated liposome to 
co-deliver c-MYC siRNA and hydrophilic small molecule drug doxorubicin (Dox) based on the 
LPD technology for the treatment of cancer [118]. Inhibiting c-MYC had been shown to 
sensitize cancer cells to chemotherapy due to the induction of P53 and the inhibition of BCL-2 
protein. To formulate LPD for siRNA delivery, siRNA was first complexed with a cationic 
polypeptide protamine with the assistance of high molecular weight calf thymus DNA, and 
loaded into liposomes by direct mixing. In this study, Dox which contains aromatic rings, was 
first complexed with calf thymus DNA by intercalation, and then loaded into liposome together 
with the siRNA. The liposomes were further modified by post-inserting 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) conjugated polyethylene glycol 
(PEG) (DSPE-PEG) or DSPE-PEG-NGR. Here, NGR is a peptide motif targeting CD13, which 
was shown to be up-regulated in tumor vasculature and multiple cancer cells. A significant 
enhancement in tumor growth inhibition was observed on mice which were treated with Dox 
and c-MYC siRNA co-formulated in liposome, compared to those that were treated with a 
mixture of c-MYC siRNA loaded liposomes and free Dox, and single agent formulated in 
liposomes at the same dosage. Kang et al formulated hydrophobic small molecule 
mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor PD0325901 
and siRNA targeting myeloid cell leukemia sequence 1 (MCL1) in N’,N”-dioleylglutamide 
(DG) based cationic liposomes for the treatment of cancer [119]. PD0325901-loaded cationic 
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liposomes (PDGL) are synthesized by drying PD0325901, DG, DOPE, and cholesterol at a 
molar ratio of 0.2:3:1:1 from organic solvent, followed by rehydration with 20 mM HEPES 
buffered-saline (pH 7.4) and extrusion three times through 0.2 μm polycarbonate membrane 
filters. The siRNA was loaded by direct mixing of the PDGL and the siRNA. The liposome 
formulation of both agents exhibited remarkably increased ability in inhibiting cell 
proliferation in monolayer cell culture and tumor growth in xenograft mice model, compared to 
liposome formulation of single agent. Chang et al conjugated small molecule anticancer drug 
mitoxantrone (MTO) with palmitoleic acid to form monopalmitoleyl MTO (mono-Pal-MTO) 
or dipalmitoleyl MTO (di-Pal-MTP) prodrugs, and then used the cationic prodrugs as building 
block to form mutilayered cationic liposome (md11-Pal-MTO) for the co-delivery MTO and 
MCL1 siRNA (siMCL1) [120]. The size formed liposomes after siRNA complexation is around 
200 nm measured by dynamic light scattering (DLS). The therapeutic efficacy of siMCL1 
loaded md11-Pal-MTO (md11-Pal-MTO/siMCL1), luciferase-specific control siRNA (siGL2) 
loaded md11-Pal-MTO (md11-Pal-MTO/siGL2), and free MTO were evaluated on KB 
epidermal carcinoma xenograft tumor mice by intratumoral injection for 3 days. It was shown 
that 17 days after the last day of injection, md11-Pal-MTO/siMCL1 completely suppressed 
tumor growth, while the tumor grew to 5 times and 6 times of their original volume after being 
treated with md11-Pal-MTO/siGL2 and free MTO, respectively.  
Solid lipid nanoparticle (SLN) 
Another class of lipid nanocarrier is the solid lipid nanoparticle (SLN) which is made of lipid 
that remains solid at body temperature. SLN consists of at least two components, the solid lipid 
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and the surfactant. The proposed advantages include physiologically well tolerated ingredients, 
long shelf life, and scalable production and sterilization [121]. SLN is good for delivery of 
hydrophobic drugs (e.g. docetaxel, doxorubicin) with high drug payload, sustained release, and 
excellent antitumor effect [122, 123]. SLN has been used for nucleic acid delivery by using 
cationic surfactant to create a positively charged surface [124]. Yu et al. co-delivered paclitaxel 
and MCL1 siRNA using a cationic SLN, in which cationic lipid 
1,2-dioleoyl-sn-glycero-3-ethylphosphocholine was used as a surfactant for complexation with 
siRNA on surface, while paclitaxel was encapsulated in the hydrophobic core by 
solvent-emulsification method [125]. The author demonstrated in vitro on KB oral carcinoma 
cell line and in vivo on KB xenograft mice model that both agents loaded SLN formulation 
achieves better efficacy than single agent loaded SLNs in terms of cytotoxicity and control of 
tumor volume, respectively. However, this siRNA loading method led to the formation of large 
aggregates and undesirable surface properties. Recently, siRNA was loaded into the core of 
SLN by first complexing siRNA with a cationic polymer which is modified with hydrophobic 
moieties. Lobovkina et al complex siRNA with a cationic lipid 
1,2-dioleoyl-3-trimethylammo-nium-propane (DOTAP), and loaded the complex into tristearin 
solid lipid particle with lecithin and DSPE-PEG as cosurfactant [126]. The SLN is 255 to 615 
nm in size and has sustained in vitro release of 90% siRNA over 10 days. A similar strategy was 
employed by Xue and Wong for the SLN delivery of siRNA [127]. This method can be easily 




2.6.4.2. Polymer  
Polymeric nanoparticle  
Nanoparticles made of biodegradable polymers such as poly(lactic acid) (PLA), 
poly(lactic-co-glycolic acid) (PLGA), poly(ε-caprolactone) (PCL) which have non-toxic 
degradation products have been used for drug and nucleic acid delivery [128]. The NPs are 
usually synthesized by oil in water emulsion and solvent evaporation method with the addition 
of surfactants. The NPs are widely used for the delivery of hydrophobic anticancer agents 
which can be trapped in the polymer matrix and slowly released following polymer degradation 
[129]. Polymeric nanoparticles have been used for co-delivery of siRNA and hydrophobic 
anticancer drugs. Two designs are available in literature. The first design is to entrap the 
hydrophobic drug in the polymer matrix and coat a cationic polymer on the negatively charged 
surface by electrostatic force for the complexation of siRNA. Su et al. loaded paclitaxel into 
PLGA NP through emulsion solvent evaporation, followed by surface coating of cationic 
polyethylenimine (PEI), and subsequent complexation with siRNA against signal transducer 
and activator of transcription-3 (STAT3) (siSTAT3) [130]. Downregulation of STAT3 had 
been shown to increase apoptosis of cancer cells. The author demonstrated on A549 lung 
cancer cells and A549/T12 paclitaxel resistant lung cancer cells that co-delivery of siSTAT3 
and paclitaxel in the NPs resulted in higher cancer cell cytotoxicity than delivery of a single 
agent formulated in NP. However, more than 50% of loaded siRNA was released from the 
surface in the first 3 h in an in vitro release buffer, suggesting a high level of siRNA release in 
the circulation if the nanoparticles are administered intravenously. Another design is to 
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incorporate both the siRNA and the hydrophobic anticancer agent in the polymer matrix by 
double emulsion method. Usually, a cationic polymer is grafted on or physically mixed with the 
matrix forming polymer such as PLA, PLGA, and PCL to improve siRNA loading and to 
reduce size. Zhou et al. encapsulated paclitaxel and Murine Pgp targeted siRNA into 
PLGA/PEI (w/w 300/1) mixed polymer nanoparticles by double emulsion, and demonstrated 
continuous release of 80% of loaded siRNA in 15 days, and 80% of loaded paclitaxel in 30 days 
with less than 20% burst release [131]. When tested on paclitaxel resistant JC tumor mice 
model, NP co-formulation of both agents showed significantly better control of tumor volume 
than NP formulation of only paclitaxel. Zhou et al. conjugated low molecular weight 
poly-L-lysine (PLL) (1000-4000 MW) with PLGA (~0.67 dL/g) (PLGA-PLL) and loaded 
siRNA together with either small molecule hydrophilic drug quinacrine (QC) or hydrophobic 
drug enoxacin (ENX) in the PLGA-PLL nanoparticle by double-emulsion solvent evaporation 
techniques [113]. In vitro release study showed that around 55% of loaded siRNA was 
gradually released from the NP in 168 h. Under the same buffer condition, around 60% of 
loaded QC was released in 168 h; however, around 90% of loaded ENX was released in the first 
24 h.  
Polymeric micelle 
Polymer micelles are made of amphiphilic polymers which can self-assemble in aqueous 
environment to form nanospheres with a core-shell structure. Polymer micelles formed by di- 
or tri- block copolymers are the most widely investigated nanocarrier for co-delivery of siRNA 
and other types of anticancer agents. The copolymers usually contain a cationic portion for 
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complexation with siRNA, a hydrophobic portion for driving the self-assembly and for 
encapsulating drugs, and in some designs a PEG portion to minimize non-specific interaction 
with serum proteins. Wang’s group synthesized a tri-block copolymer poly(ethylene 
glycol)-b-poly(ε-caprolactone)-b-poly(2-aminoethylethylene phosphate) 
(mPEG45-b-PCL80-b-PPEEA) to form micelles with a proposed core-shell structure for the 
co-delivery of paclitaxel and siRNA against polo-like kinase 1 (siPLK1) [132]. PLK1 is a key 
cell cycle regulator which is upregulated in many cancer types. Inhibition of PLK1 was shown 
to cause cell cycle arrest and apoptosis. PLK1 inhibitors were shown to function 
synergistically with microtubule stabilizing agents such as paclitaxel and docetaxel. Although 
release profiles of siPLK1 and paclitaxel were not shown, the micelles formulated with both 
agents was shown to fully suppress tumor growth 32 days post injection; during the same 
period of time, xenograft tumors grew to around three times of their original volume after being 
treated with micelles loaded with single agent. Interestingly, injection of a mixture of single 
agent loaded micelles had almost the same effect as the administration of any one of them at the 
same dosages, suggesting that co-delivery in one nanocarrier is essential to fully realize the 
benefits of synergistic effect of the two agents in vivo. Zheng et al. synthesized poly(ethylene 
glycol)-b-poly-L-lysine-b-poly-L-leucine (PEG1-PLL10-PLLeu40) triblock polypeptide 
copolymer to co-deliver docetaxel and BCL-2 siRNA (siBCL2) for the treatment of cancer 
[133]. BCL-2 is an anti-apoptotic gene which is overexpressed in multiple cancer types. 
Inhibiting BCL-2 has been shown to enhance the efficacy of chemotherapy by promoting 
apoptosis. The self-assembled micelles loaded with both the siBCL2 and docetaxel were 
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around 120 nm with positive surface charge (zeta potential = +20.48 + 1.8 mV). When tested on 
mice bearing MCF7 xenografts through i.v administration, micelles loaded with both agents 
demonstrated significantly better control of tumor volume, compared to a mixture of micelles 
loaded with single agent. Instead of using a PEG containing tri-block copolymer, Cao et al. 
coated folic acid (FA) conjugated anionic PEG-PGA copolymer (FA-PEG-PGA) by 
electrostatic interaction onto the surface of cationic PEI-PCL micelles pre-loaded with 
anticancer drug Dox in the core and siBCL2 on the surface [134]. Down-regulation of BCL-2 
has been reported to sensitive multiple cancer cells to Dox. Coating of FA-PEG-PGA led to an 
increase in size and decrease in zeta potential. When the FA-PEG-PGA carboxyl to PEI-PCL 
amine molar ratio is 1:10, the size and zeta potential of the micelles are around 150 nm and +5 
mV, respectively. The almost neutral surface charge potentially minimizes undesirable 
interaction with serum proteins. The author demonstrated on human Bel-7402 hepatic cancer 
cells that micelles co-loaded with Dox and siBCL2 caused higher level of cell apoptosis than 
micelles co-loaded with Dox and scrambled siRNA. In order to have a better control of siRNA 
release, our group conjugated siPLK1 to vitamin E TPGS via disulfide bond 
(siPLK1-SS-TPGS), the release of which can be triggered by intracellular glutathione (GSH) 
[135]. Micelles were formed with a mixture of TPGS and siPLK1-SS-TPGS and loaded with 
anticancer agent docetaxel (DTX). This system enabled precise control of loading ratio of 
siPLK1 and DTX; and sustained release of around 80% of siPLK1 and 70% of DTX over 200 h 
and 120 h in GSH (10 mM) containing release buffer, respectively. The DTX encapsulated 
TPGS micelles with surface conjugated siPLK1 demonstrated higher cytotoxicity than the 
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DTX encapsulated TPGS micelle without siPLK1 on breast cancer cell lines. Polymer micelles 
formed by other types of block copolymers such as PDMAEMA-PCL-PDMAEMA, 
mPEG-PCL-PDMAEMA, PEG-PEI-PCL, PEG-PCL-PEI, PEG-PCL-PLL, PEG-PCL-spermin, 
mPEG-PLGA-PLL, mPEG-PLA-b-Polyarginine have been synthesized for delivery of siRNA, 
or co-delivery of siRNA and anticancer drugs.  
Cyclodextrin-based polycation (CDP) siRNA delivery system has been shown to be well 
tolerated in animal models and in human at the dosage that can efficiently silence the target 
gene [136]. Cyclodextrin (CD) is a truncated conical structure formed by D-glucopyranose 
units connected through (1-4) linkages. It has a hydrophobic inner cavity and a hydrophilic 
exterior. The hydrophobic inner cavity can form inclusion complexes with variety of 
compounds. Davis group employed inclusion complex pair adamantanes (AD) and β-CD to 
coat AD-PEG and targeting moite AD-transferrin onto the surface of nanocomplex (i.e. 
nanohydrogel) formed by CDP and siRNA [137]. The hydrophobic β-CD inner cavity can also 
be used to adapt AD modified drug to realize CPD mediated co-delivery of siRNA and 
anti-cancer agents. Hu et al. chemically linked low molecular weight branched PEI (600 Da) 
and β-CD to form PEI-CyD for the co-delivery of shRNA against survivin and AD modified 
anticancer drug paclitaxel [138]. Survivin belongs to the inhibitor of apoptosis protein family 
which plays a role in cancer progression, metastasis and therapy resistance. Inhibiting survivin 
is shown to sensitize human tumor to chemical and physical anticancer agents. In this study, 
AD-paclitaxel was first complexed with PEI-CyD to form PC/Ada-PTX (PAP) which was 
amphiphilic and self-assembled in water to form micelles, followed by surface loading of 
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shRNA via electrostatic interaction. The micelles were shown to have a PH dependent and 
sustained in vitro release of paclitaxel over 300 h. It was demonstrated on SKOV-3 xenograft 
tumor model that micelles loaded with both agents had better control of tumor volume than the 
mixture of paclitaxel and micelles loaded with only shRNA.  
Dendrimer 
Dendrimer is nanosized macromolecules with tree-like architecture and narrow size 
polydispersity [139]. The size of dendrimer can be controlled by changing the number of layers 
of branches (i.e. generations) to suite its applications. Dendrimer has mathematically defined 
numbers of terminal (i.e. surface) groups with can be modified for loading of drugs, nucleic 
acids, proteins, PEG, imaging contrast agents and targeting moites. The interior void space can 
be designed to encapsulate agents through host-guest interactions [140]. Dendrmer based 
therapeutics and imaging agents are currently undergoing clinical investigations. Cationic 
poly(amidoamine) (PAMAM), PLL, and PEI dendrimers have been widely investigated for 
nucleic acids delivery with high transfection efficiency. SuperFect, a modified PAMAM 
dendrimer, has been commercialized as in vitro transfection agent for nearly a decade. 
Co-delivery of siRNA and a small molecule anticancer agent has been achieved by loading both 
agents on surface of the dendrimer. Kaneshiro et al. conjugated doxorubicin on the surface of 
PLL dendrimer which had a silsesquioxane cubic core via a biodegradable disulfide spacer, 
followed by complexation with siRNA on the dendrimer surface for the co-delivery of 
doxorubicin and siRNA targeting firefly luciferase [141]. Yu et al. synthesized amphiphilic 
dendrimers by the self-assembly of fan-shaped units containing a long alkyl tail and a low 
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generation PAMAM dendron for the delivery of siRNA [142]. The system demonstrated low 
toxicity and high transfection efficiency on human castration-resistant prostate cancer PC-3 
cells. Other amphiphilic dendrimers consist of C-18 or cholesterol hydrophobic group and low 
generation dentrons have also been synthesized for transfection of siRNA or DNA [143, 144]. 
Although not directly demonstrated in these articles, the hydrophobic core can be used to 
encapsulate small molecule hydrophobic drugs for siRNA based co-delivery. Biswas et al. 
chemically linked generation 4 poly(amidoamine) dendrimer (G(4)-PAMAM) and 
poly(ethylene glycol)-1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (PEG2k-DOPE) to form 
a G(4)-D-PEG2k-DOPE copolymer, which together with PEG5k-DOPE self-assembled into a 50 
nm micelle like structure for the co-delivery of small molecule hydrophobic drug which was 
encapsulated into the hydrophobic core, and siRNA which was loaded on the surface of the 
dendrimer [145]. The mixed micelle system was shown to have CMC value of 50 mM, 42% 
docetaxel encapsulation efficiency, enhanced siRNA serum stability and higher transfection 
efficiency when compared to G(4)-PAMAM dendrimer. 
Nanogel 
Nanogel (i.e. nanohydrogel, hydrogel nanoparticle) is a crosslinked polymeric nanostructure 
with high water content. The water soluble polymer chains can be crosslinked by physical 
means such as electrostatic interaction and hydrophobic interaction; or it can be linked by 
chemical crosslinkers (e.g. glutaraldehyde). Hydrophilic bioactive agents such as small 
molecule hydrophilic drugs, proteins, and nucleic acids can be easily loaded into the 
crosslinked matrix; and the releases are controlled by diffusion, polymer erosion and 
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crosslinker cleavage. As a polyanionic macromolecule, siRNA itself can function as a physical 
crosslinker for cationic polymers to form nanogel by electrostatic interaction. Many current 
nanosized siRNA cationic polymer complex (i.e. polyplex) can be classified as nanogels. 
However, the polyplex formed by simple mixing of siRNA and the polymer in buffer solution 
usually produces unstable nanogels with heterogeneous sizes. Other strategies such as thermal 
gelation, chemical crosslinking, emulsion polymerization, inverse emulsion and chemical 
crosslinking of polymer chains, and particle replication in nonwetting templates (PRINT) have 
been used for entrapment of siRNA. Nanogels have also been used for the delivery of small 
molecule hydrophilic and hydrophobic drugs. However, due to the large number of water 
permeable and interconnected pores, small molecule drugs with water solubility diffused out 
quickly form the gel matrix in aqueous solutions; while small molecule hydrophobic drugs 
were usually loaded in a controlled crystalline form in the gel matrix, which hinders effective 
release. Few nanogel co-delivery systems for siRNA and other therapeutic agents have been 
reported. Wei et al. developed a N-((2-hydroxy-3-trimethylammonium) propyl) chitosan 
chloride (HTCC) nanogel system crosslinked by glutaraldehyde for the co-delivery of 
chemotherapeutic drug paclitaxel (PTX) and siRNA against Telomerase reverse transcriptase 
(siTERT). Telomerase reverse transcriptase (TERT) has been shown to be correlated with 
extended telomere length and uncontrolled cell division. Silencing TERT potentially stops 
uncontrolled cell division, and may function synergistically with current chemotherapy. DTX 
loaded HTCC nanogel was prepared by oil in water in oil (OI/W/OII) double emulsion 
techniques, followed by extrusion through the Shirasu porous-glass membrane (pore size was 
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0.5 μm) under a high pressuere (2.0 MPa), and subsequent washing and collection. DTX was 
loaded into the nanogel core by controlled in-situ crystallization process, and siRNA was 
loaded on the cationic chitosan-based polymer surface by electrostatic interaction, followed by 
coating another layer of HTCC to prevent siRNA from direct exposure to the serum. The 
prepared co-delivery system had size of around 140 nm, narrow size distribution (PDI = 0.047) 
and positively charged surface (zeta potential = +32.16). When demonstrated on xenograft 
LCC lung cancer mice model, daily oral administration of HTCC nanogel formulation of both 
siTERT and DTX achieved significantly better control of tumor volume compared to a mixture 
of HTCC nanogels loaded with single agent at the same dosage, suggesting the benefits of 
co-delivery.  
To resolve the unfavorable release of small molecule anticancer agents; these agents were 
chemically linked to the polymer chain to form a prodrug nanogel, which can be further loaded 
with siRNA for co-delivery. Zhao et al synthesized polyethylene 
glycol-polyethylenimine-tetrachloroplatinum (IV) (PEG-PEI-Pt) prodrug nanogel for the 
co-delivery of the platinum anticancer agent and DNA or siRNA [146]. The formed nanogel 
was around 200 nm with positive zeta potential. PEG-PEI-Pt without DNA or siRNA was 
shown to have 3.3-fold higher cytotoxicity than anticancer drug cisplatin on A549 
drug-resistant human lung adenocarcinoma cells. In addition, the PEG-PEI-Pt micelle was 
shown to have DNA transfection efficiency comparable to PEI 25 kDa. Unfortunately, additive 
or synergistic effect of the two agents co-delivered by this micelle system had not been 
examined. Wrapping nanogel into nanostructures such as liposome or polymersome can create 
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additional spaces for small molecule drug loading. A recent article by Bui et al. demonstrated a 
strategy to encapsulate PEI/siRNA polyplex into a polymersome made of a bi-layer of 
amphiphilic block copolymer hyaluronan-block-poly(γ-benzyl L-glutamate) (HYA-b-PBLG) 
[147]. The formation of the polymersome coating on the PEI/siRNA poyplex was driven by 
changing the amphiphilicity of the HYA-b-PBGL which could be turned off in DMSO and 
turned on in water. In DMSO, HYA-b-PBGL was coated on to the polyplex by charge 
interaction between anionic HYA and cationic nanogel with PBGL facing outward. When the 
solvent was gradually switched to buffer solution (PH 7.4), another layer of HYA-b-PBGL 
coated on to the micelle by PBGL hydrophobic interaction; the bi-layer coating of 
HYA-b-PBGL created a hydrophobic shell, which permit loading of hydrophobic small 
molecules for the co-delivery of siRNA and anticancer drug.  
2.6.4.3 Inorganic nanoparticle 
Silica nanoparticle 
Silica nanoparticle composes of silicon dioxide in amorphous form [148]. Typical mesoporous 
silica nanoparticles (MSN) (i.e. MCM-41, SBA-15) are honeycomb-like porous structure 
which consists of large number of empty channels (mesopores) that can be loaded with 
bioactive agents. MSN can be synthesized by a supramolecular assembly of silica around 
surfactant micelles, followed by removal of template surfactant through calcination or solvent 
extraction. The particle size, shape, and pore size can be fine tuned by adjusting the synthesis 
conditions. MSN is a relatively stable delivery system which has long shelf life and minimal 
premature release; the rate of degradation is related to porosity. The toxicity of MSN is affected 
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by its size, porosity, surface charge, and amount of residue template surfactant and silanol 
groups; and need to be evaluated case by case [149]. MSN has two functional surfaces, the 
internal pore surface and the external particle surface. The two surfaces not only provide large 
surface area for loading but also enable selective modification of the two surfaces with different 
moites. For the co-delivery of siRNA and anticancer agents, a typical design is to load small 
molecule anticancer agents in the modified interior pore, followed by surface modification of 
cationic polymers for complexation with siRNA. Meng et al. modified 50 nm MSN surface 
(both the pore and the outer surface) with phosphonate which allow doxorubicin attachment in 
the pore and subsequent outer surface modification with 1.8 kDa PEI by electrostatic 
interaction for the co-delivery of doxorubicin (Dox) and siRNA that targets the P-glycoprotein 
(P-gp) (siPGP) [150]. The coated PEI was further covalently attached with 5 kDa PEG to 
minimize interaction with serum proteins. In order to find the best combination of Dox and 
siRNA that inhibit multidrug resistance from a panel of multidrug resistance genes in MCF7 
breast cancer cells, a high throughput cytotoxicity assay for MSN/PEI-PEG co-formulation of 
DOX and different siRNAs were carried out in 384-well plates. The selected MSN/PEI-PEG 
formulation of Dox and siPGP exhibited significantly better control of tumor volume, 
compared to MSN/PEI-PEG formulation of only Dox or free Dox on multidrug resistant MCF7 
xenograft mice model. Chen et al. modified MSN surface with 
3-iso-cyanatopropyltriethoxysilane which function for loading Dox in the pores and 
conjugation of cationic generation 2 PAMAM dendrimer (MSN-Dox-G2PAMAM) on the 
particle surface for complexation with siBCL2 for co-delivery [151]. In vitro cytotoxicity 
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experiment showed that the IC50 (the concentration of drug that kills 50% of the cells) of Dox 
that was formulated in the MSN-Dox-G2PAMAM/siBCL2 system was 1/64 of that Dox that 
was formulated in the MSN-DOX-G2PAMAM system; and was 1/132 that of free Dox. 
Taratula et al. loaded Dox or cisplatin (cispt) in the pore of pyridylthiol-terminated MSN, and 
directed conjugated of 5’ thiol-siBCL2 or 5’ thiol-siMRP1 on the MSN exterior surface via 
disulfide bond for suppression of both pump and nonpump resistance mechanisms [152]. The 
MSN formulation of both drug and siRNA showed higher cytotoxicity than MSN formulation 
of only drug on A549 human lung cancer cells. 
Gold nanoparticle 
Gold nanoparticle (AuNP) can be easily synthesized from 5 nm to 250 nm with narrow size 
distribution. The surface of AuNP can be readily modified with moites containing thiols, 
phosphines, and amines. SiRNA can be loaded on to the surface of AuNP by direct conjugation 
via gold-thiol bond or complexation with cationic groups modified AuNP surface though 
electrostatic interactions. By direct conjugation, siRNA has been densely packed on AuNP 
surface which showed greatly enhanced stability, cell uptake and in vitro gene knock down of 
the siRNA [153]. Toxicity of gold nanoparticle largely depends on the size, shape, and surface 
modifications [154]. Short DNA strand loaded 13 nm AuNP exhibit negligible toxicity and 
much lower interferon production, compared to analogous molecular DNA in in vitro studies, 
revealing its potential as a siRNA carrier for siRNA based therapy [155]. Nevertheless, in vivo 
and long term safety of siRNA loaded AuNP is still waiting to be addressed. In addition to 
direct conjugation, cationic polymers such as PLL, PEI, low generation cationic dendrimer, and 
80 
 
chitosan were directly adsorbed or conjugated on AuNP surface, or used as a reductant and 
stabilizer for AnNP synthesis to create a cationic surface for complexation with siRNA 
[156-160]. By the formation of a layer-by-layer construct which contains a charge reversal 
layer on AuNP, sustained and triggered release of siRNA is possible [161]. Since AuNP outer 
surface is the only assessable space for loading, the most straightforward strategy for 
co-delivery is to load both the siRNA and another anticancer agent on the surface. Xiao et al. 
conjugated anticancer drug Dox, cationic polymer polyarginine, and a tumor-targeting ligand 
octreotide (OCT) onto the surface of gold nanorod (AuNR) for the targeted co-delivery of Dox 
and siRNA against achaete-scute complex-like 1 (siASCL1) for the treatment of 
neuroendocrine cancer [162]. ASCL1 was shown to be a positive regulator of the Wnt signaling 
pathway which promote cell proliferation and migration and may play a role in tumor 
development. Down-regulation of ASCL1 potentially slows down tumor growth. Dox was 
conjugated via PH-labile hydrazone linkage which facilitated PH dependent release of drug; 
around 90% of Dox was released at PH 5.3, while only 10% was released at PH 7.4 after 60 h 
incubation in a release buffer. In vitro cytotoxicity assay on human BON GI carcinoid cancer 
cells which overexpressed the OCT receptor showed that Dox and siASCL1 co-loaded AuNR 
demonstrated better efficacy compared to single agent loaded AuNR; while decoration with 
OCT further increased the cytotoxicity due to the enhanced cell uptake and siASCL1 
transfection efficiency. It is worth noting that AuNP and AuNR has versatile optical properties, 
which when being used alone or forming hybrid delivery systems with other type of delivery 
vehicles (i.e. liposome, micelles) enable near-infrared (NIR) light triggered release of the 
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contents [163-166]. Furthermore, AuNR demonstrated NIR light absorption and subsequent 
generation of heat for photothermal therapy; surface functionalization of siRNA which targets 
the resistance mechanism of photothermal therapy has potential to improve the efficacy of 
AuNR based photothermal therapy.  
Calcium phosphate nanoparticle 
SiRNA can be co-precipitated with Ca2
+





appropriate additives to form siRNA encapsulated inorganic nanocarrier [167, 168]. Calcium 
phosphate (CaP) nanoparticles which are 50 nm to several hundred nanometers in size were 
shown to efficiently encapsulate siRNA with the help of di-block copolymer which contained 
PEG and an anionic polymer as a stabilizer, or by reverse-microemulsion method [169, 170]. 
CaP NPs with PEG coating or liposome coating were shown to have high siRNA encapsulation 
efficiency, low intrinsic cytotoxicity, high transfection efficiency (e.g. liposome coated CaP NP 
has higher transfection efficiency than the well established LPD), triggered release of siRNA 
by low PH and intracellular low Ca
2+
 concentration, and theoretically non-toxic degradation 
product [169, 171, 172]. Currently, to the best of my knowledge, CaP co-delivery system has 
not been reported in literature, however, the CaP-polymer or CaP-liposome hybrid delivery 
systems are readily available for co-delivery. Li et al. developed CaP NP core liposome shell 
nanocarrier for the delivery siRNA, which was loaded in the CaP core [170, 173]. This system 
are capable of co-deliver both hydrophobic agent which can be loaded in the lipid bilayer and 
hydrophilic agents which can be loaded in the core together with the siRNA. Min et al. 
synthesized CaP-polymer micelle hybrid nanocarrier by self-assembly of amphiphilic tri-block 
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copolymer poly(ethylene glycol)-b-poly(L-aspartic acid)-b-poly(L-phenylalanine) 
(PEG-PAsp-PPhe), and subsequent condensation of a CaP shell in the PAsp portion by initial 
electrostatic localization of calcium ions around anionic PAsp, followed by the addition of 
phosphate anionic to trigger the growth of CaP shell [174]. Dox was trapped into the PPhe 
hydrophobic core during micelle formation. The Dox release can be triggered in acidic PH (PH 
4.5) and suppressed in neutral PH (PH 7.4). In this design, it is possible to load siRNA during 













Chapter 3. Quantitative control of targeting effect by varying surface 
ligand density 
3.1. Introduction 
Following the discovery of nitrogen mustard in treating non-Hodgkin’s lymphoma in 1942, we 
step into the modern era of chemotherapy [175]. After sixty years of heavy investment and 
arduous research and developmental efforts, a large number of life-saving chemotherapeutic 
drugs are in clinic. Due to the fast elucidation of cellular and molecular biology, development 
of anti-cancer drugs targeting specific pathway becomes possible [176]. However, the process 
is still notorious for being highly costly with low success rate. Nanocarrier encapsulation and 
polymer conjugation give old drugs a new life. It solves the fundamental problems hunting 
chemotherapy for years, such as life-threatening side effects, fast clearance, and drug resistance 
[177].  
Nanocarrier formulation of drugs enhances efficacy and alleviates side effects by targeting 
tumor tissue via enhanced permeability and retention effect [4]. Ligand modification of 
nanocarriers enhances their penetration into cancer cells, which express the corresponding 
receptors [178]. This is extremely beneficial for chemotherapeutic drug loaded nanocarrier, 
because most of the traditional anticancer drugs function either in cytoplasm or in the nuclei.  
It has been widely accepted that properties of the nanocarriers such as size, shape, mechanical 
strength, surface charge, and surface functionalization by targeting ligands are important 
parameters in determining the delivery efficacy [64, 74, 179-181]. As for the investigation on 
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surface functionalization by targeting ligands, attention has been focused on the type of ligands. 
It seems to be little experimental investigation on the density, conformation, and distribution of 
ligands on the nanocarrier’s surface in the literature. Most information on these parameters 
comes from simulation results [73, 74, 181-183]. Recently, two investigations focused on 
quantitative control of targeting effects for the drug delivery system of ligand-conjugated 
nanoparticles (NPs) of biodegradable polymers just appeared, in which two strategies, i.e. the 
pre-conjugation strategy and the post-conjugation strategy, which make the ligand conjugation 
before and after the preparation of the drug-loaded nanoparticles of two copolymers blend 
respectively, were developed with the aim to quantitatively control the targeting effects by 
controlling the surface density of the ligands on the nanoparticles. To make close comparison 
between the two strategies, the same structure of their nanocarrier, i.e. the nanoparticles of the 
PLGA/PLGA-PEG copolymer blend, has been employed, where PEG provides moiety for 
ligand conjugation [184, 185]. In these two articles, precise control of surface ligand density 
has been achieved by controlling the copolymer blend ratio. In this article, we wish to further 
develop the post-conjugation strategy for a new nanocarrier, the PLA-TPGS/TPGS-COOH 
nanoparticles, which are supposed to have better drug delivery effects such as high cellular 
uptake and high cytotoxicity of the encapsulated drug due to the more desired 
hydrophobic-lipophilic balance (HLB) of the novel copolymer PLA-TPGS. We wish such a 
nanocarrier further confirm the advantages of the post-conjugation strategy to better control 
and quantify the density of the ligands on the nanoparticle surface. We also want to develop an 
alternative method to assess the surface ligand density to support the method used in the 
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previous literature. Moreover, we wish to visualize the presence of the ligand on the 
nanoparticles surface, which can be realized by the field emission (FESEM) with 
Herceptin-bound immunogold labeling. 
In the present research, the Poly (lactide)-D-α-tocopheryl polyethylene glycol 1,000 
succinate/carboxyl group terminated TPGS (PLA-TPGS/TPGS-COOH) nanoparticles are 
made up of a physical blend of the two copolymers of PLA-TPGS and TPGS-COOH as matrix 
materials. TPGS-COOH provides carboxyl group for ligand conjugation. The advantage of the 
post-conjugation strategy over the pre-conjugation strategy is that the former can control the 
surface ligand density in two ways: one is to adjust the copolymer blend ratio (i.e, variation of 
surface functional groups) before the nanoparticles formulation, and another is to adjust the 
feeding concentration of the ligand after the nanoparticle formulation. The PLA-TPGS 
copolymer has already been used to produce nanoparticles in our earlier publications, which 
have higher level of drug encapsulation efficiency (EE), cellular adhesion, and more desirable 
release rate than traditionally used PLGA NPs [186]. TPGS is a water soluble derivative of 
vitamin E. It has been used as emulsifier, solubilizer, and bioavailability enhancer for both 
hydrophilic and hydrophobic drugs [187]. It was observed that co-administration of TPGS with 
anticancer drugs could enhance the therapeutic efficacy by inhibiting P-glycoprotein mediated 
multi-drug resistance [188]. In addition, TPGS was demonstrated to have intrinsic toxicity for 
cancer cells, which could synergistically enhance the therapeutic efficacy of drug-loaded TPGS 
micelles [189]. Compared to using TPGS as emulsifier, including it as part of the matrix 
material in the formulation of the PLA-TPGS nanoparticles prevents desorption of TPGS from 
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the particle surface, resulted in improved EE and more desirable drug release rate [190]. 
Furthermore, TPGS also provide moiety for ligand conjugation of ligand such as Herceptin for 
targeted drug delivery.  
In this research, Herceptin is chosen as the targeting ligand to be conjugated to the surface of 
the PLA-TPGS/TPGS-COOH NPs, while docetaxel is encapsulated into the nanocarrier matrix 
as a model anticancer drug. Herceptin-decorated, docetaxel-encapsulated 
PLA-TPGS/TPGS-COOH NPs are designed for the treatment of human epidermal growth 
factor receptor 2 (HER2) positive breast cancers. Breast cancer is the top occurring type of 
cancer among women in many countries with high mortality rate. In all breast cancer patients, 
20% to 30% are diagnosed as HER2 positive. Herceptin is a humanized monoclonal antibody 
which could selectively bind to HER2 [191-194]. Herceptin monotherapy was shown to have a 
nearly equivalent level of response rate as chemotherapy on HER2 positive metastatic breast 
cancer (MBC) [195]. However, patients treated with Herceptin monotherapy alone usually still 
have their disease progression within a year [196]. Docetaxel, a semi-synthetic analog of 
paclitaxel, is a member of the taxane family [197]. Docetaxel monotherapy was shown to be 
superior to other combination regimens as second line treatment of MBC [198]. Combination 
of docetaxel and Herceptin has shown to have higher efficacy than docetaxel or Herceptin 
alone without causing intolerable toxicity in phase II and phase III clinical trials for the 
treatment of HER2 positive MBC [199]. Decorating docetaxel encapsulated nanocarrier with 
Herceptin either by physical adsorption or by chemical conjugation could further enhance the 
benefits of this combination regimen, because of the following reasons. Firstly, Herceptin, 
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functioning as targeting ligand, could enhance cellular internalization of nanocarrier 
formulated docetaxel. In addition, co-localization of the two agents is achieved at all times in 
relatively fixed dosage. Last but not least, all the benefits associated with the use of nanocarrier 
for drug delivery such as long circulation time, high cellular uptake, enhanced tumor tissue 
accumulation, and sustained release of the drug from the nanocarriers apply to the system.  
In the present study, we intend to show that the targeting effect could be quantitatively 
controlled and quantified for an enhanced nanocarriers platform, i.e. PLA-TPGS/TPGS-COOH 
NPs which are developed recently from our laboratory, by using Herceptin and docetaxel as 
model targeting ligand and anticancer drug, respectively. The impact of the surface density of 
Herceptin on cellular uptake and cytotoxicity will also be investigated on breast cancer cell 
lines. The amount of conjugated Herceptin is quantified by the colorimetric Bradford protein 
assay and flow cytometer analysis after fluorescein anti-human antibody labeling.  
3.2. Materials and methods 
3.2.1. Materials 
Herceptin (21 mg/ml, 4.76 ml) was purchased from National Cancer Centre, Singapore.  
Docetaxel (anhydrous, 99.56% purity) was obtained from Shanghai Jinhe Bio-Technology Co. 
Ltd, China. Lactide (3,6-dimethyl-1,4-dioxane-2,5-dione, C6H8O4 ) was purchased from 
Aldrich. Vitamin E TPGS (d-α-tocopheryl polyethylene glycol 1000 succinate, 
C33O5H54(CH2CH2O)23 ) was from Eastman Chemical Company, USA. Succinic anhydride, 
4-(Dimethylamino)pyridine (DMAP), stannous octoate (Sn(OOCC7H15)2 ), acetone, dimethyl 
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sulfoxide(DMSO), coumarin-6, phosphate buffered saline(PBS, pH 7.4), Boric acid, Bradford 
reagent (for 1 - 1,400ug/ml protein), N-(3-Dimethylaminopropyl)-N
’
-ethylcarbodiimide 
hydrochloride (EDC), N-Hydroxysuccinimide (NHS), 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, 
trypsin-ethylenediaminetetraacetic acid (EDTA), Triethylamine (TEA), α-tocopheryl- 
succinate (TOC), Trifluoroacetic acidacid (TFA) and 4
’
,6-diamidino-2-phenylindole (DAPI) 
were purchased from Sigma-Aldrich (St. Louise, MO, USA). N-Boc-ethylenediamine was 
purchased from Alfa Aesar (Ward Hill, MA, USA). Ethanol was obtained from VWR 
Singapore Pte Ltd. Tween-80 was from ICN Biomedicals, Inc. (OH, USA). Triton X-100 was 
from USB Corporation (OH, USA). Fetal bovine serum (FBS) and penicillin-streptomycin 
solution were provided by Invitrogen. Dulbecco’s Modified Eagle’s Medium (DMEM) was 
purchased from Thermo Scientific Hyclone (South Logan, USA). SK-BR-3 and MCF7 breast 
cancer cells were obtained from American Type Culture Collection (ATCC). Water was treated 
with the Milli-Q Plus System (Millipore Corporation, Bedford, USA). Fluorescein anti-human 
IgG was purchased from Vector Laboratories (Burlingame, CA, USA). Hydrogen 
tetrachloroaurote (III) trihydrate and trisodium citrate dihydrate were purchased from Alpha 
Aesar (Ward Hill, MA, USA).  
3.2.2. Synthesis of PLA-TPGS and TPGS-COOH copolymers 
PLA-TPGS was synthesized via ring-opening polymerization as previously reported [190]. 
Briefly, weighted amount of lactide, TPGS and 5% of stannous octoate (in distilled toluene) 
was added to a 250 ml round bottom flask. The mixture was heated gradually from room 
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temperature to 145 
o
C in an oil bath under reduced pressure for 12 h. After the reaction, the 
mixture was dissolved in 50 ml DCM, and precipitated in 250 ml cold methanol. The 
precipitant was collected by filtration and dried in vacuum oven for 2 days.  
TPGS-COOH was activated by succinic anhydride through ring-opening reaction in the 
presence of DMAP as described previously [198].  In brief, TPGS (0.77 g, 0.5 mM), succinic 
anhydride (0.10 g, 1 mM) and DMAP (0.12 g, 1 mM) were mixed and heated at 100 
o
C under 
nitrogen atmosphere for 24 h. The mixture was cooled to room temperature, dissolved in 5.0 ml 
cold DCM, filtered to remove excessive succinic anhydride and then precipitated in 100 ml 
diethyl ether at -10 
o
C overnight. The white precipitant was filtered and dried in vacuum to 
obtain TPGS succinate reagent. 
3.2.3. Preparation of nanoparticles 
The nanoparticles were prepared by the nanoprecipitation method as mentioned in our earlier 
publication [200]. Briefly, weighted amount of PLA-TPGS, TPGS-COOH and 5 wt% 
docetaxel were dissolved in 10 ml acetone and added dropwisely into 20 ml ultrapure water 
under vigorous stirring at 400 rpm. After 4 h, the suspension was washed and centrifuged twice 
at 13,000 rpm for 15 min each time at 4
o
C. The same procedure was used for the synthesis of 
fluorescent coumarin-6 loaded PLA-TPGS nanoparticles, except that docetaxel was replaced 
by 0.05 wt% coumatin-6. 
It has been observed that increase of the TPGS-COOH copolymer component weightage in the 
PLA-TPGS/TPGS-COOH copolymer blend in the nanoparticle matrix will result in higher 
drug encapsulation efficiency and thus higher drug load, which is the weightage of the drug in 
90 
 
polymeric nanoparticles. However, in order to quantitatively investigate the targeting effect of 
the various nanoparticle formulations in the in vitro cell line experiments, it is favorable to keep 
the drug load constant among all formulations. Therefore, a three component system 
PLA-TPGS/(TPGS-COOH+TPGS) is synthesized to adjust the amount of the TPGS-COOH 
while keep the weightage of the (TPGS-COOH+TPGS) mixture constant. The synthesis 
procedure of the nanoparticles is the same as that of the PLA-TPGS/TPGS-COOH 
nanoparticles, in which, for this research, the drug load is kept 5% and the (TPG-COOH+TPGS) 
was kept at 50 wt%, while the weight ratio of TPGS-COOH in the (TPG-COOH+TPGS) 
mixture may vary from 10% to 50%.  
3.2.4. Herceptin conjugation 
Herceptin was conjugated to the NPs by previously established method [201]. Briefly, before 
conjugation, the carboxyl group on particle surface (from TPGS-COOH) was first converted to 
primary amine group by conjugating TPGS-COOH and N-Boc-ethylenediamine by 
carbodiimide chemistry with the assistance of EDC and NHS in a buffer solution (PH 8.4). 
After that, the protective Boc group was removed by incubating conjugated product with 0.1% 
v/v TFA. Then, heceptin carboxyl group was conjugated to the nanoparticle primary amine 
group by carbodiimide chemistry with the assistance of EDC and NHS in a buffer solution (PH 
9.2).  
3.2.5. Particle size  
Size and size distribution of nanoparticle were measured by the dynamic light scattering (DLS) 
(90 plus particle size analyzer, Brookhaven Instruction Corporation, TX, USA). The samples 
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were prepared by diluting the nanoparticle suspension with deionised water to a count rate of 
300-500 kcps and sonicated for 5 min before measurement.  
3.2.6. Surface charge 
Zeta potentials of the nanoparticles were measured by Doppler anemometry (zeta plus analyzer, 
Brookhaven Corporation, USA). Samples were prepared by diluting the nanoparticle 
suspension until slightly opaque in a PDMS cuvette. The data was obtained with the average of 
five measurements. 
3.2.7. Surface morphology 
Nanoparticle surface morphology was imaged by the field emission scanning electron 
microscopy (FESEM, JSM-6700F, JEOL, Japan) at an accelerating voltage of 10kV. Before 
loading to the instrument chamber, samples were coated with platinum by JFC-1300 platinum 
coater (JEOL, Tokyo, Japan) for 30 s at 30 mA.  
3.2.8. Surface chemistry 
Surface chemistry of nanoparticles was analyzed by X-ray photoelectron spectroscopy (XPS, 
Kratos Ultra DLD, Shimadzu, Japan) under fixed transmission mode with pass energy of 80 
mV and the binding energy ranged from 0 to 1,100 eV. 
3.2.9. Surface Herceptin visualization 
Immunogold were synthesized according previously published method [202]. The synthesized 
Herceptin conjugated PLA-TPGS/TPGS-COOH (50% TPGS-COOH) was blocked with 1% 
BSA for 1 h, and then labeled with immunogold in 1x PBS overnight. After labeling, the 
92 
 
immunogold labeled nanoparticles were imaged using field emission transmission electron 
microscope (FETEM, JEM-2200FS, JEOL, Japan).  
3.2.10. Drug load 
The amount of docetaxel loaded in the nanoparticle was determined by high performance liquid 
chromatography (HPLC, Agilent LC1100, Agilent, Tokyo, Japan) with absorption peak at 230 
nm. A reverse-phase column (Eclipse XDB-C18, 4.6x250 mm, 5 µm) was used. Briefly, 3 mg 
of freeze-dried nanoparticles were dissolved in 1 ml DCM, followed by overnight evaporation 
of DCM. The resulting sample was reconstituted in 1 ml mobile phase consisting of acetonitrile 
and water (50:50 v/v) under ultrasonication. After centrifugation at 10,000 for 10 min, 
supernatant of the suspension was collected for HPLC analysis. Flow rate was set to be 1.0 
ml/min. 
For fluorescence encapsulated nanoparticles, the encapsulation efficiency was determined with 
the same method. Mobile phase used was acetonitrile/water (60:40 v/v). Flow rate was set to be 
1.3 ml/min and the excitation and emission wavelength were set at 462 nm and 502 nm. 
3.2.11. Determination of Herceptin surface density 
3.2.11.1. Bradford protein assay 
Bradford assay was used to quantify the amount of conjugated Herceptin by measuring the free 
Herceptin in the supernatant after each conjugation reaction. The amount of conjugated 
Herceptin was deduced by subtracting the amount of free Herceptin from the amount of added 
Herceptin. Standard protocol of Bradford assay was used. Briefly, 50 µl of Herceptin solution 
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was mixed with 1.5 ml Bradford reagent and incubated for 15min before measuring absorption 
at 590 nm using a UV-Vis spectrophotometer (UV-1601, Shimadzu, Japan). 
3.2.11.2. Fluorescent staining and flow cytometer analysis 
Designated amount of Herceptin conjugated NPs were blocked in 1% (w/v) BSA for 1h. The 
NPs were then resuspended in sodium borate buffer (PH 9) and stained with excess amount of 
FITC conjugated anti-human IgG antibody in 4 
o
C overnight. The stained NPs were then 
washed twice with 1x PBS and resuspended at a concentration of 10
8
 NPs/ml for flow 
cytometer (Dako Cytomation Cyan LX, Blur Lion Biotech, Snoqualmie, WA) analysis. The 
nanoparticle concentration was determined by nanosight nanoparticle tracking analysis system 
(Nanosight Ltd, Whiltshire, UK). Summit 4.3 software was used to analyze the measurement 
results.   
3.2.12. Cell culture 
SK-BR-3 and MCF7 breast cancer cells were cultured using Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% FBS and 1% penicillin-streptomycin solution in 25 
ml cell culture flask. Cells were cultivated in an incubator at 37 
o
C with 5% carbon dioxide.  
3.2.13. Cellular uptake study of the HER2 conjugated NPs 
3.2.13.1. Qualitative study: confocal microscopy 
After reaching confluence, cells were detached, counted, and seeded in a 4-well coverglass 
chamber (LAB-TEK, Nagle Nunc, IL, USA) overnight. Then, the medium was replaced by NP 
suspension (NPs suspended in cell culture medium) at concentration of 0.125 mg/ml and 
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incubated for 2 h. The cells were washed twice with pre-warmed 1x PBS and fixed with 70% 
ethanol for 20 min. After that, the cells were washed twice with PBS and then the nuclei were 
counterstained by PI for 45 min. The cells were washed again twice by 1x PBS and immersed in 
1x PBS for confocal microscopic imaging.  
3.2.13.2. Quantitative study: Microplate reader 
After reaching confluence, cells were detached, counted, and seeded in 96-well black plate 
(Costar, IL, USA) at 2x10
5
 cells/ml concentration. After 24 h incubation, medium was replaced 
by coumarin-6 loaded NP suspensions with NP concentration of 0.125mg/ml. After 2 h 
incubation, the NP suspension was removed. Cells were washed twice with 1x PBS, and 
immersed in 50 µl of 0.5% Triton X-100 in 0.2 N NaOH solutions. After 15 min incubation 
under gentle shaking, the fluorescent intensities were measured with a microplate reader at 
excitation wavelength of 430 nm, and emission wavelength of 485 nm.  
3.2.14. In vitro cytotoxicity 
SK-BR-3 cells were seeded in 96-well transparent plates (Costar, IL, USA) at 5x10
3
 cells/well 
(0.1ml) and after 12 h, the medium was replaced by NP suspensions with designated 
concentrations for 24 h. The NPs were sterilized with UV irradiation overnight before the 






3.3. Results and discussion 
3.3.1. Characterization of PLA-TPGS/TPGS-COOH NPs before and after Herceptin 
conjugation  
3.3.1.1. Size and size distribution 
The DLS measurement shows that the sizes of the NPs synthesized by the nanoprecipitation 
method were around 160 nm. It has been reported that the size of the nanoparticle drug carrier 
should be bigger than 10 nm to escape the first-pass elimination by the kidney, and has to be 
smaller than 400 nm to be able to enter tumor by penetrating the leaky vasculature [4, 203]. 
Hence, the PLA-TPGS/TPGS-COOH NPs and the PLA-TPGS/(TPGS-COOH+TPGS) NPs 
synthesized in this research are in the effective range for the intended application. The 
polydispersity (PDI) of NPs is smaller than 0.2, indicating narrow size distribution.  
When NPs were conjugated with different amount of Herceptin due to variation in the 
Herceptin feeding concentration, the diameter of the conjugated NPs are around 190 nm, and no 
obvious differences could be found among them (Table 3.1). However, compared to 
unconjugated NPs (NPB), Herceptin conjugated NPs (NPH) demonstrate ~30 nm increases in 
diameter. Variation in weight percentage of TPGS-COOH leads to less than 10 nm differences 
in NPB diameter, the only exception is when no TPGS-COOH was added to polymer blend, for 
which the diameter of the NPB is 20 nm smaller than the average NPB diameter of the rest. 
After being conjugated with the excess amount of Herceptin, the size of the NPHs with 
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different TPGS-COOH percentage increases by 30-40 nm, which is consistent with the finding 
of the first control method.  
3.3.1.2. Surface charge  
ζ-potential is a widely accepted parameter to represent the surface charge of the NPs [128]. NP 
surface charge influences on both its colloidal stability in suspension, and its interaction with 
cells. For NPBs, the ζ-potentials range from -20 mV to -30 mV.  They are considered to be 
stable in aqueous environment without flocculation [204]. For NPBs, the absolute value of 
ζ-potential has a positive correlation with the percentage of TPGS-COOH in the polymer blend. 
This is due to the negative charge of carboxyl groups on NP surfaces in ultrapure water pH (PH 
5.5). After Herceptin conjugation, the absolute values of ζ-potential decrease in general. Higher 
surface Herceptin content correlates with lower absolute value of ζ-potential. Both phenomena 
attribute to the overall positive charge of Herceptin (pI=9.2) in ultrapure water [205].  
 
Table 3.1. Particle size, size distribution, zeta potential and drug load of the 
PLA-TPGS/TPGS-COOH blend nanoparticles with various feeding Herceptin concentration in 








0 157.30 + 0.61 0.088 + 0.008 -36.6+9.06 3.85 
2 194.07 + 4.85 0.196 + 0.118 -31.1+4.47 3.53 
4 193.70 + 2.95 0.274 + 0.016 -33.3+9.44 3.22 
6 188.73 + 4.02 0.161 + 0.056 -26.1+4.43 3.70 
8 189.40 + 0.69 0.100 + 0.014 -25.0+4.38 3.58 




Table 3.2. Particle size, size distribution, zeta potential and drug load of the 
PLA-TPGS/TPGS-COOH blend nanoparticles with various TPGS-COOH blending ratio 
before and after Herceptin conjugation. Data represent mean + SE, n=3.  
Before Herceptin conjugation 
Ratio of 
TPGS-COOH in 
the blend (% 
w/w) 




0 158.43 + 1.69 0.085 + 0.005 -21.9 + 12.3 5.05 
10 182.20 + 2.72 0.207 + 0.037 -23.8 + 12.1 4.96 
20 182.93 + 3.80 0.181 + 0.039 -25.1 + 11.6 6.00 
30 172.73 + 2.54 0.155 + 0.068 -26.4 + 13.8 5.76 
40 176.93 + 2.37 0.172 + 0.053 -29.0 + 13.3 5.59 
50 191.47 + 9.33 0.205 + 0.068 -30.8 + 11.1 5.15 
After Herceptin conjugation 
Ratio of 
TPGS-COOH in 
the blend (% 
w/w) 




0 196.20 + 0.05 0.132 + 0.054 -21.8 + 14.4 4.21 
10 204.00 + 0.01 0.187 + 0.011 -22.9 + 10.1 4.37 
20 216.93 + 0.06 0.156 + 0.057 -18.2 + 11.6 5.67 
30 222.07 + 0.09 0.180 + 0.087 -21.8 + 10.7 5.51 
40 203.30 + 0.11 0.204 + 0.112 -24.8 + 11.5 5.26 
50 239.97 + 0.03 0.106 + 0.026 -25.9 + 13.3 4.97 
3.3.1.3. Surface morphology 
Surface morphology was examined by the field-emission scanning electron microscope 
(FESEM). NPHs with 20% TPGS-COOH and excess Herceptin feeding concentration are 
shown in Fig. 3.1 as representative. It is shown from the image that the NPs are generally 
spherical in shape. The size and PDI directly measured from this figure are in good agreement 
with the DLS measurements. It could be seen from the image that after conjugation, the NPs are 
more aggregated and have rougher surfaces. This phenomenon has been observed in the 




Fig. 3.1. Representative field-emission scanning electron microscopy (FESEM) images of 
NPB20 (A), NPH20 (B). 
 
3.3.1.4. Drug load 
The drug load is defined as the weight percentage of the drug in the drug-loaded NPs. The drug 
load of the various docetaxel-loaded PLA-TPGS nanoparticle was determined and the results 
were listed in Table 3.1 and Table 3.2. In Table 3.1, it could be found that before conjugation (0 
feeding concentration of Herceptin), the drug load is 3.85% w/w, and after conjugation, the 
drug loads are around 3.5% w/w. The slight drug loss is due to the release of docetaxel from the 
NPs in the conjugation process, during which repeated ultrasonication and prolonged stirring 
were applied. The same phenomenon occurred for the NPs synthesized with the second control 
method (Table 3.2). It could be observed that in Table 3.1, the drug load ranges from 3.22 to 
3.85% w/w; while in Table 3.2, the drug load ranges from 4.95 to 6.00% w/w. It could be 
explained by the following reason. During the study, a positive correlation between the 
percentage of TPGS and the drug load was observed. The ability of TPGS to increase the 
encapsulation efficiency (the ratio between the amount of the encapsulated drug to the amount 
of drug added in the preparation process) has been reported previously [206]. In the variation of 
Herceptin feeding concentration study, the NPs were made up of the PLA-TPGS/TPGS-COOH 
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copolymer blend with 20% w/w TPGS-COOH, while in the variation of polymer ratio study, 
the NPs were made up of the PLA-TPGS/TPGS/(TPGS-COOH+TPGS) blend with 50% w/w 
of the (TPGS-COOH+TPGS) mixture in which the TPGS-COOH was varied from 0 – 50% 
(TPGS was thus varied from 50 -0% accordingly such that the drug load can be kept at 5%). 
3.3.1.5. Surface chemistry 
Surface chemistry of the docetaxel-loaded PLA-TPGS/TPGS-COOH NPs before and after 
Herceptin conjugation was examined using the X-ray photoelectron spectroscopy (XPS). The 
results were shown in Fig. 3.2, where the lower curve represents the NPs before Herceptin 
conjugation. By removing Boc to expose the primary amine group; the upper curve represents 
the Herceptin conjugated NP. NPHs with 20% TPGS-COOH and excess Herceptin feeding 
concentration are shown as representative. The inset highlighted the signal at the position 
corresponding to the binding energy of N 1s. Nitrogen can only from either docetaxel or 
Herceptin. The N 1s signal is undetectable before conjugation due to the small amount of N 
from -NH2 on the surface. There is no detectable level of docetaxel on particle surface either, 
indicating that drugs are encapsulated inside the NPs. Hence, after conjugation, the appearance 




Fig. 3.2. Representative X-ray photoelectron spectroscopy (XPS) spectrum of widescan 
spectrum and N 1s peaks (the inset) from the NPB20 (lower curve), and NPH20 (upper 
curve). 
 
3.3.1.6. Surface Herceptin visualization 
Herceptin conjugated on the NP surface, which is labeled with the fluorescein anti-human IgG 
decorated 16 nm gold nanoparticles, was visualized by the field emission transmission electron 
microscope (FETEM). The images obtained were shown in Fig. 3.3. The black spots on the 
nanoparticle surfaces indicate the presence of Herceptin on NPH surfaces.  
 





3.3.2. Quantification of surface antibody density 
3.3.2.1. Bradford assay 
The surface density of the targeting ligand has been shown to have profound influence on the 
therapeutic efficacy of the drug loaded NPs in vitro and in vivo [184, 185]. In the literature the 
surface density of the targeting ligand could be adjusted in two ways either by the 
pre-conjugation strategy, in which the ligand conjugation was made before the formulation of 
the copolymer blend nanoparticles [14], or by the post-conjugation strategy, in which the ligand 
conjugation was made after the formulation of the copolymer blend nanoparticles [184, 185]. In 
this study, when antibody is used at the targeting ligand, the pre-conjugation strategy is not 
practical since the antibody may lose its activity in the nanoparticle formulation process. 
Therefore, we adopted the post-conjugation strategy. By using Bradford protein assay, the 
correlation between the amount of the conjugated Herceptin on the NP surface and the 
weightage of the TPGS-COOH component in the TPGS-COOH/TPGS-COOH or the 
TPGS-COOH/(TPGS-COOH+TPGS) blend matrix was investigated first. The results were 
shown in Fig. 3.4(A), in which a series of the PLA-TPGS/TPGS-COOH NPs of 0, 10, 20, 30, 
40 and 50 wt% TPGS-COOH were prepared and then conjugated with Herceptin of excess 
supply (0.1 mg/ml). The amount of the Herceptin conjugated on the NP surface was measured 
to be 0.047, 0.060, 0.075, 0.095, 0.121, and 0.157 mg per mg of the NPs. The non-zero 
Herceptin conjugation for the 0% TPGS-COOH formulation is due to non-specific binding, 
which has been minimized by adjusting the pH. A positive correlation could be observed 
between the amount of conjugated Herceptin and the weightage of the TPGS-COOH 
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component in the polymer blend. Then, 20% TPGS-COOH was chosen as a prototype 
formulation to examine the correlation between the amount of the conjugated Herceptin and the 
Herceptin feeding concentration used in the Herceptin conjugation process. The results were 
shown in Fig. 4(B). The amount of the conjugated Herceptin was found to be 0, 0.009, 0.016, 
0.026, 0.035, and 0.047 mg per mg of NPs for 0, 0.02, 0.04, 0.06, 0.08, and 0.1 mg/ml 
Herceptin feeding concentrations, respectively. The linear fit for these data (R
2
 = 0.9911) 
shows that the amount of the conjugated Herceptin on the NP surface, and accordingly the drug 
targeting effect, could be precisely controlled this way. The two graphs in Fig. 3.3 prove that 
the amount of the conjugated Herceptin on the NP surface could be precisely controlled by 
using these two methods. Furthermore, if we compare the two graphs, it is not difficult to find 
that Fig. 3.3(A) reveals the saturating amount of Herceptin, while Fig. 3.3(B) is the fine 
adjustment of the conjugated amount by varying Herceptin feeding concentration within this 
saturating amount. Therefore, a coarse adjustment could be made by choosing the appropriate 
NP composition, i.e. the copolymer blend ratio, and a fine adjustment could be made by 
changing the antibody feeding concentration in the Herceptin conjugation process. By doing 





Fig. 3.4. Control of the amount of Herceptin conjugated on PLA-TPGS/TPGS-COOH 
nanoparticles by varying the feeding Herceptin concentration (A), and by varying the blending 
ratio of functional group containing TPGS-COOH (B). 
 
3.3.2.2. Fluorescent labeling and flow cytometer analysis 
Surface Herceptin content of NPH with 0, 10, 20, and 40 wt% TPGS-COOH and conjugated 
with Herceptin of excess supply (NPH0, NPH10, NPH20, and NPH40) were labeled with 
fluorescein anti-human IgG and quantified by flow cytometer. The flow cytometer histograms 
in Fig. 3.5 show the fluorescent intensity profile of the fluorescein anti-human IgG stained 
NPHs. The x axis represents logarithm of FITC intensity, while y axis represents nanoparticle 
counts. With an increase of the TPGS-COOH blending ratio, the peak of the fluorescent 
intensity increases, corresponding to an increase in the amount of the Herceptin on the NP 
surface. The mean logarithm of intensity values are 38.50, 491.56, 1341.33, 2345.27 for NPH0, 
NPH10, NPH20, NPH40, respectively. The trend is in good agreement with that observed in the 
Bradford assay analysis. In addition, this quantification method could provide information of 




Fig. 3.5. Herceptin on PLA-TPGS/TPGS-COOH nanoparticles were labeled with fluorescein 
anti-human IgG and analyzed by flow cytometer. Flow cytometer histogram represents 
logarithm of fluorescent intensity in x axis and cell counts in y axis of labeled NPH0 (A), 
NPH10 (B), NPH20 (C), and NPH40 (D). 
 
3.3.3. Cellular uptake: quantitative study 
The cellular uptake studies are aimed at revealing how the surface density of the targeting 
ligand Herceptin could affect the cellular internalization of the NPs in a designated period, 
which is investigated quantitatively by measuring the percentage of the internalized coumarin-6 
loaded PLA-TPGS/TPGS-COOH NPs in the SK-BR-3 cells, which are of high HER2 
overexpression, and the MCF7 cells, which are of moderate HER2 over expression. Fig. 3.6 
shows the results obtained after 2 hour culture, from which a positive correlation between the 
surface density of Herceptin and the cellular uptake could be observed in the SK-BR-3 cells, 




3.3.4. Cellular uptake: confocal microscopy study 
Confocal laser scanning microscopy (CLSM) was employed in this research to visualize the 
cellular uptake of the coumarin-6 loaded PLA-TPGS/TPGS-COOH NPs with (NPH) or 
without (NPB) Herceptin conjugation NPB and NPH by the MCF7 and SK-BR-3 cells after 2 h 
incubation. The images obtained are listed in Fig. 3.7, in which Row A and B show the images 
for the MCF7 cells incubated with coumarin-6 loaded NPB and NPH, respectively. Row C and 
D show the image for the SK-BR-3 cells incubated with coumarin-6 loaded NPB and NPH, 
respectively. Column 1 demonstrates the images obtained from FITC channel which represents 
coumarin-6 loaded nanoparticles; Columns 2 demonstrates the images obtained from the 
propidium iodide (PI) channel, which shows the PI stained nuclei; and Column 3 demonstrates 
the merged images of the two channels. It can be seen from Column 3 that the nuclei stained by 
PI are circumvented by green fluorescence which represents the coumarin-6 loaded NPs 
internalized in the cytoplasm. In addition, it can be observed that the green fluorescence in Row 
D is much brighter than that in Rows A, B, and C. Since the coumarin-6 contents inside the NPs 
are the same among all formulations and the pictures are taken under the same exciting laser 
intensity from the same confocal microscope, the observation indicates that Herceptin 
conjugation does promote the entry of the NPs into the HER2 overexpressed cells by 
receptor-mediated endocytosis [207]. This observation visually confirms the findings in the 




Fig. 3.6. Cellular uptake efficiency of the coumarin-6 loaded 
PLA-TPGS/(TPGS-COOH+TPGS) nanoparticles on MCF7 and SK-BR-3 cells, with variation 
in Herceptin feeding concentration (A), and with variation of weight percentage of 




Fig. 3.7. Representative confocal laser scanning microscopy (CLSM) images show the cellular 
uptake of the fluorescent coumarin-6 loaded nanoparticles (2 h incubation at 0.125 mg/ml 
concentration). Column 1: FITC channels showing the green fluorescence from coumarin-6 
loaded nanoparticles in cytoplasm. Column 2: PI channels showing the red fluorescence from 
propidium iodide stained nuclei. Column 3: Merged channels of FITC and PI channels. Row A 
and B: MCF7 cells were used. Row C and D: SK-BR-3 cells were used. In row A and C, NPBs 
were incubated while in row B and D, NPHs were incubated. 
 
3.3.5. In vitro cytotoxicity 
Cytotoxicity of the various drug formulations with the cancer cells demonstrates their 
therapeutic effects in vitro. The cytotoxicity of the various NP formulations on the SK-BR-3 
cells after 24 h incubation was accessed and listed in Fig. 3.8, in which the cell viability after 24 
h treatment is plotted against the drug concentration in the various NPs formulations, The 
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PLA-TPGS/TPGS-COOH NPs and PLA-TPGS/(TPGS-COOH+TPGS) NPs with the various 
surface density of Herceptin, which was adjusted by variation of either the Herceptin feeding 
concentration in the conjugation process (Fig. 3.8(A)), or the TPGS-COOH weightage in the 
copolymer blend matrix (Fig. 3.8(B)). It could be observed from the figure that when the drug 
concentration is fixed, the cell viability after 24 h treatment has a negative correlation with 
surface density of Herceptin. The decrease in the cell viability following the increase in surface 
density of Herceptin could attribute to enhanced cellular uptake (Fig. 3.6) as well as the 
increased intrinsic toxicity of Herceptin. In addition, all formulations show drug concentration 
dependent cytotoxicity. The calculated IC50 of 24 h incubation time is shown in Table 3, which 
is defined as the drug concentration needed to kill 50% of cells in a designated time period. The 
IC50 values further illustrate the correlation between the surface density of Herceptin and the 




Fig. 3.8. Cell viability of SK-BR-3 cells after 24 h incubation with PLA-TPGS/TPGS-COOH 
nanoparticles at different drug concentration. The effect of variation in Herceptin feeding 
concentration (A), and variation in weight percentage of TPGS-COOH in polymer blend (B) 
are shown in the figure. Data shown were taken average from six repeats. 
 
Table 3.3. IC50 (μg/ml) values of SK-BR-3 cells treated with various formulations of docetaxel 
after 24 h incubation.  
Variation of Herceptin feeding concentration 
Feeding concentration 
of Herceptin (mg/ml) 




5.09 2.57 1.69 0.94 0.55 0.50 
Variation of TPGS-COOH ratio in polymer blend 
TPGS-COOH in 
polymer blend (% w/w) 








3.4. Conclusion  
A drug delivery system made of PLA-TPGS and TPGS-COOH copolymer blend is developed 
for targeted delivery of docetaxel to the HER2 positive breast cancer cells with an aim to 
quantitatively control the targeting effects by two ways: one is to adjust the PLA-TPGS/ 
TPGS-COOH blend ratio, which thus determine the surface density of the conjugated 
Herceptin  via controlling the surface density of TPGS which provides the conjugation moiety 
on the NP surface, and another is to adjust the feeding concentration of Herceptin in the 
conjugation process, which controls the amount of Herceptin available for surface conjugation. 
We demonstrated that by these two simple ways, the targeting effect of the ligand-conjugated, 
drug-loaded nanoparticles of the copolymer blend can be precisely controlled. The strategy 
developed in this research can be called a copolymer technology for quantitative control of the 
targeting effects of the drug formulated in the nanoparticles of a copolymer blend, in which one 
of the component copolymer should provide the moiety for surface conjugation of the ligand 
[40], which will have wide applications in clinics for controlled and targeted delivery of 
diagnostic, therapeutic and reporting agents by various nanocarriers such as micelles, 






Chapter 4. Quantitative control of targeting effect by variation in 
tethering PEG chain length 
4.1. Introduction 
Nanocarrier formulations of anticancer agents alleviate side effects by targeting tumor via 
enhanced permeability and retention effect [177]. Ligand mediated nanomedicine improves the 
efficacy further by incorporating ligands to the nanocarriers. The ligands assist the nanocarriers 
in penetrating into cancer cells which overexpress the corresponding receptors [178]. The 
benefits of nanocarrier could be maximized through rational design and optimization. The 
physiochemical characteristics which were shown to affect the efficacy of nanocarrier 
formulation of anticancer agents include size, surface charge, shape and mechanical strength, 
ligand type, ligand density, and the tethering chain length.  In many designs, PEG is the 
tethering chain which harbors the functional group for ligand conjugation. 
Poly (lactide)-D-α-tocopheryl polyethylene glycol 1,000 succinate (PLA-TPGS) has been 
proven to be a suitable matrix material, which has been shown to have higher level of drug 
encapsulation efficiency (EE) and cellular adhesion than traditionally used poly (d, 
l-lactide-co-glycolide) PLGA copolymer [208]. D-α-tocopheryl polyethylene glycol succinate 
(TPGS) is a water soluble derivative of vitamine E. Its ampiphilicity enables its usage as 
emulsifier, solubilizer, and bioavailability enhancer for both hydrophobic drugs and colloidal 
nanocarriers [50]. In addition, it was found that co-administration of TPGS with anticancer 
drugs could enhance their efficacy by inhibiting P-glycoprotein mediated multi-drug resistance 
[188]. Furthermore, TPGS was demonstrated to have intrinsic toxicity for cancer cells, which 
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could synergistically enhance the therapeutic efficacy of drug that was encapsulated in the 
TPGS micelles [189]. Compared with TPGS emulsified PLGA NP, including TPGS as part of 
the matrix material in the form of PLA-TPGS prevents desorption of TPGS from the particle 
surface, generating particles with improved EE and more desirable release rate [190]. 
Furthermore, TPGS with functional groups could also be easily synthesized to provide 
functional groups for conjugation of targeting ligands. It has been approved feasible to blend 
carboxyl group terminated TPGS (TPGS-COOH) with PLA-TPGS to form carboxyl groups 
functionalized NPs with satisfactory properties [201]. Therefore, in this paper, PLA-TPGS and 
TPGS-COOH was mixed by physical blending for the conjugation of Herceptin. 
Herceptin (trastuzumab) is a humanized monoclonal antibody, which has been approved by 
FDA as the first line treatment of human epidermal growth factor receptor type 2 (HER2) 
positive breast cancer [195]. The potential antitumor mechanisms of action include activation 
of antibody-dependent cellular toxicity, inhibition of extraxellular domain cleavage, abrogation 
of intracellular signalling, reduction of angiogenesis, and decrease DNA repair [209]. However, 
patients treated with Herceptin monotherapy usually have disease progresses within one year 
[210]. Combination of Herceptin and other traditional cytotoxic drugs such as paclitaxel 
demonstrated synergistic effect and has been used clinically as first-line treatment for women 
with HER2 positive metastatic breast cancer (MBC) [210]. Docetaxel, a semisynthetic analog 
of paclitaxel, demonstrates superior efficacy in terms of overall survival and median time to 
regression than paclitaxel in a phase III clinical trial for the treatment of MBC [211]. Its 
combination with Herceptin showed significant benefits than docetaxel alone in phase II 
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clinical trials [212]. The benefits of combining docetaxel with Herceptin could be maximized 
by modifying docetaxel encapsulated nanoparticle surface with Herceptin[201].  
Therefore, we developed a delivery system with PLA-TPGS and TPGS-COOH as matrix 
materials, which was loaded with docetaxel by physical entrapment, and decorated with 
Herceptin by chemical conjugation. PEG, the hydrophilic component of TPGS, can make the 
particle “stealth” after being injected into the circulation. In commercially available TPGS, the 
PEG is of molecular weight 1000. However, it was reported by previous literature that only 
when PEG molecular weight is beyond a threshold(e.g. 1500 [213], 2200 [214], 3000 [215], 
3500 [216]), the resistance to plasma protein adsorption could be maximized, and the 
nanocarrier could have prolonged circulation time [217]. Although there is less argument on 
whether PEG coating could extend the circulation time of a nanocarriers, there is a debate on 
whether PEG coating could increase drug accumulation in tumor site. Wang and Dormidontova 
established a nanocarrier model which had a hard core and a shell consisting of flexible 
polymers, the end of which was attached with a monomeric ligand for targeting [74]. Using 
Monte Carlo simulation, design parameters such as nanoparticle core size, ligand-receptor 
binding energy, ligand density, tether chain length and density were examined. The simulation 
results suggested that in close proximity of cell surface, increasing the number of tethering 
chains or increasing the tether chain length without increasing the number of ligands increased 
the conformational penalty (entropy) due to the stretching or compression of the flexible 
polymer chains, and hence led to a decrease in targeting effect. However, larger number or 
longer tether chains increased the probability of ligand-receptor interaction in far distance over 
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larger cell surface area. In addition, two independent in vivo experiments show that compared 
to non-PEG containing liposome, PEG containing formulations have equal or even less 
accumulation of drugs in tumor, due to either reduced particle cell interaction or hindered 
payload release [69, 218]. Kawano and Maitani evaluated the targeting effect of folic acid 
modified PEGylated liposome at different PEG (the tether chain) molecular weight of 2000, 
3400, and 5000 on KB cells which have an overexpression of folate receptor. Folic acid 
modification was achieved through post-insertion of folic acid conjugated 
PEG-distearoylphosphatidylethanolamine (FA-PEG-DSPE) into the liposome. The flow 
cytometer results showed at low surface ligand density (0.01 to 0.3 mol% Folic 
acid-PEG-DSPE), the highest cell uptake occured at long PEG chain length (Mw 5000).  
In this study, Herceptin decorated PLA-TPGS/TPGS-COOH nanoparticles are used as 
platform to investigate how different PEG molecular weights can affect nanoparticle 
physicochemical characteristics and their interactions with cells.  
4.2. Materials and methods 
4.2.1. Materials 
Herceptin (21mg/ml, 4.76ml) was purchased from National Cancer Centre, Singapore.  
Docetaxel (anhydrous, 99.56%) was obtained from Shanghai Jinhe Bio-Technology Co. Ltd, 
China. Lactide (3,6-dimethyl-1,4-dioxane-2,5-dione, C6H8O4 ) was purchased from Aldrich. 
Vitamin E TPGS (d-α-tocopheryl polyethylene glycol 1000 succinate, C33O5H54(CH2CH2O)23 ) 
was from Eastman Chemical Company, USA. Polyethylene glycol (PEG), stannous octoate 
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(Sn(OOCC7H15)2 ), acetone, dimethyl sulfoxide (DMSO), coumarin-6, phosphate buffered 
saline (PBS, pH 7.4), sodium borate, Bradford reagent (for 1-1400ug/ml protein), 
N,N’-dicyclohexylcarbodiimide (DCC), 4-Dimethylaminopyridine (DMAP), 
N-(3-Dimethylaminopropyl)-N
’
-ethylcarbodiimide hydrochloride (EDC), 
N-Hydroxysuccinimide (NHS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay, trypsin-ethylenediaminetetraacetic acid (EDTA), triethylamine (TEA), 
α-tocopheryl- succinate (TOS) and propidium iodide (PI) were purchased from Sigma-Aldrich 
(St. Louise, MO, USA). Ethanol was obtained from VWR Singapore Pte Ltd. Tween-80 was 
from ICN Biomedicals, Inc. (OH, USA). Triton X-100 was from USB Corporation (OH, USA). 
Fetal bovine serum (FBS) and penicillin-streptomycin solution were provided by Invitrogen. 
Dulbecco’s Modified Eagle’s Medium (DMEM) was purchased from Thermo Scientific 
Hyclone (South Logan, USA). SK-BR-3 and MCF7 breast cancer cells were obtained from 
American Type Culture Collection (ATCC). Water was treated with the Milli-Q Plus System 
(Millipore Corporation, Bedford, USA).  
4.2.2. Synthesis of PLA-TPGS 
PLA-TPGS was synthesized from lactide and TPGS from ring-opening polymerization with 
stannous octoate as a catalyst based on previous publication from our group. Brieftly, weighted 
amount of freeze-dried lactide and TPGS (85:15 w/w), and 0.5 wt% stannous octoate (in 
distilled toluene) were added to a round bottom flask (RBF). The RBF was purged three times 
with liquid nitrogen and connected to a vacuum pump via condenser. The reaction was carried 
on at 145 
o
C for 12 h under reflux. After the reaction, the product was dissolved in DCM and 
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precipitated in excess cold methanol to remove unreacted lactide monomers and TPGS. The 
final product was collected by filtration and vacuum dried at 45 
o
C for two days. The product 
formed was analyzed by 
1
H NMR at 500 Hz (Bruker AMX500). The number average molecular 
weight was calculated from the NMR spectrum. 
4.2.3. Synthesis of TPGS-COOH of different PEG molecular weight 
TOS, PEG, DCC and DMAP were weighed and dissolved in dichloromethane (DCM) with a 
stoichiometric ratio of 1:1:2:0.1 and concentrations of TOS and PEG at 0.2 mol/L. The 
resulting reaction mixture was then left to stir in a nitrogen environment overnight. After 
reaction, the solution was filtered to remove by-products such as N,N-dicyclohexylurea (DCU). 
The filtrate which carried the TPGS synthesized was purified by three times precipitation in 
cold anhydrous ethyl ether. This entire procedure was carried out for PEG with MW of 2000, 
3350 and 5000. 
TPGS, glutaric acid, DCC and DMAP were weighed and dissolved in DMSO with a 
stoichiometric ratio of 1:1:1:0.1. The resulting reaction mixture was then left to stir in a 
nitrogen environment overnight. After reaction, the solution was filtered to remove by-products 
such as DCU. The filtrate which carried the TPGS-COOH synthesized was dialyzed against 
DMSO to remove excess DCC. It was then dialyzed against ultrapure water to remove DMSO 
before it was freeze dried and collected. The procedure was carried out for TPGS1000, TPGS2000, 
TPGS3350, and TPGS5000. 
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Gel permeation chromatography (GPC) was used to verify the molecular weight (MW) of the 
synthesized TPGS-COOH. Calibration was first performed with a total of 4 standards. The 
samples of TPGS-COOH synthesized with different PEG MW were then dissolved in the 
mobile phase (THF) and injected into the GPC with a volume of 200 μL for a run time of 20 
minutes. Results for number average MW (Mn), weight average MW (Mw), peak MW (MP), 
higher average MW (Mz) and polydispersity are then obtained from the GPC. 
4.2.4. Preparation of nanoparticles 
The docetaxel loaded PLA-TPGS/TPGS-COOH NPs (NPBs) were prepared by 
nanoprecipitation method as reported by previous literature. Briefly, PLA-TPGS, 
TPGS-COOH, and docetaxel (95:5:5 w/w/w) were dissolved in acetone at a concentration of 10 
mg polymer/mL acetone. 10 ml of such solution was added dropwisely to 20 ml ultrapure water 
under magnetic stirring (650 rpm). After 4 h, the NPs were collected and washed by 
centrifugation at 15,000 rpm and 4 
o
C for 15 min. For fluorescence coumarin-6 loaded NPs, the 
same procedures applied, except that the docetaxel was replaced by 0.05 wt% coumarin-6 in 
acetone.  
4.2.5. Herceptin conjugation and quantification of surface Herceptin  
The conjugation procedure for preparing and Herceptin conjugated PLA-TPGS/TPGS-COOH 
NP (NPH) was developed based on previous literature [185, 201]. Herceptin was diluted in 0.2 
M sodium borate buffer (PH 8.6) to acquire 1 mg/ml concentration stock solution. The prepared 
NP suspensions were diluted to 1.1 mg/ml in 4.5 ml 0.2 M sodium borate buffer (PH 8.6) with 
addition of 10 mg of EDC and 4 mg of NHS, followed by 0.5 ml Herceptin stock solution and 5 
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µl TEA. The reaction mixture was stirred at low speed (60 rpm) for 4 h in room temperature. 
After the reaction, the NPs were collected and washed by centrifugation at 10,000 rpm for 15 
min. To quantitatively analyze the surface Herceptin content the supernatant after first 
centrifugation was collected. The protein concentration in the supernatant was measured by 
standard protocol of Bradford assay. The Herceptin on the NPs’ surfaces were thus obtained by 
subtracting the amount of Herceptin from the total amount of Herceptin added. Surface 
Herceptin content is defined to be the amount of Herceptin (mg) per mg of NPs.  
4.2.6. Characterization of NPs 
4.2.6.1. Size and size distribution 
Size and size distribution of NPs with or without Herceptin conjugation were measured by 
dynamic light scattering (DLS) (90 plus particle size analyzer, Brookhaven Instruction 
Corporation, TX, USA). The NPs was diluted with ultrapure water to a count rate of 300-500 
kcps and sonicated before measurement. 
4.2.6.2. Surface charge 
ζ-potential of nanoparticle is measured by the ZetaPlus ζ-potential analyzer (Brookhaven 
Instruction Corporation) at room temperature in ultrapure water. All samples were measured at 
similar concentration and PH value. The reported values were average of 3 measurements, each 





4.2.6.3. Drug load 
The amounts of drug loaded in the NPs were measured by HPLC (Agilent LC1100, Agilent, 
Tokyo, Japan). A reverse-phase HPLC column (Agilent Eclipse XDB-C18, 4.6x250 mm, 5 µm) 
was used. 1 mg of freeze dried particles was dissolved in DCM. Upon complete evaporation of 
DCM, the drug was reconstituted with 1 ml of mobile phase (acetonitrile: UP water, 50:50). 
After dissolving the drug completely by ultrasonication and vertexing, the supernatant was 
collected by centrifugation and transferred to a HPLC vial. The column effluent was detected at 
230 nm with 1.0 mL/min flow rate. The calibration curve was linear in the range of 50-50,000 
ng/mL with a correlation coefficient of R
2
 = 0.999.  
For fluorescence-encapsulated NPs, the cuomarin-6 load was determined by the same 
extraction process as described for the drug loaded NPs. The fluorescence was measured by 
HPLC with a flow rate of 1.3 ml/min mobile phase consisting of acetonitrile and water (60:40 
v/v). The excitation and emission wavelength were set at 462 nm and 502 nm, respectively, 
using a fluorescence detector module.  
4.2.6.4. Surface morphology 
Surface morphologies of NPs were imaged by a field-emission scanning electron microscope 
(FESEM, JSM-6700F, JEOL, Tokyo, Japan). After sonication, sample suspensions were 
diluted and dried on copper tape overnight. Before imaging, the samples were coated with a 




4.2.6.5. Surface chemistry analysis  
The existence of Herceptin on NP surface was confirmed by X-ray photoelectron spectroscopy 
(XPS, AXIS His-165 Ultra, Kratos Analytical, Shimadzu Corporation, Kyoto, Japan). The 
elements on the NP surfaces were identified according to the specific binding energy (eV), 
which was recorded from 1 to 1200 eV with pass energy of 80 eV under the fixed transmission 
mode. The nitrogen element was particularly tested under fine mode with 0.5 eV as step. The 
date was processed by specific XPS software.  
4.2.6.6. In vitro drug release 
Weighted amount of drug loaded NPs were suspended in 1x PBS buffer (PH 7.4) with 0.1% v/v 
Tween-80, and were gently shaking in a water bath at 37
o
C. At designated time intervals, the 
particle suspensions were centrifuged to collect the supernatant, and the particles were 
re-suspended in fresh buffer solutions. The collected supernatants were freeze dried, dissolved 
in mobile phase (acetonitrile: ultra pure water, 50:50 v/v), and filtered to remove inorganic salts. 
The obtained solution was sent for HPLC analysis using the same method as that for measuring 
drug load.  
4.2.7. Cell culture 
SK-BR-3 and MCF7 breast cancer cells were cultured using Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% PBS and 1% penicillin-streptomycin solution in 
25ml cell culture flask. Cells were cultivated in an incubator at 37
o




4.2.8. In vitro cellular uptake  
4.2.8.1. Quantitative study: Microplate reader 
After reaching confluence, cells were detached, counted, and seeded in 96-well black plates 
(Costar, IL, USA) at 2x10
4
 cells/well (0.1 ml). After 24 h incubation, medium was replaced by 
coumarin-6 loaded NPs at concentration of 0.125 mg/ml. After 2 h incubation, the NPs 
suspensions were removed. Cells were washed twice with 1x PBS, and immersed in 50 µl of 0.5% 
Triton X-100 in 0.2 N NaOH solutions. After 15 min incubation under gentle shaking, the 
fluorescence intensities were measured with a microplate reader (Genios, Tecan, Switzerland) 
at excitation wavelength of 430 nm, and emission wavelength of 485 nm.  
4.2.8.2. Quanlitative study: confocal microscopy 
After reaching confluence, cells were detached, counted, and seeded in a 4-well coverglass 
chamber (LAB-TEK, Nagle Nunc, IL, USA) overnight. Then, the medium was replaced by NP 
in medium suspension at concentration of 0.125 mg/ml and incubated for 2 h. The cells were 
washed twice with pre-warmed 1x PBS and fixed with 70% ethanol for 20 min. After that, the 
cells were washed three times with 1x PBS, and the nuclei were counterstained by PI for 45 min. 
The cells were washed three times by 1x PBS and immersed in 1x PBS for confocal 
microscopic imaging.  
4.2.9. In vitro cytotoxicity 
SK-BR-3 cells were seeded in 96-well transparent plates (Costar, IL, USA) at 5x10
3
 cells/well 
(0.1ml) and after 12 h, the medium was replaced by NPs in medium suspension with designated 
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concentrations for 24 h. The NPs were sterilized with UV irradiation overnight before the 
experiment. MTT assay was used to measure the cell viability. The absorbance of the wells was 
measured by the microplate reader at 570 nm. Reference wavelength was set to be 620 nm. Cell 
viability is calculated by the following equation: 
Cell Viability (%) = [Abs of sample/Abs of control] x 100 
Where Abs of sample is the absorbance of the transformed MTT in cells incubated with the NP 
suspension, while the Abs of control is the absorbance of transformed MTT in cells incubated 
with culture medium only 
4.3. Results 
4.3.1. Synthesis of TPGS and TPGS-COOH  
The molecular weights of synthesized TPGS were evaluated using GPC (Table 4.1). The 
measured molecular weights show an increasing trend when molecule weights of PEG used in 
the synthesis is increased from 1000 to 5000. The values are generally in agreement with the 
theoretical values with some deviations. The polydispersity values represented by Mz/Mw also 
falls within the range of 1 to 1.3 for each of the synthesized TPGS-COOH, indicating a narrow 







Table 4.1. Molecular weight of TPGS1000, TPGS2000, TPGS3350, and TPGS5000 measured by 
GPC. 
 PEG MW Theoretical 
value 
Mn Mw MP Mz Mz/Mw 
TPGS1000 1000 1621 1993 2715 2967 3426 1.26 
TPGS2000 2000 2621 3045 3901 4366 4574 1.17 
TPGS3350 3350 3971 3293 4446 5224 5271 1.19 
TPGS5000 5000 5621 5632 6415 8307 7004 1.09 
 
4.3.2. Characterization of NPBs and NPHs 
4.3.2.1. Size and Size distribution 
The size and size distribution of NPBs and NPHs were shown in Table 4.2. Sizes of all NPBs 
are around 180 nm, and sizes of all NPHs are around 210 nm. Theoretically, all of these 
particles are capable of extravasation into tumors by EPR effect [4]. The variation in TPGS 
molecular weight did not cause a significant change in size. It can be observed that Herceptin 
conjugation led to an increase in NP sizes due to the surface Herceptin layer. This is in 
aggremment with previsou observations. The polydispersities are in the range of 0.157-0.294, 







Table 4.2.Characteristics of docetaxel-loaded PLA-TPGS/TPGS-COOH nanoparticles (NPB) 
and docetaxel-loaded Herceptin modified PLA-TPGS/TPGS-COOH nanoparticles (NPH): 
particle size, size distribution, ζ-potential, Drug load, and surface Herceptin content. Data 
represent mean + SE, n=3.  





NPB 1000 182.07 + 0.96 0.157 ± 0.052 -21.22 ± 1.20 6.10 ± 0.32 - 
2000 174.80 + 0.80 0.212 ± 0.025 -20.28 ± 0.71 7.28 ± 0.176 - 
3350 182.03 + 3.22 0.183 ± 0.047 -20.17 ± 0.84 9.87 ± 0.160 - 
5000 186.10 + 3.06 0.261 + 0.053 -19.00 + 1.40 9.00 + 0.132 - 
NPH 1000 223.91 ± 4.12 0.294 ± 0.024 -10.08 ± 1.05 4.42 ± 0.091 12.47 + 1.25 
2000 198.57 + 3.81 0.254 ± 0.058 -11.30 ± 1.30 5.55 ± 0.367 11.53 + 0.56 
3350 211.40 + 5.42 0.275 ± 0.033 -15.60 ± 1.05 5.11 ± 0.112 12.06 + 2.15 
5000 221.00 + 4.85 0.204 + 0.007 -10.09 + 1.56 5.15 + 0.103 13.12 + 1.73 
 
4.3.2.2. ζ-potential 
NP surface charge has influence on both its colloidal stability in suspension, and its interaction 
with cells. The ζ-potentials of NPBs listed in Table 4.2 are around -20 mV, suggesting a stable 
suspension in aqueous environment without flocculation [204]. Conjugations of Herceptin lead 
to decreases in the absolute value of ζ-potentials due to the positive charge of Herceptin 
(isoelectric point =9) in water.  
4.3.2.3. Drug load 
The drug load is defined as the weight percentage of docetaxel in the docetaxel loaded NPs. By 
this definition, the calculated drug load for NPB1000, NPB2000, NPB3350, and NPB5000 are 6.103 ± 
0.315 %, 7.28 ± 0.176 %, 9.87 ± 0.160 %, and 9.00 + 0.132, respectively. The drug loads are 
similar among the four NPB formulations. It could be due to the reason that only 5 % (w/w) of 
TPGS-COOH were added during particle preparation process, hence, the drug load are mainly 
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determined by the PLA-TPGS component. For Herceptin conjugated NPs, the drug loads are 
4.42 + 0.091 %, 5.55 + 0.367 %, 5.11 + 0.112 %, and 5.15 + 0.103 for NPH1000, NPH2000, 
NPH3350, and NPH5000, respectively. The slight decreases of drug load may attribute to the 
prolonged stirring and repeated washing process during Herceptin conjugation.  
4.3.2.4. Surface morphology 
Surface morphology was examined by field-emission scanning electron microscope (FESEM) 
(Fig. 4.1). It is shown in the image that the NPs are generally spherical in shape. The size and 
PDI are in good agreement with those determined by DLS. It can be seen from the images that 
after conjugation, the NPs are more aggregated and have rougher surfaces, and the shape is not 
as well defined as that of bear NPs. This phenomenon has been observed in previous literatures 
[185, 201]. 
 
Fig. 4.1. FESEM images of NPB1000 (A), NPB2000 (B), NPB3350 (C), NPB5000 (D), NPH1000 (E), 





4.3.2.5. Surface chemistry 
Surface chemistry of the NPs before and after Herceptin conjugation was examined using x-ray 
photoelectron spectroscopy (XPS). Fig. 4.2 shows the representative XPS wide scan spectrum 
of the targeted and non-targeted NPs (i.e. NPB2000 and NPH2000). The inset highlighted the 
signal at the position corresponding to the binding energy of N 1s. Nitrogen can only from 
either docetaxel or Herceptin. The N 1s signal is undetectable before conjugation suggesting 
that docetaxel are encapsulated inside the polymer matrix. However, after conjugation, the 
nitrogen peak appears, indicating the existence of nitrogen containing Herceptin.  
 
Fig. 4.2. Representative X-ray photoelectron spectroscopy (XPS) spectrum of widescan 
spectrum and N 1s Peaks (the inset) from NPB2000 (lower curve) and NPH2000 (upper curve).  
 
4.3.2.6. Herceptin content 
It has been shown in literatures that there is a positive correlation between surface ligand 
density and the efficacy of nanocarrier formulation of anticancer agents. From the last column 
in Table 4.2, all NPHs have similar Herceptin content (amount (mg) of Herceptin conjugation 
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per mg of particles). The differences may attribute to the following reasons:  (1) different 
amount of functional groups are present on nanoparticle surface for conjugation; (2) there are 
differences in PEG chain confirmation. PEG chains on NP surface are highly flexible and have 
a large number of possible conformations. The rate of conformational change depends on 
factors such as PEG molecular weight, density and the way PEG is attached to the surface 
[219].  
4.3.3. In vitro release 
Fig. 4.2 shows 6-day in vitro cumulative release profiles of docetaxel from the NPBs and NPHs. 
Generally, the drug release follows a biphasic pattern: an initial burst release followed by slow 
zero-order release. It can be observed for all NPs that 60 % - 80 % of docetaxel was released in 
the first 24 h. The fast release may attribute to the relatively higher hydrophilicity of 
PLA-TPGS and TPGS, when compared with widely used PLGA [190]. After Herceptin 
conjugation, the release rate was slightly increased possibly due to the migration of docetaxel 
to the surface of the NPs and reduction in matrix integrities during conjugation reaction. The 
increase in drug release rate after Herceptin conjugation was also shown in literature [201]. It 
could be seen from Fig. 4.2 that increases in PEG molecular weight lead to reduction in release 
rates. It has been hypothesized by others that PEG coating could hinder the release of payload 
[220]. Hence, the phenomenon we observed might due to the reason that PEG with higher 
molecular weight (longer and more flexible chains) has higher ability in hindering the release of 




Fig. 4.3. In vitro docetaxel release profile from the drug-loaded NPBs (A), and NPHs (B). 
Phosphate buffered saline (PBS, 0.1 M, PH = 7.4) with 0.1 % w/v Tween-80 was used as the 
release medium.  
 
4.3.4. Cellular uptake: quantitative study 
Cellular uptake of NPs without and with Herceptin conjugation in 2 h was studied 
quantitatively by measuring the percentage of internalized coumarin-6 loaded NPs in SK-BR-3 
cells. Fig. 4.3 shows that NPHs have higher extent of cell internalization than NPBs in 
SK-BR-3 cells which have an overexpression of HER2 receptors. This confirms that Herceptin 
conjugation on surface enhances uptake of NPs in cells with an overexpression of HER2. It can 
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be observed that for NPBs, PEG molecular weight, when varied from 1000 to 5000, the cellular 
uptake decreases significantly (P<0.05). The observation indicates that the tethering chain 
length of these NPs affect their non-specific cellular uptake. In addition, Herceptin conjugated 
nanoparticles follow a similar trend (P<0.05). It is possibly due to the reason that the ligand 
receptor affinity is not high enough to overcome the entropic penalty of tethering chain 
conformational change which is higher for longer tethering chains [74]. Hence, for the NPHs of 
size, ζ-potentials, and surface Herceptin content of around 210 nm, -10, and 12 % (w/w), 
respectively; the TPGS1000 led to the highest cellular uptake of NPs.  
 
Fig. 4.4. Cellular uptake efficiency of the coumarin-6 loaded NPBs and NPHs with different 
PEG molecular weight on SK-BR-3 cells after 2 h incubation at 125 µg/ml nanoparticle 
concentration. Data represent mean + SE, n=6. 
 
4.3.5. Cellular uptake: confocal microscopy study 
The cellular uptake of the NPBs and NPHs after 2 h incubation with SK-BR-3 cells was further 
investigated by confocal laser scanning microscopy (CLSM) to visualize the internalization of 
NPs into cells (Fig. 4.4.). Coumarin-6 loaded NPs were detected by the FITC channel. The 
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nuclei were stained with PI and detected by the PI channel. All images show the merged 
channels of FITC and PI channels. Column 1 shows cells incubated with NPBs; while Column 
2 represents cells incubated with NPHs. Row 1, Row 2, Row 3, and Row 4 demonstrate cells 
incubated with NPs with PEG molecular weight of 1000, 2000, 3350, and 5000, respectively. It 
can be seen from the images that nuclei stained by PI are circumvented by green fluorescence 
which represents the internalization of coumarin-6 loaded NPs in cytoplasm. In addition, the 
green fluorescence in column 1 are dimmer than that in Column 2, suggesting a higher cell 
internalization of NPHs than NPBs in SK-BR-3 cells. Furthermore, it can be observed that row 
A and row B have higher green fluorescent intensity than row C and row D, indicating a higher 
level of cellular uptake. The observations are in good agreement with the results of the 




Fig. 4.5. Confocal laser scanning microscopy (CLSM) images show the internalization of 
coumarin-6 loaded nanoparticles in SK-BR-3 cells, incubated with NPB1000 (1A), NPB2000 (2A), 
NPB3350 (3A), NPB5000 (4A),  NPH1000 (1B), NPH2000 (2B), NPH3350 (3B), and NPH5000 (4B). 
The nuclei were stained with PI. The images show merged FITC and PI channels.  
 
4.3.6. In vitro cytotoxicity 
The SK-BR-3 cell viability after 24 h incubation with various NPH formulations was shown in 
Fig. 4.6 and the calculated IC50 was shown in Table 4.3. Both NPBs and NPHs showed 
dose-dependent toxicity on SK-BR-3 cells. Decoration of Herceptin decreased the IC50 of 
NPH1000, NPH2000, NPH3350, and NPH5000 by 89.6%, 81.5%, 61.3%, and 55.6%, compared to the 
corresponding NPBs. The decrease in IC50 can be due to the intrinsic toxicity of Herceptin and 
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the improved cellular uptake. In addition, NPH1000 showed the highest cytoticity (i.e. lowest 
IC50) compared to other NPH formulations. The IC50 of NPH1000 is 68.1%, 90%, and 92.6% 
lower than that of NPH2000, NPH3350, and NPH5000, respectively. The decrease in IC50 may 
attribute to the faster cellular uptake because of the lower energy barrier for the nanoparticles 
with shorter tethering chains to enter receptor expressing cells.  
 
Fig. 4.6. In vitro cell viability of SK-BR-3 cells after 24 h incubation of the NPHs at various 
docetaxel concentrations. Data represent mean + SE, n=6.  
 
Table 4.3. IC50 (μg/ml) values of SK-BR-3 cells treated with various formulations of docetaxel 
after 24 h incubation. 
 PEG molecular weight  
1000 2000 3350 5000 
NPB 3.29 5.8 9.23 10.37 







Surface PEG have two functions: stealth effect and providing functional group. The PEG 
molecular weight is of importance; maximum stealth effect appears beyond a threshold value. 
This value varies for different nanocarriers, and to the best of my knowledge all of them are 
above 1,000 [213, 214, 216, 221]. Hence, PEG 1,000 was chosen as the lowest PEG molecular 
weight of investigation. However, PEGylation reduces the interaction between nanoparticle 
(NP) and cancer cells [222, 223]. Hence, an optimum PEG molecular weight may exist when 
taking both effects into consideration. For ligand modified NP, the situation was more 
complicated. Models have been established for the receptor mediated endocytosis. A detailed 
literature review is provided in the introduction part. Here, I would like to explain our finding, 
i.e. PEG 1,000 leads to the best in vitro therapeutic efficacy in terms of surface thermodynamics. 
In a milestone work published in Langmuir 1999, Feng gave clear definition of surface pressure 
(π), interfacial tension (γ) and surface tension (σ) of a lipid monolayer at an interface, which 
must satisfy the following relation [29,30]. 
Π=γ-σ or σ=γ-π 
The surface tension (the tension force per unit edge in a unit say, dyn/cm in the cm-g-s system) 
represents the total mechanical effects of the surface pressure and the interfacial tension. 





. From surface thermodynamics of the monolayer of an amphiphilic 
molecule at an interface, the magnitude of surface pressure (π) is determined by the density of 
the hydrophilic head groups on the surface and the length and unsaturation of the hydrophobic 
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chains. The shorter the chains, the smaller the conformational entropy and thus the smaller of 
the surface pressure, which, according to the above equation, would result in larger surface 
tension or equivalently, larger surface energy [31]. It is well-known that the biological cells 
internalize nanoparticles by a mechanism called endocytosis. In this process, the surface energy 
of the nanoparticle is transferred into the edge energy of the detached small circular piece of 
bilayer membrane, which is then used to overcome the bending energy needed to engulf the 
nanoparticle. That is why there must be an optimal size of nanoparticles used for drug delivery 
since too small nanoparticles would not have enough surface energy to overcome the bending 
energy needed to engulf the nanoparticles of too small radius of curvature. It can thus be 
concluded that the nanoparticles of PLA-TPGS/TPGS-COOH blend of the shortest PEG 
tethering chain length, i.e. PEG 1000, could have the highest surface energy to overcome the 
bending energy needed to penetrate into the biological cells by the mechanism of endocytosis, 
that is in favor of the therapeutic effects of the nanoparticles formulation of the therapeutics. 
4.5. Conclusion  
Herceptin-conjugated docetaxel-loaded PLA-TPGS/TPGS-COOH polymeric nanoparticles 
were produced for targeted drug delivery to HER2 overexpressed cancer cells. The matrix of 
the particle consists of a physical blending of PLA-TPGS and TPGS-COOH, in which 
TPGS-COOH provides functional group for the conjugation of Herceptin. It has been reported 
in literature that variation in tethering chain length between the nanoparticle and the targeting 
moites would affect the particles’ interaction with cells. Here, we investigated how the 
molecular weight of PEG (the tethering chain) in TPGS-COOH affects drug release rate, 
135 
 
cellular uptake, and cytotoxicity of the aforementioned nanoparticle drug delivery system. It 
has been found that for non-targeted NPs, increase in PEG molecular weight caused a decrease 
in cellular uptake and cytotoxicity. We also found in our study that for ligand decorated 
nanoparticles, the tethering chain length plays a minor role if the surface ligand density is high 
enough. Nevertheless, the in vitro cytotoxicity of our NP formulation of docetaxel could be 
maximized by reducing the tethering PEG molecular weight and increasing the surface 













Chapter 5. Targeted co-delivery of docetaxel and siPLK1  
by Herceptin conjugated vitamin E TPGS based immunomicelles 
5.1. Introduction 
Cancer is still the leading cause of death worldwide [224]. Chemotherapy is a major treatment 
modality, which uses anticancer drugs to kill cancer cells. One important class of anticancer 
drugs is the anti-mitotic drugs, which target the tubulin and microtubule system and block 
cells from completing mitosis [225]. This class of anticancer drugs consists of microtubule 
hyperpolymerizing agents (e.g. taxanes and epothilones) and microtubule depolymerizing 
agents (e.g. vinca alkaloids) [226]. Cancer cells exposed to anti-mitotics have potential to 
experience mitotic arrest and subsequent apoptosis [227]. Although these anticancer drugs 
have been proven to be effective in suppressing progression of cancer for a period of time, in 
many cases, however, they are defeated by multidrug resistance eventually due to 
overexpression of p-glycoprotein, mutation of β-tubulin, or variation in 
microtubule-associated proteins (MAP) as cancer progresses [225, 228]. To overcome side 
effects and multidrug resistance, nanomedicine strategy, i.e. formulation the anticancer drugs 
in the various nanocarriers such as prodrugs, micelles, liposomes, solid lipid nanoparticles, 
nanoparticles of biodegradable polymers, nanogels and dedrimers, have been developed  and 
nanomedicine for multimodality treatment has been under intensive investigation [128, 
229-234]. 
Due to severe side effects and gradually developed resistance of those traditional anticancer 
drugs, new drugs are being developed based on the increasing knowledge on molecular biology 
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and biochemistry [235]. Many of these new drugs are small molecules, antibodies, DNAs, and 
RNAs, which target specific carcinogenic pathways. Therapy employing these drugs is named 
as targeted therapy. Among them, siRNA (21-23 nucleotides) is an important category [137, 
236, 237]. It functions by guiding the ribonucleoprotein complex RNA-induced silencing 
complex (RISC) to the complementary target mRNA, and cleave it at specific sites [101, 238]. 
After cleavage, the target mRNA become less stable, and can be easily degraded by RNase, 
leading to reduction in the mRNA and the corresponding protein level. SiRNAs developed for 
the treatment of cancer usually down regulate proteins that promote cell survival, multidrug 
resistance, angiogenesis, or metastasis [239-244]. SiRNA holds great promise because 
theoretically it can be designed to silence nearly any gene of interest. In addition, it has a high 
potency that only a few molecules could induce a robust response [238]. The efficacy of siRNA 
for the treatment of cancer in human has been proven in a phase I clinical trial [137]. However, 
its application is hindered by enzymatic degradation, fast clearance, immunogenicity, and 
inability to efficiently penetrate cell membrane [101, 245]. Besides, although siRNA shows 
efficacy for cancer treatment, they, when used alone, usually cannot compare with the 
traditional anticancer drugs in in vivo experiments at designated dosage [246-248]. Indeed, 
delivery problem is also there for siRNA administration. Therefore, there are two methods to 
enhance the therapeutic efficacy of siRNA: one is to apply nanomedicine strategies to solve the 
problem in siRNA delivery and another is to develop strategies for rational combination of 
siRNA with traditional anticancer drugs. 
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Breast cancer is a top occurring type of cancer around the world with high mortality rate [249, 
250]. Taxane has been proven to be effective in the form of combination therapy or 
monotherapy for the treatment of breast cancer [199, 251]. Docetaxel, a second generation 
taxane, shows superior efficacy as monotherapy compared to the established combination 
regimes as a second line treatment of metastatic breast cancer (MBC) [252]. Its combination 
with Herceptin further enhances the efficacy for the treatment of human epidermal growth 
factor receptor 2 (HER2) positive metastatic breast cancers [253]. However, after diagnosed 
with metastatic breast cancer, even with the most advanced treatment method; recurrence-free 
survival could only be expected for around 5 years. Hence, there is a need for the development 
of treatment regimes with improved efficacy and reduced side effects.  
Polo-like kinase 1 (PLK1) is overexpressed in a broad range of tumors and has a pivotal role in 
cell mitosis [254]. It has been shown that inhibition of PLK1 causes mitotic arrest which 
subsequently may lead to apoptosis [255]. PLK1 siRNA (siPLK1) could downregulate PLK1 
protein by post-transcriptional degradation of PLK1 mRNA. Rationally, combing siPLK1 with 
taxane may be able to prolong G2/M phase arrest. It has been shown that the longer the cells are 
arrested in M phase, the more likely they will undergo apoptosis instead of mitotic slippage 
[256-258]. In addition, combination therapy suggests a better efficacy by countering biological 
compensation pathways and allowing a reduction in drug dosage and related toxicity [233, 259]. 
Experimentally, it has been shown in vitro and in vivo that the combination of siPLK1 and 
paclitaxel indicates better therapeutic efficacy than siPlk1 or paclitaxel alone [99, 132, 247].  
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Nanocarrier drug delivery systems improve selectivity of anticancer drugs to tumor cells by 
enhanced permeability and retention (EPR) effect [128, 236]. They solve most problems of 
anticancer drugs such as poor solubility, narrow therapeutic window, and severe side effects. In 
the case of siRNA, delivery system could assist its accumulation in tumor and penetration into 
cancer cells, reduce its degradation, clearance and immunogenicity [260]. Co-delivery of two 
anticancer agents in one nanocarrier reduces the complexity of combination by enabling a 
better time, location, and dosage control. Moreover, synergistic effects may also be resulted. 
For co-delivery of cancer therapeutic siRNA and hydrophobic chemotherapeutic drug, 
self-assembly of block copolymer consisting of a hydrophobic block and a cationic block is the 
most popular strategy, by which, the hydrophobic drug could be encapsulated inside the 
hydrophobic core and siRNA could be absorbed on the cationic surface by electrostatic 
interaction [132, 134, 261]. In such design, however, the release of siRNA may not be well 
controlled, because upon changing in pH or salt concentration, siRNA could dissociate from 
the surface. When siRNA is conjugated to other molecules such as cholesterol, peptide, or 
aptamer, biodistribution of siRNA is changed, and its stability can be improved [262, 263]. In 
addition, it has been shown that when siRNA conjugated DSPE-PEG forms micelles, the 
stability of siRNA against enzymatic degradation could be further improved in comparison 
with the conjugate itself [107]. Another strategy is to incorporate cationic polymer such as 
polyethyleneimine (PEI) or poly-L-lysine (PLL) as part of the PLA or PLGA matrix by 
physical blending or chemical conjugation [113, 264]. However, the release rates of siRNA 
from the nanoparticle matrix are usually slow, especially in the first 48 h.  
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In this study, siPLK1 was conjugated to D-α-tocopheryl polyethylene glycol succinate 
(Vitamin E TPGS or TPGS) to form TPGS-siPLK1 via disulfide bond. TPGS is a water soluble 
derivative of vitamin E. It has been used as emulsifier, solubilizer, and bioavailability enhancer 
for both hydrophilic and hydrophobic drugs [129]. Micelles made up of TPGS2k were shown to 
have good stability, sustained drug release over 144 h, and desirable interaction with cells [265]. 
Disulfide bond between siPLK1 and TPGS enable a triggered release in cell cytoplasm due to 
elevated glutathione concentration [266]. In this research, we developed a nanocarrier system 
of Herceptin-conjugated micelles made up of a mixture between TPGS-siPLK1 conjugate and 
TPGS or amine terminated TPGS (TPGS-NH2) at designated ratio for targeted co-delivery of 
siPLK1 and docetaxel (Fig. 5.1). Characterization of such a system for size and size 
distribution, encapsulation efficiency and in vitro release of siPLK1 and docetaxel is conducted. 
The synergistic effects and the targeting effects are assessed in vitro by IC50, the agent 
concentration needed to kill 50% of the cancer cells in a designated time period, of the cancer 
cells of low, moderate, and high over expression of HER2.  
 
Fig. 5.1. Schematic illustration of formulation of the docetaxel loaded TPGS-siPLK1/TPGS 






5.2. Materials and methods 
5.2.1. Materials 
Vitamin E TPGS (α-tocopheryl polyethylene glycol 1000 succinate, C33O5H54(CH2CH2O)23 ) 
was from Eastman Chemical Company, USA. Herceptin (21 mg/mL, 4.76mL) was purchased 
from National Cancer Centre, Singapore. SiRNA targeting human Plk1 (siPlk 1) (sense strand, 
50-UGAAGAAGAUCACCCUCCUUA dTdT-30 and antisense strand, 
50-UAAGGAGGGUGAUCUUCUU CAdTdT-30) were supplied by Shanghai GenePharma 
Co. Ltd. (Shanghai, China). Rabbit anti-PLK1 antibody and HRP-goat anti-rabbit antibody 
were purchased from Cell Signaling Technology (Danvers, MA). Rabbit anti-GAPDH 
antibody was purchased from Goodhere (Hangzhou, China). Docetaxel (anhydrous, 99.56%) 
was obtained from Shanghai Jinhe Bio-Technology Co. Ltd, China. 1,1’-Carbonyldiimidazole 
(CDI), 3-(2-Pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP), 
ethylenediamine, diethyl pyrocarbonate (DEPC), dioxane, chloroform, dimethyl 
sulfoxide(DMSO), acetonitrile, nile red, phosphate buffered saline (PBS, pH 7.4), 
triethylammonium acetate buffer (TEAA), boric acid, bradford reagent (for 1-1400ug/ml 
protein), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, 
trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA), TWEEN® 20, glycerol, glycine, 
sodium dodecyl sulfate (SDS), Trizma® base, Trizma® hydrochloride, 
ethylenediaminetetraacetic acid (EDTA), bromophenol blue, and 
4
’
,6-diamidino-2-phenylindole (DAPI) were purchased from Sigma-Aldrich (St. Louise, MO, 
USA). Ethanol was obtained from VWR Singapore Pte Ltd. TWEEN® 80 was from ICN 
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Biomedicals, Inc. (OH, USA). Triton X-100 was from USB Corporation (OH, USA). Fetal 
bovine serum (FBS), penicillin-streptomycin solution, and lipofectamine 2000 were provided 
by Invitrogen. Dulbecco’s Modified Eagle’s Medium (DMEM) was purchased from Thermo 
Scientific Hyclone (South Logan, USA). Complete ultra tablets, mini, easypack was 
purchased from Roche (Mannheim, Germany). NIH3T3, MCF7, and SK-BR-3 cells were 
obtained from American Type Culture Collection (ATCC). Water was treated with the 
Milli-Q Plus System (Millipore Corporation, Bedford, USA). Amicon ultra-0.5 centrifugal 
filter units were purchased from Merk Millipore (Billerica, MA).  
5.2.2. Synthesis of TPGS-siPLK1 
TPGS was first activated by carbonyldiimidazole (CDI) to form an imidazole carbamate 
intermediate (TPGS-CDI). Briefly, weighted amount of TPGS and CDI (1:5 mol/mol) was 
dissolved in dioxane and reacted at 37 
o
C for 2 h. The reaction mixture was then precipitated 
three times in cold diethyl ether and dried overnight in a vacuum oven.  
Subsequently, amine terminated TPGS (TPGS-NH2) was synthesized by reacting TPGS-CDI 
with ethylenediamine (1:5 mol/mol) for 24 h in DMSO at room temperature. The reaction 
mixture was dialyzed (MWCO 1000) against DMSO for 48 h, and then against ultrapure (UP) 
water for another 48 h. The remaining reaction mixture in the dialysis tube was freeze-dried.  
TPGS-siPLK1 was then synthesized by conjugating TPGS-NH2 and siPLK1 using SPDP 
linker (100:1:10 mol/mol/mol) in DEPC treated sodium borate buffer (50 mM, PH 8.2) for 24 
h in nitrogen atmosphere at room temperature. The reaction mixture was then purified using 
143 
 
centrifugal filters with MWCO 10 kDa (Amicon ultra-0.5 mL, Ultracel-10 membrane, 10 
kDa).  
Synthesis of TPGS-siPLK1 was verified using ion-pair reverse-phase high performance 
chromatography (HPLC, Agilent HPLC 1200, Agilent, Tokyo, Japan) with C18 column 
(Agilent Poroshell 120 EC-C18) as described previously [267]. Mobile phase A consists of 5% 
acetonitrile in 0.1 M triethylammonium acetate (TEAA) buffer. Mobile phase B consists of 15% 
acetonitrile in 0.1 M TEAA buffer. siPLK1, TPGS-NH2, and TPGS-siPLK1 were separated 
and detected at 260 nm, with a gradient elution from 20% B to 57.7% B in 15 min, followed 
by stabilizing at 20% B for 5 min. The column temperature is kept at 60 
o
C throughout the 
analysis.  
5.2.3. Preparation of micelles 
To prepare docetaxel loaded TPGS-siPLK1/TPGS micelle, weighed amount of TPGS, 
TPGS-siPLK1, and docetaxel were dissolved in chloroform, followed by evaporation of 
chloroform by rotary vacuum evaporator. The film was further dried in vacuum overnight and 
hydrated in 1X PBS buffer. The suspension was incubated at 37 
o
C for 15 min under constant 
agitation, followed by 15 min ultrasound sonication. Micelles functionalized with amine 
groups were prepared in the same way, except that 50 wt% of TPGS is replaced by 
TPGS-NH2. Herceptin was then conjugated to the micelles by carbodiimide chemistry with 
the assistance of EDC and NHS in a DEPC-treated sodium borate buffer solution (50 mM, PH 
9.2). The same procedure was used for the synthesis of fluorescent nile red loaded micelles, 
except that docetaxel was replaced by 0.05 wt% nile red. 
144 
 
From now on, we denote by micD, micSD and micSDH the docetaxel (or re fluorescence nile 
red) loaded TPGS micelles, the docetaxel (or re fluorescence nile red) loaded 
TPGS-siPLK1/TPGS micelles without and with herceptin conjugation respectively. 
5.2.4. Micelle shape, size and size distribution 
Micelles were visualized using field emission transmission electron microscope (FETEM, 
JEM-2200FS, JEOL, Japan). Size and size distribution of micelles were measured by dynamic 
light scattering (DLS) (90 plus particle size analyzer, Brookhaven Instruction Corporation, TX, 
USA). The samples were prepared by diluting the micelle suspensions with ultrapure water to a 
count rate of 300-500 kcps and sonicated for 2 min before measurement.  
5.2.5. Drug load and siPLK1 load 
The amount of docetaxel loaded in the micelles was determined by high performance liquid 
chromatography (HPLC, Agilent LC1100, Agilent, Tokyo, Japan) with absorption peak at 230 
nm. A reverse-phase column (Eclipse XDB-C18, 4.6x250 mm, 5 µm) was used. Briefly, 0.4 mg 
of freeze-dried micelles were dissolved in 0.4 mL DCM, followed by overnight evaporation of 
DCM. The resulting sample was reconstituted in 0.2 mL mobile phase consisting of acetonitrile 
and water (50:50 v/v) under ultrasonication. After centrifugation at 10,000 for 10 min, 
supernatant of the suspension was collected for HPLC analysis. Flow rate was set to be 1.0 
ml/min. Drug load is defined as weight percent of drug per milligram of drug loaded micelles.  
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SiPLK1 load is defined as nmol of siPLK1 per mg of siPLK1 loaded micelles. It is 
determined by Picogreen assay (Invitrogen, Carlsbad, USA) using unmodified siPLK1 for 
plotting the standard curve. 
5.2.6. Controlled release of docetaxel and siPLK1 
For docetaxel release study, a designated volume of docetaxel encapsulated 
TPGS-siPLK1/TPGS micelles (0.26 nmol/mg siPLK1 load and 3.9 wt% docetaxel load) with 
the addition of 0.1% w/v TWEEN® 80 was loaded into a dialysis bag (MWCO 10 kDa). The 
dialysis bag was immersed into 20 mL of 1X PBS buffer (pH 7.4) containing 0.1% w/v 
TWEEN® 80 with or without glutathione (GSH) at 37 
o
C under constant shaking. The 
incubation medium outside dialysis bag was collected and replaced with fresh incubation 
medium in designated time points. After the collected incubation medium being freeze-dried, 
the amount of docetaxel was quantified using HPLC by the same method for the measurement 
of drug load.  
For siPLK1 release study, dialysis tubes (MWCO 30 kDa) containing 2 mL of 
TPGS-siPLK1/TPGS (0.26 nmol/mg siPLK1 load and 3.9 wt% docetaxel load) micelles were 
immersed in 1X PBS buffer (PH 7.4) containing 0.1% w/v TWEEN® 80 with or without 
glutathione (GSH). The assemblies were kept at 37 
o
C under constant shaking. At designated 
time points, incubation medium outside dialysis bags was collected and replaced by fresh 
incubation medium. The siPLK1 concentrations in the collected release mediums were 
measured using Picogreen assay.  
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5.2.7. Cell culture 
NIH3T3, MCF7, and SK-BR-3 cells, which are of low, moderate and high overexpression of 
the human epidermal growth factor receptor 2 (HER2) respectively, were cultured using 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS and 1% 
penicillin-streptomycin solution in 75 mL cell culture flask. Cells were cultivated in an 
incubator at 37 
o
C with 5% carbon dioxide. 
5.2.8. In vitro siPLK1 transfection efficiency 
SK-BR-3 cells were seeded in 6-well tissue culture plates at 2x10
5
 cells/well and incubated at 
37 
o
C in 5% CO2 for 24 h. The cells were then incubated with various TPGS-siPLK1/TPGS 
micelle formulations for 24 h (for RNA isolation) and for 48 h (for protein isolation). PLK1 
mRNA and PLK1 protein expression level were analyzed by qRT-PCR and western blot, 
respectively. More specifically, for qRT-PCR measurement, total RNA was isolated using 
RNeasy mini-kits (Qiagen, Germantown, MD) according to supplier’s protocol. PLK1 mRNA 
level was quantified using iScript
TM
 one-step RT-PCR kit with SYBR
® 
green (Bio-Rad) and 
iQ
TM
5 real-time PCR detection system according to the manufacturer’s protocol with slight 
modification. Relative gene expression level was calculated using ΔΔCT method with 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene expression level as a reference. 
Data are normalized to PLK1 expression level of control cells without any treatment. 
Specificity was verified by melting curve analysis.  
Western blot was employed to analyze the relative expression level of PLK1 protein. Briefly, 
cells were washed once with 2 mL cold PBS and resuspended in 200 μL of lysis buffer (50 mM 
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Tris-Hcl, PH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol) freshly 
supplemented with Roche’s Complete Protease Inhibitor Cocktail Tablets. The cell lysates 
were transferred into 1.5 mL Eppendorf tube, sonicated, vortexed and incubated on ice for 30 
min under constant agitation. After the incubation, lysates were centrifuged at 12,000 rpm for 
20 min. Supernatants were collected, and the total protein concentrations were measured using 
Bradford assay mode of Nanodrop 1000 (Thermo Scientific, Wilmington, USA). 20 μg of total 
protein was loaded and separated on 10% Ready Gel Tris-HCL Gel (Bio-Rad, Hercules, CA) 
and transferred (at 200 mA for 1.5 h) to PVDF membranes (Millipore, Bedford, MA). 
Subsequently, the PVDF membrane was blocked in blocking buffer (5% bovine serum albumin 
in phosphate buffer saline with TWEEN® 20 (TBST, PH 7.2)) for 1 h, and stained with primary 
antibody in blocking buffer (1:500) overnight at 4 
o
C. After washing with TBST for several 
times, the membrane was further stained with HRP labeled secondary antibody in TBST 
(1:1000) for 1 h at room temperature. Bands were detected using ECL system (Pierce) and 
ChemiDoc
TM
 MP Imager (Bio-rad).  
5.2.9. In vitro co-localization of docetaxel, siPLK1 and Herceptin in cell cytoplasm 
After reaching confluence, cells were detached, counted, and seeded in a 4-well coverglass 
chamber (LAB-TEK, Nagle Nunc, IL, USA) overnight. Then, the medium was replaced by nile 
red encapsulated picogreen-siRNA conjugated or nile red encapsulated FAM-herceptin 
decorated micelle suspension (micelles suspended in cell culture medium) at concentration of 
0.125 mg/mL and incubated for 2 h. The cells were washed five times with pre-warmed 1x PBS 
and fixed with 70% ethanol for 20 min. After that, the cells were washed twice with 1x PBS and 
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then the nuclei were counterstained by DAPI for 45 min. The cells were washed again twice by 
1x PBS and immersed in 1x PBS for confocal microscopic imaging.   
5.2.10. In vitro cytotoxicity 
NIH3T3, MCF7, and SK-BR-3 cells were seeded respectively in 96-well transparent plates 
(Costar, IL, USA) at 5x10
3
 cells/well (0.1ml) and after 12 h, the medium was then replaced by 
Taxotere
®
 or micellar formulations at the various designated concentrations and incubated for 
24 h, 48 h, and 72 h, respectively. The micellar formulations were sterilized with UV irradiation 
for 2 h before the experiment. Cell viability was measured using MTT  
((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay 
standard protocol.  
5.2.11. Phase-contrast time-lapse study of cell division 
NIH3T3, MCF7, and SK-BR-3 cells were seeded in a 12-well transparent plate at 1x10
4
 
cells/well (1 mL) and after 12 h, the medium was replaced by Taxotere or micelle formulations 
of docetaxel in medium at docetaxel concentration of 0.25 μg/mL. SiRNA concentration for 
micSD is 125 nM. The plate was then loaded into the Cell IQ (Cybeles Life Science, Finland) 
for 48 h. Images was taken for each position every 15 min.   
5.2.12. In vitro quantitative study of cellular uptake before and after herceptin 
conjugation 
After reaching confluence, cells were detached, counted, and seeded in 96-well black plate 
(NUNC, NY, USA) at 2x10
4
 cells/well concentration. After 24 h incubation, medium was 
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replaced by nile red loaded micelle suspensions with micelle concentration of 0.125mg/ml. 
After 2 h incubation, the micelle suspension was removed. Cells were washed twice with 1x 
PBS, and immersed in 50 µl of 0.5% Triton X-100 in 0.2 N NaOH solutions. After 15 min 
incubation under gentle shaking, the fluorescent intensities were measured with a microplate 
reader at excitation wavelength of 430 nm, and emission wavelength of 485 nm.  
5.2.13. In vitro cytotoxicity of micSD before and after herceptin conjugation 
NIH3T3, MCF7, and SK-BR-3 cells were seeded in 96-well transparent plates (Costar, IL, 
USA) at 5x10
3
 cells/well (0.1ml) and after 12 h, the medium was replaced by micelle 
suspensions at designated concentrations for 24 h. The micelles were sterilized with UV 
irradiation for 2 h before the experiment. Cell viability was measured using MTT 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay 
standard protocol.  
5.3. Results and Discussions 
5.3.1. Synthesis of TPGS-siPLK1 
TPGS-siPLK1 was synthesized by conjugating TPGS-NH2 and siPLK1-SH via SPDP linker. 
With this strategy, disulfide bond was formed between TPGS and siPLK1, giving siPLK1 
character of enzyme triggered release. The success of synthesis is verified using ion-pair 
reverse-phase HPLC according to previously established method [107]. The HPLC absorption 
maximum of siPLK1-SH, TPGS-NH2, and TPGS-siPLK1 are shown at 1.993, 1.614, and 
1.854 min retention time (Fig. 5.2). The shift of retention time of siPLK1-SH from 1.993 min 
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to 1.854 min indicates that the chemical modification of siPlk1-SH with TPGS is successful. 
The additional peak at 1.614 min in Fig. 5.2 (C) shows that TPGS-NH2 is not completely 
removed from the reaction mixture after purification. The amount of TPGS-NH2 in the 
reaction mixture could be quantified by establishing a standard curve of TPGS-NH2. It is not 
necessary to completely eliminate free TPGS, because the micelles could be formed by 
mixing appropriate amount of TPGS with the synthesis product with consideration of the 
quantity of TPGS-NH2 in the reaction mixture.   
 
Fig. 5.2. High performance liquid chromatography (HPLC) spectrum of siPLK1 (A), 
TPGS-NH2 (B), and a mixture of TPGS-NH2 and TPGS-siPLK1 (C). 
 
5.3.2. Characterization of micD, micSD, and micSDH 
The size and size distribution of the micelles were measured by dynamic light scattering (DLS) 
and visualized by field emission transmission electron microscope (FETEM). The DLS 
measurement and FETEM images (Fig. 5.3) show that before the incorporation of 
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TPGS-siPLK1, the size of the TPGS micelles (micD) was around 15 nm. After incorporation of 
designated amount of TPGS-siPLK1 (micSD), the micelle size increased to around 120 nm. 
This phenomenon could be attributed to the addition of modified biomacromolecules (e.g. 
protein, siRNA) during micelle formation [268]. Furthermore, after the conjugation of 
herceptin on micelle surface, the size of micelles (micSDH) further increased to around 190 nm 
with wider size distribution. Although there was an increase in size after incorporating siPLK1 
and herceptin in TPGS micelle, the micSDH micelle size was still smaller than 200 nm, which 
is appropriate for penetration of the micelles through the leaky vasculature at tumor site to 
realize passive targeting [269, 270].  
 
Fig. 5.3. Representative field emission transmission electron microscope (FETEM) images 
(upper row) and dynamic light scattering (DLS) measurement (lower row) of the docetaxel 
loaded TPGS micelles (A), the docetaxel loaded TPGS-siPLK1/TPGS micelles (B), and the 
herceptin conjugated docetaxel loaded TPGS-siPLK1/TPGS micelles (C). 
5.3.3. Drug and siPLK1 load 
Drug load and siPLK1 load could be quantitatively controlled by adjusting the drug to polymer 
ratio and TPGS-siPLK1 to TPGS ratio respectively in the process of micelle preparation. When 
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the weight ratios of docetaxel to polymer were varied from 35% to 0.0035%, the drug loads 
changed from 30.3% to 0.006% after washing using centrifugal filtering unit as shown in Fig. 
5.4 (A). However, after 2 month storage at 4
o
C, the micellar formulation with 30.3% drug load 
became slightly opaque. This could be due to the reduction in drug solubility when they were 
released out of the micelles. In addition, when the input TPGS-siPLK1 to TPGS ratio were 5 
nmol/mg, 2.5 nmol/mg, 1.25 nmol/mg, 0.5 mol/mg, and 0.25 nmol/mg, the siPLK1 load was 
measured to be 1.34 nmol/mg, 0.59 nmol/mg, 0.26 nmol/mg, 0.10 nom/mg, and 0.05 nmol/mg, 
respectively. It can be seen from Fig. 5.4(B) that there is a positive correlation between the 
input TPGS-siPLK1 ratio and the siPLK1 load, indicating that siPLK1 load could be controlled 
by adjusting the TPGS-siPLK1 to TPGS ratio.  
 
 
Fig. 5.4. Quantification of drug load by HPLC (A), and quantification of siPLK1 load by 
picogreen assay (B). Data represent mean + SD, n = 3. 
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5.3.4. Transfection efficiency 
Transfection efficiency of siPLK1 formulated in the TPGS-siPLK1/TPGS micelles was 
assessed by measuring the relative PLK1 protein level and PLK1 mRNA level of SK-BR-3 
cells after 48 h incubation (Fig. 5.5). The cells without treatment was used as negative control, 
while the cells treated with lipofectamine 2000 formulated siPLK1 according to suppliers 
protocol was used as positive control. It can be seen from the image that siPLK1, when 
conjugated via disulfide bond onto TPGS micelles, siPLK1 could still effectively down 
regulate PLK1 mRNA level and PLK1 protein level in a dose dependent manner. The result 
suggests that conjugation of thio-modified siPLK1 with TPGS does not impair its function as a 
post-transcriptional regulator.  
 
Fig. 5.5. PLK1 protein expression level measured by western blot (A) and relative PLK1 
mRNA level measured by quantitative real-time PCR (B) without treatment (control), and after 
being treated with lipofectamine 2000 formulation of 50 nM siPLK1 (50 nM lipo), and 
TPGS-siPLK1/TPGS micelles formulation of 25 nM, 50 nM, 125 nM, and 250 nM of siPLK1. 




5.3.5. In vitro drug and siRNA release 
The in vitro drug release profiles of docetaxel from the TPGS-siPLK1/TPGS micelles in 120 h 
are shown in Fig. 5.6(A). There is an initial burst release of docetaxel in the first 10 h, during 
which 44.2% and 53.9% of drug is released from micelles incubated in the medium without and 
with glutathione (GSH), respectively. This phenomenon, which could be attributed to the 
docetaxel located near the surface of the micelles, was also observed for the docetaxel loaded 
TPGS2k micelles [265]. In the following hours, docetaxel was released in a sustained manner 
with a much slower rate. After 120 h, 55.6% and 69.8% of docetaxel had been released from the 
micelles incubated in release medium without and with GSH, respectively. Generally, the 
release of docetaxel was faster when the release medium was supplemented with 10 mM GSH, 
which could cleave the disulfide bond between siPLK1 and TPGS, leading to instability of the 
micelles and thus accelerated drug release.  
The in vitro release profiles of siPLK1 from the TPGS-siPLK1/TPGS micelles in 216 h are 
shown in Fig. 5.6(B). Compared to the micelles incubated in 1x PBS release buffer, faster 
release of siPLK1 was triggered in the GSH supplemented 1x PBS release buffer, especially in 
the first 48 h. In the first 48 h, 67.3% of the siPLK1 was released in the GSH containing buffer, 
while only 43.4% of the siPLK1 was released in the buffer without GSH. After 216 h 
incubation, 89.0% and 74.7% of the conjugated siPLK1 were released when incubated in the 
release buffer with and without GSH, respectively. Hence, faster intracellular release of siPLK1 
could be expected due to elevated GSH level in cell cytoplasm. Moreover, accelerated drug 
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release could be facilitated due to reduced stability of the micelles upon the cleavage of 
disulfide bond.  
 
Fig. 5.6. In vitro accumulative release profile of docetaxel (A) and siPLK1 (B) from docetaxel 
loaded TPGS-siPLK1/TPGS micelles. Data represent mean + SD, n = 3. 
 
5.3.6. Co-delivery of drug, siRNA and Herceptin to cell cytoplasm  
Confocal laser scanning microscopy (CLSM) was employed to visualize cellular uptake of the 
fluorescent nile red loaded TPGS-siPLK1/TPGS micelles (also denoted by micD, micSD and 
micSDH respectively depending on with or without siPLK1 and with or without herceptin 
involved) by SK-BR-3 cells after 2 h incubation (Fig. 5.7). Row A and row B show the images 
of red fluorescent dye nile red loaded micelles with green fluorescent staining of siPLK1 and 
herceptin, respectively. Column 1 demonstrates images obtained from DAPI channel, which 
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represent DAPI stained nuclei; column 2 shows images obtained from PI channel, which 
represent red fluorescent hydrophobic dye nile red loaded in the TPGS-siPLK1/TPGS micelles 
as a representative of hydrophobic drug docetaxel; column 3 shows images obtained from FITC 
channel, which represent the green fluorescent dye stained siPLK1 (Fig. 5.7(A)) or Herceptin 
(Fig. 5.7(B)); column 4 demonstrates the merged images of the three channels. It can be seen 
from column 4 that DAPI stained nuclei is circumvented by red and green fluorescence 
overlapping each other, suggesting that herceptin and siPLK1 decorated, docetaxel loaded 
TPGS micelles had been internalized into the cytoplasm of the SK-BR-3 cells.  
 
Fig. 5.7. Representative confocal laser scanning microscopy (CLSM) images show the cellular 
uptake of the fluorescent nile red loaded micelles with surface picogreen stained siPLK1 (A) or 
FITC stained herceptin (B). 
 
5.3.7. SiPLK1 enhanced therapeutic efficacy of docetaxel loaded TPGS micelles 
Docetaxel is a powerful anti-mitotic anticancer drug; however, its application is limited by its 
narrow therapeutic window and low solubility issues. Not only does the TPGS micellar 
formulation of docetaxel realize sustained and controlled delivery and passive targeting, but 
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show significantly enhanced therapeutic effects as well [265]. Surface conjugation of siPLK1 
to the docetaxel loaded TPGS micelles could further enhance the therapeutic efficacy of the 
formulation by suppressing the multidrug resistance and arousing synergistic effects between 
the two agents. The cytotoxicity of the docetaxel loaded TPGS-siPLK1/TPGS micelles (micSD) 
was investigated on NIH3T3 fibroblast, ER-positive MCF7, and HER2 positive SK-BR-3 
breast cancer cell lines, which are of low, moderate and high overexpresstion of Her 2 receptors, 
respectively in comparison to the docetaxel loaded TPGS micelles (micD), and commercial 
formulation of docetaxel (Taxotere®) (Fig. 5.8). The siPLK1 concentration in the micSD was 
chosen to be 125 nM, because at this concentration, 88.8% of PLK1 mRNA expression could 
be inhibited (Fig. 5.5).  
It can be observed from Fig. 5.8 that all formulations demonstrated dose and time dependent 
toxicity on all the three cell lines, except for Taxotere and the micD formulation at 0.0025 
μg/mL docetaxel concentration on NIH3T3, which showed little anti-proliferative effect. 
Similar to what has been reported in literature, the micD improves the efficacy of the drug in 
comparison with Taxotere in in vitro [265]. Fig. 5.8 also shows that the micSD also greatly 
enhanced the therapeutic effects. It can be seen from Table 5.1 that compared to micD, the IC50 
of the micSD after 24 h, 48 h, and 72 h incubation is reduced by 99%, 99.5%, and 99.8% for 
NIH3T3 fibroblast cells; by 88.0%, 98.3%, and 83.0% for MCF7 cell line; and by 92.4%, 
89.5%, and 90.4% for SK-BR-3 cells respectively. The significant decrease in IC50 for NIH3T3 
cells suggests that combining siPLK1 with docetaxel could potentially increase the cytotoxicity 
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to the normal cells. However, IC50 for NIH 3T3 cells could be alleviated by passive targeting of 
the nanosized micelles, and active targeting of ligand decorated micelles.  
 
Fig. 5.8. Cell viability study of NIH3T3 (A, D, and G), MCF7 (B, E, H), and SK-BR-3 (C, F, I) 
cells incubated with docetaxel loaded TPGS-siPLK1/TPGS micelles of 125 nM siPLK1 
concentration, docetaxel loaded TPGS micelles, and Taxotere for 24 h (A, B, C), 48 h (D, E, F), 








Table 5.1. IC50 (µg/mL) of docetaxel formulated in Taxotere, TPGS micelles (micD), and 
TPGS-siPLK1/TPGS micelles (micSD) after 24, 48, and 72 h incubation with NIH3T3 
fibroblast, MCF7, and SK-BR-3 breast cancer cells. 
Incubation 
time (h) 
Formulation NIH3T3 MCF7 SK-BR-3 
 
24 h 
Taxotere 45.37 7.49 1.72 
micD 0.11 0.020 0.042 
micSD 0.0011 0.0024 0.0032 
 
48 h 
Taxotere 0.64 0.052 0.182 
micD 0.124 0.0126 0.0143 
micSD 0.00057 0.0022 0.00150 
 
72h 
Taxotere 0.65 0.0145 0.00126 
micD 0.060 0.0054 0.0048 
micSD 0.000117 0.00092 0.00046 
 
5.3.8. Phase-contrast time-lapse analysis of cell division 
NIH3T3, MCF7, and SK-BR-3 cells with and without treatment were observed for 48 h under 
live cell imaging system (Cell IQ, Finland). The images are shown in Fig. 5.9(A), Fig. 5.9(B), 
and Fig. 5.9(C), respectively, in which 0 min corresponds to the time point at which the 
treatment started. Row 1, 5, and 9 are cells without any treatment, serving as control; row 2, 6, 
10 are cells treated with Taxotere; row 3, 7, and 11 are cells treated with the micD; while row 4, 
8, and 12 are cells treated with micSD. The docetaxel concentration of all formulations is kept 
at 0.25 μg/mL; while the siPLK1 concentration for micSD is 125 nM.  
It has been observed that under the treatment of all formulations of docetaxel, cells were 
arrested in mitosis, and most of them failed to split into two daughter cells. The time of mitotic 
arrest was longer for the cells treated with micD than for the same cells treated with Taxotere. 
Although the concentration of docetaxel was the same for both formulations, the TPGS 
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micelles promoted drug accumulation into cytoplasm, which could elevate the intracellular 
level of docetaxel. It has been shown that increase in taxol dosage prolong the time of mitotic 
arrest [271]. Hence, the improvement in drug efficacy is potentially attributed to the increase in 
intracellular drug dosage. In addition, the duration of mitotic arrest was further increased for the 
micSD treated cells. It is shown in literature that PLK1 plays an important role in mitotic entry 
and mitotic exit. Reduction in the PLK1 level using siPLK1 causes cell cycle arrest in G2/M 
phase [272, 273]. Extension of the time of mitotic arrest after introducing siPLK1 to the 
docetaxel formulated in the TPGS micelles could be the reason that leads to a reduction in cell 




Fig. 5.9. Phase-contrast time-lapse analysis of cell division of NIH3T3 (A), MCF7 (B), and 
SK-BR-3 (C) without treatment (1, 5, 9) or being treated with Taxotere (2, 6, 10), docetaxel 
loaded TPGS micelles (3, 7, 11), and docetaxel loaded TPGS-siPLK1/TPGS micelles (4, 8, 12). 
Docetaxel concentration for all formulations is 0.25 μg/mL, and siPLK1 concentration for 
TPGS-siPLK1/TPGS micelles is 125 nM. 0 min is when the cells are under treatment for 24 h. 
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5.3.9. Targeting effect after Herceptin conjugation 
Herceptin decoration on nanoparticles could enhance the therapeutic efficacy of nanocarrier 
formulation of anticancer drugs in the treatment of HER2 positive breast cancer due to its 
intrinsic toxicity to cancer cells as well as its ability in assisting nanocarriers get into cytoplasm 
via receptor mediated endocytosis [274, 275]. It is shown in Fig. 5.10 that herceptin conjugated 
TPGS-siPLK1/TPGS micelles (micSDH) demonstrated 20.1% and 26.5% cell internalization, 
which are 53.4% and 38.6% higher than the micelles without herceptin after 0.5 h and 2 h 
incubation with SK-BR-3 cells of high HER2 overexpression, respectively (Fig. 5.10(A)). Such 
results suggest that herceptin could accelerate cellular uptake of the micelles.  
Cytotoxicity of the micSD and the micSDH at the various designated docetaxel concentrations 
were investigated on SK-BR-3 cells of high HER2 overexpression, the results are shown in Fig. 
5.10(B). In general, both the micSD and the micSDH demonstrated dose and time dependent 
toxicity. A positive correlation between cytotoxicity and drug dose or time could be observed. 
At the same drug dose and incubation time, the micSDH (with herceptin conjugation) showed 
significantly higher toxicity than the micSD (with no herceptin conjugation) on SK-BR-3 cells. 
For example, at 0.1 μg/mL doxetaxel and 125 nM siPLK1 concentraton, the cell viability after 
treatment for 24 h, 48 h, and 72 h are 35.5%, 21.8%, and 13.2% for the micSDH in comparison 
with 37.1%, 26.8%, and 18.1% viability for micSD, respectively. When compared to that of 
micSD, the IC50 of micSDH on SK-BR-3 cells is decreased by 89.2%, 61.1%, and 94.7% after 
24 h, 48 h, and 72 h of incubation, respectively (Table 5.2). The results suggest the therapeutic 




Fig. 5.10. Cellular uptake efficiency of nile red loaded micSD and micSDH (A); and 
cytotoxicities of micSD and micSDH at 125 nM siPLK1 concentration and 0.1 μg/mL, 0.05 
μg/mL, 0.01 μg/mL, and 0.001 μg/mL docetaxel concentrations. Data represent mean + SD, 
n=6. 
 
Table 5.2. IC50 (µg/mL) of docetaxel formulated in Taxotere, micD, micSD, and micSDH after 
24, 48, and 72 h incubation with HER2 overexpressed SK-BR-3 breast cancer cells. 
SK-BR-3 IC50 
 Taxotere micD micSD micSDH 
24 h 1.72 0.0420 0.00621 0.000671 
48 h 0.182 0.0143 0.001148 0.000446 





We developed a system of Herceptin conjugated micelles of vitamin E TPGS and 
TPGS-siPLK1 conjugate for targeted co-delivery of docetaxel and siPLK1 to achieve 
synergistic effects between chemotherapy and gene therapy of breast cancer of HER2 
overexpression. Conjugation of siRNA to the micelles are made via disulfide bond that could 
prevents premature release of siRNA and facilitates triggering of its release in glutathione 
elevated environment such as in the cell cytoplasm. Such a sophisticated micellar structure 
showed great advantage in nanomedicine design: (1) it can be applied to co-delivery 
hydrophilic drug, which can be conjugated to TPGS, and the hydrophobic drug, which can be 
encapsulated in the micellar core; (2) it can arouse a synergistic interaction between siRNA and 
the anticancer drug, which is realized by suppression of the multidrug resistance of the cancer 
cells; (3) targeted co-delivery can be realized through ligand conjugation on the micellar 
surface, which could greatly increase the specificity of the drug to the cancer cells thus enhance 
its therapeutic effects and reduce its side effects. Further in vivo experiments are definitely 








Chapter 6. Co-delivery of cisplatin and siPLK1 by 
PLL-TPGS/cisplatin prodrug nanogels 
6.1. Introduction 
The treatment of cancer in the past 30 years has been surgery, radiotherapy and chemotherapy. 
With failure of these treatments, the patients have only less than 10% to survive. Efforts at 
improving current therapies include development of new therapy methods such as targeted 
therapy, thermotherapy, immunotherapy, gene therapy, etc.; classification of breast cancer into 
subgroups based on immunohistology and gene expression profile to realize personalized 
medicine; synthsis of prodrug or nanocarrier formulation of drug to solve the delivery problems 
by improving pharmacokinetics and biodistribution of existing therapy agents; and to develop 
new combination regimens for better efficacy. Breast cancers are historically classified into 
estrogen receptor (ER) positive, progesterone receptor (PR) positive, human epidermal growth 
factor receptor 2 (HER2) positive, and triple negative (i.e. ER, PR, and HER2 negative) breast 
cancer based on immunohistology analysis of cell surface biomarkers. HER2 positive and triple 
negative breast cancers are correlated with poor prognosis and high tendency of metastasis. 
Targeted therapy has been developed for HER2 positive breast cancers, but not for the triple 
negative breast cancer (TNBC) subtypes due to the heterogeneity. Gene expression analysis 
using DNA arrays classified breast cancer into five subtypes, luminal A, luminal B, 
HER2-enriched basal-like, and claudin-low; which was widely recognized and was found to 
have prognostic value (e.g. risk in recurrence and metastasis). 
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Cis-diamminedichloroplatinum (II) (cisplatin or cispt) is a widely used chemotherapy agent for 
the treatment of many tumors, especially testicular and ovarian. Platinum-based agents which 
include cisplatin, carboplatin, and oxaliplatin have emerged in recent years to be drugs of 
interest for the treatment of TNBC. Cisplatin can bind to DNA and form adducts which are 
poorly repaired due to the shielding effect of high-mobility-group (HMG) proteins which 
prevent effective DNA repair [276]. Cisplatin inhibition of DNA synthesis and induction of G2 
arrest and apoptosis are two proposed mechanisms which attribute to the antitumor activity of 
cisplatin. Induction of G2/M arrest and apoptosis is widely accepted as the main contributor. It 
was proposed that the G2/M arrest and apoptosis were due to the translesion DNA synthesis 
(random incorporation of nucleotides opposite to the DNA-cisplatin adducts), and subsequent 
mismatch repair machinery, which was shown to induce apoptosis via P53 or P73 mediated 
pathways. The major limitations of the use of cisplatin include the severe dose-limiting 
toxicities (e.g. renal toxicity, neurotoxicity); inefficient cellular uptake into certain types of 
cancer cells; significant reduction in activity by increase in PH, chloride concentration, serum 
protein binding, glutathione (GSH), etc.; as well as intrinsic or acquired drug resistance due to 
mutations in P53, P73, and alterations in gene repair machineries [277].  
Polo-like kinase 1 (PLK1) is a regulator of mitosis which include mitotic entry, spindle 
formation, chromosomal segregation, and mitotic exit (i.e. cytokinesis). It is overexpressed in a 
broad range of tumors. Inhibition of PLK1 by small molecule inhibitors or small interfering 
RNA (siPLK1) was shown to cause mitotic arrest and subsequent apoptosis in a 
dose-dependent manner. PLK1 inhibitors have entered clinical trials. Knockdown of PLK1 
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using siPORT Neo Fx transfection reagent has been shown to sensitive cisplatin via 
up-regulation of p73α in P53 mutant human carcinoma cells [278]. The enhancement in 
cisplatin sensitivity was manifested by the reduction in IC50, increase in capspase-3 activity, 
DNA fragmentation, and sub-G1 population. The proposed reason was the induction of 
irreversible DNA damage-induced G2 arrest and subsequent apoptosis by siPLK1. It was 
shown that PLK1 plays a pivotal role in the recovery of cells from DNA-damage induced G2 
arrest; i.e. the resume of mitosis after G2 arrest [279, 280]. In addition, PLK1 was shown to 
reduce the activity of P53, which is an important mediator of DNA-damage induced apoptosis 
[281]. Furthermore, it was found that during cisplatin-induced apoptosis in neuroblastoma 
SH-SY5Y cells, PLK1 was significantly reduced at both mRNA and protein level, whitch then 
led to a remarkable stabilization of p53. Hence, simultaneous inhibition of PLK1 during 
cisplatin treatment may increase cell apoptosis and reduce cell recovery for G2 arrest.  
The developments of small molecule inhibitors are the mainstream in current pharmaceutical 
industry; the process involves intensive screening of enormous structurally similar compounds, 
however, many of these molecules failed at phase II or phase III clinical trials due to lack of 
potency or specificity. SiRNA is a double strand RNA with 21-23 nucleotides. It functions by 
guiding the ribonucleoprotein complex RNA-induced silencing complex (RISC) to target 
messenger RNA (mRNA), cleaving it at specific sites, leading to fast degradation of the mRNA 
and a reduction in the corresponding protein level. SiRNAs which are designed following the 
established design criteria usually have a high efficiency in silencing the target genes, 
eliminating the labor intensive screening process. However, the main obstacle for the in vivo 
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application of siRNA therapeutics is its delivery, because of the unfavorable properties of 
siRNAs such as sensitivity to enzymatic degradation, fast renal clearance, immunogenicity, and 
inability to efficiently penetrate cell membrane. SiRNA based nanomedicine, i.e. nanocarrier 
formulation of siRNA, could solve the delivery problems of siRNA by facilitating sustained, 
controlled and targeted delivery, and provide a platform for co-delivery of siRNA and other 
therapeutic agents.  
Nanogels (i.e. Nanohydrogels, hydrogel nanoparticles) are physically or chemically 
crosslinked nanostructures with high water content. Hydrophilic bioactive agents can be easily 
loaded into the crosslinked matrix; and the releases are controlled by diffusion, polymer erosion 
and crosslinker cleavage. SiRNAs as negatively charged macromolecules can facilitate 
physical gelation of positively charged polymers to form siRNA loaded nanogels which is also 
called siRNA polyplex. However, the nanogels formed by direct mixing are usually unstable 
with heterogeneous sizes. To improve the size uniformity and stability, methods such as 
thermal gelation, chemical crosslinking, emulsion polymerization, inverse emulsion and 
chemical crosslinking of polymer chains, and particle replication in nonwetting templates 
(PRINT) have been used for entrapment of siRNA. Hydrophilic small molecule drugs such as 
cisplatin and doxorubicin can also be loaded into nanogel matrix; however, due to the large 
number of water permeable and interconnected pores, the drugs can diffuse out quickly form 
the gel matrix into aqueous solutions. Conjugation of the hydrophilic small molecule drugs via 
cleavable linkages to form prodrug based nanocarriers has the potential to increase loading, 
reduce premature release, and realize environmentally triggered release. Kolishette et al. loaded 
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cisplatin into polymeric nanoparticles by first conjugating cisplatin-succinic acid (cisplatin-SA) 
and a polylactide (PLA) derivative with pendant hydroxyl groups through ester bonds; the 
synthesized PLA-Pt was mixed with PLGA-PEG to form nanoparticle of 100 nm size via 
nanoprecipitation method which was achieved using microfluidic channels [282]. The 
encapsulation efficiency (EE) and drug load of cisplatin was 95% and 5% (< 50 wt% PLA-Pt 
input) compared to 5% EE and 0.5% drug load when free drug were attempted to be loaded into 
PLGA-PEG nanoparticles. Mi et al. conjugated cisplatin-SA and D-α-tocopheryl polyethylene 
glycol 1000 succinate (TPGS); and used the synthesized amphiphilic polymer TPGS-cisplatin 
and TPGS to form micelles of 12.56 nm in diameter and a narrow size distribution [283]. The 
drug load was precisely controlled by variation of TPGS-cisplatin to TPGS ratio. The cisplatin 
was released sustainably from the micelle in 120 h, and a faster release can be triggered by a 
reduction in PH (e.g. the PH in endosome). Interestingly, the author demonstrated on 
SH-SY-5Y (i.e. in vitro model of neuronal function) that the use of TPGS lead to a reduction in 
neuronal toxicity which is a dose-limiting toxicity of cisplatin.  
In this study, we modified 5% (mol/mol) of the ε-amines in poly-l-lysine (PLL, Mw 210k) with 
TPGS and use the synthesized PLL-TPGS to form siPLK1 loaded cisplatin-SA crosslinked 
prodrug nanogel by water-in-oil emulsion for the co-delivery of siPLK1 and cisplatin. PLL is a 
hydrophilic cationic biodegradable polymer which is widely investigated for gene delivery. 
PEG modification of PLL was shown to reduce toxicity, and increase stability and transfection 
efficiency [284]. TPGS is a water soluble derivative of vitamin E. It has been used as emulsifier, 
solubilizer, and bioavailability enhancer for both hydrophilic and hydrophobic drugs [129]. 
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Modification of PLL with TPGS can (1) potentially shield the highly positive surface charge of 
PLL nanogel, reducing the unspecific interaction with serum proteins and healthy cells; (2) 
improve stability due to the PEG component of TPGS which can provide steric hindrance; have 
better interaction with cells than PEG modified PLL; (3) serve as emulsifier in water-in-oil 
emulsion to reduce nanogel size. Co-delivery of two agents in one nanocarrier has been shown 
to have better efficacy than free agents cocktails due to the spatially controlled drug ratio and 
release sequence, and hence resolves the complexity of variation in pharmacokinetics and 
biodistribution. Characterizations of the nanogel for size and size distribution, surface charge, 
encapsulation efficiency, and in vitro release of siPLK1 and cisplatin were conduced. The 
improvement of cisplatin efficacies by co-delivered siPLK1 were assessed in vitro by IC50, the 
agent concentration needed to kill 50% of the cancer cells in a designated period, of the cancer 





Fig. 6.1. Schematic illustration of formulation of the cisplatin crosslinked siPLK1 loaded 
PLL-TPGS nanogel (GelSiPtcros) (A), and the crosslinking reaction (B).  
 
6.2. Materials and methods  
6.2.1. Materials 
Vitamin E TPGS (α-tocopheryl polyethylene glycol 1000 succinate, C33O5H54(CH2CH2O)23 ) 
was from Eastman Chemical Company, USA. Poly-L-lysine (PLL) (Mw 21,000) was 
purchased from Alamanda Polymers, Inc (Huntsville, AL, USA). Cis, cis, 
trans-diamminedichlorodisuccinatoplatinum (IV) (cisplatin-SA) was synthesized with 
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previously published method [283]. SiRNA targeting human Plk1 (siPLK 1) (sense strand, 
50-UGAAGAAGAUCACCCUCCUUA dTdT-30 and antisense strand, 
50-UAAGGAGGGUGAUCUUCUU CAdTdT-30) were supplied by Shanghai GenePharma 
Co. Ltd. (Shanghai, China). Succinic anhydride (SA), N,N'-Dicyclohexylcarbodiimide (DCC), 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-Hydroxysuccinimide (NHS), 
2,4,6-trinitrobenzene sulfonic acid (TNBS), diethyl pyrocarbonate (DEPC), nile red, 
phosphate buffered saline (PBS, pH 7.4), boric acid, bradford reagent (for 1-1400ug/ml 
protein), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, 
trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA), TWEEN® 20, and 
4
’
,6-diamidino-2-phenylindole (DAPI) were purchased from Sigma-Aldrich (St. Louise, MO, 
USA). Dimethylformamide (DMF) anhydrous, hexane, dichloromethane (DCM) anhydrous, 
dimethyl sulfoxide (DMSO) were purchased from Thermo Fisher Scientific (Waltham, MA, 
USA). Ethanol was obtained from VWR Singapore Pte Ltd. TWEEN® 80 was from ICN 
Biomedicals, Inc. (OH, USA). Triton X-100 was from USB Corporation (OH, USA). Fetal 
bovine serum (FBS), penicillin-streptomycin solution, and lipofectamine 2000 were provided 
by Invitrogen. Dulbecco’s Modified Eagle’s Medium (DMEM) was purchased from Thermo 
Scientific Hyclone (South Logan, USA). NIH3T3, MCF7, and SK-BR-3 cells were obtained 
from American Type Culture Collection (ATCC). Water was treated with the Milli-Q Plus 
System (Millipore Corporation, Bedford, USA). Amicon ultra-0.5 centrifugal filter units were 




6.2.2. Synthesis of PLL-TPGS 
TPGS was first conjugated with succinic anhydride to form carboxyl terminated TPGS 
(TPGS-COOH) through esterification reaction. Briefly, TPGS and succinic anhydride at molar 
ratio 1:5 were dissolved in anhydrous DMF at 5% concentration, and stirred at 70
o
C for 24 h 
under nitrogen atmosphere. Product was precipitated in cold diethyl ether three times, and dried 
in vacuum oven.  
PLL-TPGS was synthesized by conjugating TPGS-COOH and PLL at designated molar ratio 
by cabodiimide chemistry. Firstly, TPGS-COOH was activated to TPGS-NHS by dissolving 
TPGS-COOH, DCC, and NHS at a molar ratio of 1:2:2 in DCM anhydrous, incubating for 4 h 
under stirring and nitrogen atmosphere at room temperature for 4 h; followed by three times 
precipitation in cold diethyl ether. The precipitant was then dried in vacuum oven. 
Subsequently, PLL and TPGS-NHS were dissolved and mixed in sodium borate buffer (50 mM, 
PH 8.5) at molar ratio of 1:5; the reaction mixture was stirred at room temperature under 
nitrogen atmosphere for 24 h before being purified using centrifugal filters with MWCO 10 
kDa (Amicon ultra-0.5 mL, Ultracel-10 membrane, 10 kDa). The product was collected, 
freeze dried and stored in -20
o
C.  
The synthesis was verified by 
1
H NMR in D2O at 300 Hz (Bruker ACF300). The degree of 
modification was examined by quantifying the amine groups on PLL-TPGS by TNBS method. 
Briefly, weight amount of PLL and PLL-TPGS were dissolved in 1 mL 0.1 M sodium borate 
buffer in separate tubes, then 0.5 mL of 0.1% TNBS solution (TNBS in 0.1 M sodium borate 
buffer) was added to each tube. After 100 min incubation at 40 
o
C, absorption was measured 
174 
 
at 424 nm. The mixture of 1mL buffer and 0.5 mL of 0.1% TNBC solution was used as 
reference, and different concentrations of PLL (0.2 mg/mL to 1 mg/mL) were used for 
plotting the standard curve. 
6.2.3. Preparation of nanogel 
SiPLK1 loaded cisplatin crosslinked PLL-TPGS nanogel (GelSiPtcros) was prepared by 
oil-in-water emulsion method. Weighted amount of PLL-TPGS, siPLK1, EDC and NHS were 
dissolved separately in DEPC treated water; and cisplatin-SA was dissolved in MES buffer 
(50mM, PH 5.5). The aqueous phase of PLL-TPGS, siRNA, cisplatin-SA, EDC, and NHS 
(4:2:2:1:1 volume ratio) were added dropwise and separately into hexane (1:25 Vaqueous/Voil) 
under fast stirring. When hexane was evaporated to less than one tenth of the original volume, 
DEPC treated water with 0.03% w/v TPGS was added at volume one fifth of the original 
volume of hexane. Upon evaporation of the residual hexane, the suspension was collected and 
washed using centrifugal filters with MWCO 100 kDa (Amicon ultra-15). SiPLK1 loaded 
PLL-TPGS nanogel (GelSi), cisplatin crosslinked PLL-TPGS nanogel (GelPtcros), SiPLK1 
loaded cisplatin entrapped PLL-TPGS nanogel (GelSiPt), cisplatin entrapped PLL-TPGS 
nanogel (GelPt), FITC conjugated nonsense siRNA (siRNAsramble-FITC) loaded PLL-TPGS 
nanogel (GelSiscramble-FITC), and nonsense siRNA (siRNAscramble) loaded PLL-TPGS nanogel 
(GelSiscramble) were synthesized in similar ways with the addition of proper aqueous components. 
SiRNAscramble-FITC loaded PLL nanogel (PLLSiscramble-FITC) was prepared by dissolving 
siRNASramble-FITC and PLL separately in DEPC treated water and direct mixing under vertex, 
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followed by 30 min incubation at room temperature. The PLLSiscramble-FITC was synthesized 
freshly before adding into cells as suggested by literature.  
6.2.4. Nanogel shape, size, size distribution, and zeta potential 
Nanogels were visualized using field emission transmission electron microscope (FETEM, 
JEM-2200FS, JEOL, Japan). Size and size distribution were measured by dynamic light 
scattering (DLS) (90 plus particle size analyzer, Brookhaven Instruction Corporation, TX, 
USA). The samples were prepared by diluting the nanogel suspensions with ultrapure water to a 
count rate of 300-500 kcps before measurement. Zeta potentials of the nanogels were measured 
by Doppler anemometry (zeta plus analyzer, Brookhaven Corporation, USA). The data was 
obtained with the average of five measurements 
6.2.5. Drug load and encapsulation efficiency 
Cisplatin encapsulation efficiency was defied as the percentage of loaded cisplatin in the total 
amount of input cisplatin. Cisplatin load is defined as weight percentage of cisplatin in the 
cisplatin loaded nanogel formulations. The amount of cisplatin in the nanogels was analyzed 
with ICP-MS (Agilent ICP-MS 7500 Series). More specifically, weighted amount of 
GelSiPtcros, GelSiPt, GelPtcros, or GelPt was placed in glass a test tube, followed by the 
addition of 2 mL of concentrated nitric acid. The solution was heated to 90 °C for 45 min. Then 
the samples were diluted with sufficient ultra pure water. The analysis of platinum element was 
done by ICP-MS and the content of cisplatin was calculated according to its atomic mass. 
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SiPLK1 encapsulation efficiency was examined by agarose gel electrophoresis. In details, 
GelSiPtcross were prepared at different N/P ratios (i.e. the molar ratio between the nitrogen in 
PLL-TPGS and the phosphate in siPLK1). During preparation, the GelSiPtcross were collected 
and washed using centrifugal filters with MWCO 10 kDa which retained all nanogels and 
siPLK1, but washed off other components. After concentrated to the same volume, the 
mixture was loaded into 3% agarose gel and run at 100 V for 45 min to separate loaded and 
unloaded siPLK1.  
6.2.6. In vitro controlled release of cisplatin and siPLK1 
For cisplatin release study, a designated amount of GelPt, GelPtcros, GelSiPt, and 
GelSiPtcros at the same Pt and SiPLK1 loading was dissolved in 1x PBS (PH7.4) and loaded 
into a dialysis bag (MWCO 50 kDa). The dialysis bag was immersed into 20 mL of 1X PBS 
buffer (pH 7.4) containing 0.1% w/v TWEEN® 80 at 37 
o
C under constant shaking. The 
incubation medium outside dialysis bag was collected and replaced with fresh incubation 
medium in designated time points. The collected incubation medium was free-dried and the Pt 
content was measured with ICP-MS using the same protocol for measurement of cisplatin 
encapsulation efficiency. 
For siPLK1 release study, dialysis tubes (MWCO 50 kDa) containing designated amount of 
GelSi, GelSiPt, and GelSiPtcros in 1X PBS buffer (PH 7.4) were immersed in 1X PBS buffer 
(PH 7.4) containing 0.1% w/v TWEEN® 80. The assemblies were kept at 37 
o
C under 
constant shaking. At designated time points, incubation medium outside dialysis bags was 
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collected and replaced by fresh incubation medium. The siPLK1 concentrations in the 
collected release mediums were measured using Picogreen assay.  
6.2.7. Cell culture 
NIH3T3, SK-BR-3, MDA-MB-231 which are fibroblast, HER2 positive breast cance, and 
luminal type TNBC respectively were cultured using Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% FBS and 1% penicillin-streptomycin solution in 75 mL cell 
culture flask. HCC38 which is basal type TNBC was cultured using RPMI-1640 medium 
supplemented with 10% FBS and 1% penicillin-streptomycin solution in 75 mL cell culture 
flask. All cells were cultivated in an incubator at 37 
o
C with 5% carbon dioxide. 
6.2.8. In vitro transfection efficiency 
The transfection efficiency of GelSi was examined by quantifying PLK1 mRNA expression 
level via real-time quantitative PCR (qRT-PCR). SK-BR-3 cells were seeded in 24-well tissue 
culture plates at 2x10
4
 cells/well and incubated at 37 
o
C in 5% CO2 for 24 h. The cells were then 
incubated with GelSi formulations at different siPLK1 concentration for 24 h. Total RNA was 
isolated using RNeasy mini-kits (Qiagen, Germantown, MD) according to supplier’s protocol. 
PLK1 mRNA level was quantified using iScript
TM





5 real-time PCR detection system according to the manufacturer’s protocol. 
Relative gene expression level was calculated using ΔΔCT method with glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) gene expression level as a reference. Data are 
normalized to PLK1 expression level of control cells without any treatment. Specificity was 
verified by melting curve analysis.  
178 
 
6.2.9. Cellular uptake 
6.2.9.1. Qualitative study: confocal microscopy 
After reaching confluence, cells were detached, counted, and seeded in a 8-well coverglass 
chamber (LAB-TEK, Nagle Nunc, IL, USA) overnight at 10
4
 cells/well. Then, the medium was 
replaced by GelSiscramble-FITC or PLLSiscramble-FITC suspension (nanogels suspended in cell 
culture medium) at the same nanogel concentration of 0.05 mg/mL and incubated for 2 h. The 
cells were washed five times with pre-warmed 1x PBS and fixed with 70% ethanol for 20 min. 
After that, the cells were washed twice with 1x PBS and then the nuclei were counterstained by 
DAPI for 45 min. The cells were washed again twice by 1x PBS and immersed in 1x PBS for 
confocal microscopic imaging.   
6.2.9.2. Quantitative study: Microplate reader 
After reaching confluence, cells were detached, counted, and seeded in 96-well black plate 
(Costar, IL, USA) at 10
5
 cells/ml concentration. After 24 h incubation, medium was replaced by 
GelSiscramble-FITC or PLLSiscramble-FITC suspension at concentration of 0.05 mg/mL. After 2 h 
incubation, the NP suspension was removed. Cells were washed twice with 1x PBS, and 
immersed in 50 µl of 0.5% Triton X-100 in 0.2 N NaOH solutions. After 15 min incubation 
under gentle shaking, the fluorescent intensities were measured with a microplate reader at 






NIH3T3, SK-BR-3, MDA-MB-231, and HCC38 cells were seeded respectively in 96-well 
transparent plates (Costar, IL, USA) at 5x10
3
 cells/well (0.1ml) and after 12 h, the medium was 
replaced by nanogel formulations at designated concentrations and incubated for 48 h. Cell 
viability was measured using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay standard protocol. The nanogel formulations were synthesized in a sterilized 
conditions, more specifically, all glass containers and spatulas are autoclaved, magnetic stirrers 
and equipments such as working bench, magnetic stirring plate, chemical fumehood are 
cleaned with 70% ethanol and Ambion® RNaseZap® surface decontamination solution that 
destroy RNases (invitrogen). All materials solutions are passed through a 0.2 μm filter to 
remove bacteria before synthesis of the nanogels. Hence, no additional sterilization procedure 
was performed before the in vitro cell line experiments.  
6.2.11. Cell cycle 
For cell cycle analysis, SK-BR-3 cells were seeded in 6-well plate at 2x10
4
 cells/well. After 12 
h incubation, medium was replaced by cisplatin in water (i.e. free cisplatin), GelPtcros, and 
GelSiPtcros suspension in medium at cisplatin concentration of 0.075 μg/mL. The siPLK1 
concentration for GelSiPtcros is 10 nM. After 24 h, cells were harvested, washed with cold 1x 
PBS, and fixed using 75 % ethanol by dropwise addition of 3 mL ethanol into 1 mL of cells 
under gentle vortexing, and 24 h incubation at 4 
o
C. The cells were then collected, washed with 
1x PBS, and stained in room temperature for 30 min with propidium iodide (PI) staining 
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solution which contains 50 μg/mL PI, 100 μg/mL RNase A, and 0.1% Triton X-100 in 1x PBS. 
Then, the cell cycle was investigated using flow cytometer.  
6.3. Results and discussions 
Table of abbreviations 
Abbreviation  Explanation 
GelPt cisplatin entrapped TPGS-PLL nanogel 
GelPtcros cisplatin crosslinked TPGS-PLL nanogel 
GelSi SiPLK1 loaded TPGS-PLL nanogel 
GelSiPt SiPLK1 loaded cisplatin entrapped TPGS-PLL nanogel 
GelSiPtcros SiPLK1 loaded cisplatin crosslinked TPGS-PLL nanogel 
PLLSi SiPLK1 loaded PLL nanogel 
GelSiscramble-FITC FITC conjugated nonsense siRNA loaded TPGS-PLL nanogel 
PLLSiscramble-FITC FITC conjugated nonsense siRNA loaded PLL nanogel 
GelSiscramble nonsense siRNA loaded TPGS-PLL nanogel 
 
6.3.1. Synthesis of PLL-TPGS 
For the synthesis of PLL-TPGS, TPGS was first conjugated with succinic anhydride to form 
TPGS-succinic acid (TPGS-SA), which was then conjugated with PLL by carbodiimide 
chemistry to form PLL-TPGS (Fig. 6.1). The synthesis was verified by 
1
H NMR spectroscopy; 
the image of PLL and PLL-TPGS was shown in Fig. 6.2. The correlations between chemical 
shifts and the hydrogen item positions were identified by analysis of the chemical environments 
and by referring to literatures. The success of conjugation was shown by (1) the presence of the 
characteristic peak of PEG at 3.6 ppm; and (2) the presence of peak B’ (3.1 ppm) adjacent to 
peak B (2.9 ppm) which represents the hydrogen on the epsilon carbon of the lysine unit. The 
degree of TPGS grafting was determined by TNBS method to be 4.8 mol%, which means 4.8 















6.3.2. Size and size distribution of PLL-TPGS nanogel formulations 
The size and size distribution of the nanogels were measured by dynamic light scattering (DLS) 
and visualized by field emission transmission electron microscope (FETEM). The DLS 
measurement shows that the sizes of the nanogels synthesized by the water-in-oil (w/o) 
emulsion method were around 130 nm with narrow size distribution (Polydispersity index (PDI) 
< 2.5). The N/P ratio of PLL/siPLK1 and the lysine/cisplatin-SA ratio for the listed nanogel 
formulations are both 40:1 (mol/mol). Loading the nanogel with siRNA, cisplatin or both of 
them did not lead to a significant difference in size and zeta potential. The cross-linking process 
increased the size by less than 10%. In comparison, the size of freshly prepared siRNA loaded 
PLL nanogel (PLLSi) by direct mixing of PLL solution and siRNA at the same N/P ratio (40:1) 
was larger (345 nm) with wider size distribution (PDI = 0.42). Furthermore, the FETEM 
images shows that TPGS-PLL nanogel formulations (i.e. GelPt, GelPtcros, GelSiPt, and 
GelSiPtcros) made by w/o emulsion have well defined spherical shape, and the sizes perceived 





Fig. 6.4. Representative FETEM images of Gelpt (A); GelPtcros (B); GelSiPt (C); 
GelSiPtcros (D). 
 
Table 6.1. Characteristics of various PLL-TPGS nanogels: particle size, size distribution (PDI), 
encapsulation efficiency (EE), and drug load. Data represent mean + SD, n=3.  
Particle type Size PDI Zeta Potential 
GelPt 126.67 + 0.76 0.153 + 0.0145 17.24 + 0.29 
GelPtcros 137.87 + 0.61 0.24 + 0.0100 13.90 + 0.26 
GelSi 123.33 + 1.23 0.24 + 0.0047 20.67 + 0.27 
GelSiPt 123.60 + 1.25 0.23 + 0.0078 12.42 + 0.35 
GelSiPtcros 132.90 + 1.25 0.21 + 0.0056 8.74 + 0.190 
PLLSi 345.63 + 94.9 0.42 + 0.046 45.50 + 0.26 
 
Particle type Cisplatin 
EE (%) 
Cisplatin 
drug load (%) 
SiRNA 
EE (%) 
GelPt 47.94 + 1.02 4.66 + 0.39 - 
GelPtcros 30.89 + 0.53 4.02 + 0.20 - 
GelSi - - 91.2 + 1.25 
GelSiPt 67.01 + 1.26 4.89 + 0.68 84.1 + 3.60 
GelSiPtcros 48.18 + 2.07 3.90 + 0.038 79.8 + 2.37 





6.3.3. Cisplatin and siPLK1 encapsulation efficiency 
The cisplatin encapsulation efficiencies (EE) were determined by inductively coupled plasma 
mass spectrometry (ICP-MS). The cisplatin EE was primarily determined by the 
lysine/cisplatin-SA ratio. When the lysine/cisplatin-SA ratio is varied from 5:1 to 80:1, the 
highest EE (48.18%) appeared at 40:1 (Fig. 6.5(A)). Simultaneous encapsulation of siPLK1 has 
the effect of improving cisplatin EE, which may be explained by the improvement in core 
compaction. Co-formulation of calf thymus DNA and siRNA with protamine was shown to 
result in a 20% - 80% increase in siRNA delivery efficiency compared with the formulation 
without calf thymus DNA, due to improved compaction of the formed complex [285].  
The siPLK1 encapsulation efficiency was examined first by agarose gel electrophoresis, and 
then by quantifying the unencapsulated siPLK1 in the supernatant by Picogreen assay. It can be 
observed from the gel retardation assay that GelSi can fully complex with siPLK1 with the N/P 
ratios ranging from 10:1 to 160:1, which is shown by no observable free siPLK1 band in the 
GelSi columns (Fig. 6.5(B)). However, there are background signals along the migration lane 
of GelSi formulations, the intensity of which is correlated with N/P ratio. The signal may from 
siPLK1 aggregates. N/P ratio of 40:1 was chosen for quantitative analysis of siPLK1 EE (Table 
6.1). It can be observed that co-encapsulation of cisplatin-SA leads to a reduction in siPLK1 EE 
from 91.2% to 84.1%, and the cross-linking process further decreases siPLK1 EE to 79.8%. 
The reduction may attribute to the introducing of another negatively charged species 
(cisplatin-SA) which occupied a portion of the possitively charged amine groups on PLL-TPGS. 
The siPLK1 EE of PLLSi by direct mixing method at 10:1 N/P ratio is 95.1% which is close to 
185 
 
full complexation of the siPLK1; this result is consistent with the result obtained from gel 
retardation assay in literature, which shows the complete complexation of siRNA by PLL 
(degree of polymerization = 37) when the N/P ratio is larger than 1:2 [286, 287].  
 
Fig. 6.5. Encapsulation efficiency and drug load of cisplatin crosslinked siPLK1 loaded 
PLL-TPGS nanogel (GelSiPtcros) with different lysine to cisplatin-SA molar ratio (A); and 
electrophoretic mobility of siPLK1 loaded in PLL-TPGS nanogels (GelSi) at various N/P ratios. 
Data represent mean + SD, n=6. 
 
6.3.4．In vitro cisplatin and siPLK1 release 
The release of cisplatin from GelPt, GelPtcros, GelSiPt, and GelSiPtcros in 140 h was 
examined in release buffer at 37 
o
C under gentle shaking (Fig. 6.6(A)). For all formulations, 
there are burst releases in the first 10 h, during which 27.5%, 21.2%, 47.6%, and 37.8% of 
loaded cisplatin was released from GelPt, GelPtcros, GelSiPt, and GelSiPtcros, respectively. In 
the following hours, cisplatin was released in a sustained manner with a much slower rate. After 
140 h, 34.4%, 29.9%, 53%, and 37.78% of cisplatin was released from GelPt, GelPtcros, 
GelSiPt, and GelSiPtcros, respectively. Prodrug crosslinked nanogel formulations 
demonstrated a slower release rate compared with noncrosslinked nanogels; and more 
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importantly, crosslinking reduces the percentage of cisplatin burst release in the total cisplatin 
release. If we name this value as burst release ratio, GelPtcros reduces the burst release ratio by 
9.1% compared with GelPt; and GelSiPtcros reduces the burst release ratio by 8.8% compared 
with GelSiPt. The release of cisplatin was possibly due to the breakage of the ester bound 
between cisplatin and succinic acid, the stability of which in aqueous environment is lower than 
that of the amide bond formed between cisplatin-SA and PLL [288]. It can also be observed that 
complextion with siPLK1 significantly increased the release rate. In 140 h, the accumulative 
release of cisplatin from GelSiPt is increased by 35.1% compared with that from GelPt; and the 
accumulative release of cisplatin from GelSiPtcros is increased by 36.9% compared with that 
from GelPtcros; the reason for the change in release rate has not been examined in this paper, 
but the phenomenon is probably due to the releases of siPLK1 which reduce the stability of the 
nanogel. 
The releases of siPLK1 from GelSi, GelSiPt, and GelSiPtcros in 200 h were examined by 
picogreen assay (Fig. 6.6(B)). Similar to the release of cisplatin, there is a burst release in the 
first 10 h, during which 34.8%, 28.1%, and 20.2% siPLK1 were released from GelSi, GelSiPt, 
and GelSiPtcros, respectively. The burst releases are probably due to the siPLK1 on or near the 
surface of the nanogels. After 200 h, the accumulative releases of siPLK1 from GelSi, GelSiPt, 
and GelSiPtcros are 58.5%, 51.7%, and 35.8%, respectively. The release rate of siPLK1 from 
GelSi is the fastest, followed by GelSiPt and GelSiPrcros. Cisplatin-SA, a negatively charged 
small molecule with two carboxyl groups may function as a physical crosslinker which 
strengthened the stability of the siPLK1 loaded nanogel, leading to a slower release of siPLK1. 
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Moreover, chemically crosslinked GelSiPtcros through formation of amide bound between the 
carboxyl group in cisplatin-SA and the epsilon amine group in PLL further stabilized the 
nanogel and led to a slower release of siPLK1 compared with that of GelSiPt.  
 
Fig. 6.6. In vitro accumulative release profile of cisplatin from cisplatin entrapped PLL-TPGS 
nanogel (GelPt), cisplatin crosslinked PLL-TPGS nanogel (GelPtcros), cispt entrapped siPLK1 
loaded PLL-TPGS nanogel (GelSiPt), and cispt crosslinked siPLK1 loaded PLL-TPGS 
nanogel (GelSiPtcros) of 10 nM siPLK1 concentration (A); and siPLK1 from siPLK1 loaded 
PLL-TPGS nanogel (GelSi), GelSiPt, and GelSiPtcros (B).  
 
6.3.5. Transfection efficiency 
Transfection efficiency of siPLK1 formulated in the GelSi was assessed by measuring the 
relative mRNA level of SK-BR-3 cells after 24 h incubation (Fig. 6.7). The cells without 
treatment was used as negative control, and the cells treated with lipofectamine 2000 
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formulated siPLK1 according to suppliers protocol was used as positive control. It can be seen 
from the image that siPLK1, when loaded into the PLL-TPGS nanogels by the oil-in-water 
emulsion method, siPLK1 could still effectively down regulate Plk1 mRNA level in a dose 
dependent manner. The result suggests that complexation of siPLK1 with PLL-TPGS does not 
impair its function as a post-transcriptional regulator.  
 
Fig. 6.7. PLK1 mRNA expression levels of SK-BR-3 cells incubated with siPLK1 loaded 
PLL-TPGS nanogel (GelSi) for 24 h. Data represent mean + SD, n=6. 
 
6.3.6. Cellular uptake 
The cellular uptake studies are aimed at investigating (1) whether siRNA loaded PLL-TPGS 
nanogel can achieve cell internalization; (2) to compare the efficiency of cellular uptake 
between siRNA loaded PLL-TPGS nanogel prepared by oil-in-water emulsion method and the 
well studied siRNA loaded PLL nanogel prepared by direct mixing method. The cellular 
uptakes of FITC labeled scramble siRNA loaded TPGS-PLL nanogel (GelSiscramble-FITC) and 
FITC labeled scramble siRNA loaded PLL nanogel (PLLSiscramble-FITC) were examined on 
NIH3T3 fibroblast and breast cancer cell lines of different subtypes (MCF7, MDA-MB-231, 
and HCC38). The confocal laser scanning microscopy (CLSM) was used to visualize green 
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fluorescent dye FITC labeled scramble siRNA loaded nanogels and their internalization into 
cell lines, the nuclei of which were stained with blue fluorescent dye DAPI. The CLSM images 
in Fig. 6.8(A) shows that the blue stained nuclei is circumvented by green fluorescent, 
indicating the internalizations of GelSiscramble-FITC and PLLSiscramble-FITC into cytoplasm of 
the cells. In Fig. 6.8(A), row I are images of cells incubated with GelSiscramble-FITC and row II 
are images of cells incubated with PLLSiscramble-FITC. Columns correspond to different cell line. 
In addition, it can be observed from the representative images that the green fluorescence in the 
second row are of higher intensity than that in the first row; suggesting that the cellular uptake 
efficiency of PLLSiscramble-FITC is higher than that of GelSiscramble-FITC. Quantitative cellular 
uptake study shows similar results. The slight reduction in cellular uptake efficiency after 
TPGS modification may due to the combined effect of decrease in surface positive charge and 
the presence of the PEG portion of TPGS on surface. Highly positively charged surfaces were 
shown to have high affinity to negatively charged cell membrane, leading to fast internalization. 
Reduction in surface positive charge may function to decrease the interaction. This can be 
beneficial for in vivo applications because extensive interaction of highly positively charged 
nanocarriers with negatively charged serum proteins and cells leads to fast clearance and 
off-target effects. Furthermore, the quantitative cellular uptake study showed a difference of 
cellular uptake efficiency of the same nanocarrier formulation on different cell lines. This is 
consistent with the observations that the same nanocarrier can enter different cells at different 




Fig. 6.8. Representative confocal laser scanning microscopy (CLSM) images show uptake of 
siRNASramble-FITC loaded PLL-TPGS nanogel (row I) and PLL nanogel (row II) on NIH3T3 
(column 1), SK-BR-3 (column 2), MDA-MB-231 (column 3), and HCC38 (column 4) (A); 
Quantitative cellular uptake efficiency of siRNASramble-FITC loaded PLL-TPGS nanogel and 
PLL nanogel on NIH3T3, SK-BR-3, MDA-MB-231, and HCC38 cell lines. Data represent 
mean + SD, n=6. 
 
6.3.7. Cytotoxicity 
6.3.7.1. Cytotoxicity of GelSiscramble and GelSi 
The in vitro toxicity of the PLL-TPGS nanogel matrix was evaluated by incubating NIH3T3 
fibroblast with scramble siRNA loaded TPGS-PLL nanogel (GelSiscramble) at different nanogel 
concentrations (Fig. 9(A)). GelSiscramble showed a dose dependent toxicity from 0.1 to 1 mg/mL. 
The nanogel has negligible toxicity below 0.2 mg/mL. The toxicity is much lower than the 
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widely investigated branched 25 kDa PEI [289, 290]. In subsequent cytoxicity experiments, the 
nanogel concentrations were chosen with the consideration that no toxicity was contributed by 
the matrix material (i.e. PLL-TPGS).  
Viabilities of NIH3T3, SK-BR-3, MDA-MB-231, and HCC38 cells after being treated with 
siPLK1 loaded TPGS-PLL nanogel (GelSi) at different concentrations were shown in Fig. 
6.9(B). The classification of primary tumor has been extended to breast cancer cell lines which 
can function as preclinical models for early stage drug screening based on cancer subtypes; the 
classification is especially useful for developing targeted therapy or therapy combinations for 
TNBC. In this experiment, SK-BR-3 is a HER2 positive luminal type breast cancer cell line. 
MDA-MB-231 and HCC38 are both TNBC and basal-like according to the intrinsic subtype 
classification. However, cluster analyses identified significant differences between this two cell 
lines. In one analysis when TNBC was classified into 6 subgroups, MDA-MB-231 was 
classified as mesenchymal-like TNBC and HCC38 was classified as basal-like 1 (BL1) TNBC. 
In another analysis, MDA-MB-231 was classified as claudin-low, and HCC38 was classified as 
basal-like. To be more specific, HCC displays mainly epithelial characteristics, and 
MDA-MB-231 displays mesencymal characteristics which are associated with angiogenesis, 
immune response and cancer-stem cell link features. PLK1 is an important mitotic regulator, 
the inhibition of which causes mitotic arrest and subsequent apoptosis. Delivery of siPLK1 
using PLL-TPGS nanogel (GelSi) was shown to have dose dependent toxicity on all cell lines 
tested. The IC50 after 48 h incubation were calculated to be 29.53 nM, 25.87 nM, 11.87 nM, and 
32.20 nM for NIH3T3, SK-BR-3, MDA-MB-231, and HCC38 cells, respectively. It can be 
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seen from the cell viability that MDA-MB-231 are more sensitive to siPLK1 treatment in 
comparison with other cell types. The sensitivity of MDA-MB-231 to siPLK1 may attribute to 
the mutation in ras gene; cells with ras gene mutation were shown to be more susceptible to cell 
death under PLK1 inhibition compared to cells without the mutation.  
 
Fig. 6.9. Viability of NIH3T3 cells incubated with siRNAscramble loaded PLL-TPGS Nanogel 
(GelSiscramble) at various nanogel concentrations for 48 h (A); viability of NIH3T3, SK-BR-3, 
MDA-MB-231, and HCC38 cells incubated with siPLK1 loaded PLL-TPGS nanogel at various 
siPLK1 concentrations for 48 h (B). Data represent mean + SD, n=6. 
 
6.3.7.2. SiPLK1 enhanced therapeutic efficacy of PLL-TPGS nanogels 
Platinum-based therapy is not a standard regimen for breast cancer treatment. Recent 
pre-clinical investigations and clinical trials demonstrated the potential of platinum-based drug 
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as single agent or in combination therapies for breast cancers, especially for TNBC. The 
toxicity of cisplatin has been tested on multiple TNBC cell lines, and the results suggested a 
large variation in efficacy. For example, the IC50 of cisplatin is 5 μM for HCC38, and the IC50 of 
the same cisplatin formulation is higher than 30 μM. Nanogel formulation of cisplatin can 
improve the drug aqueous solubility, cell permeability, and sustained release; which can be 
manifested by the improvement in efficacy (i.e. increase in cytotoxicity). In addition, 
co-delivery siPLK1 with cisplatin further enhance the therapeutic efficacy of the formulation 
by suppressing the cisplatin resistance and arousing synergistic effects between the two agents. 
The siPLK1 concentration chosen was 10 nM, under the treatment of which by GelSi, around 
80% of NIH3T3, SK-BR-3, and HCC38 cells are viable; the siPLK1 concentration was chosen 
to be 5 nM for MDA-MB-231 to achieve similar viability. It can be observed from Fig. 6.10 
that all formulations demonstrated dose dependent toxicity on all the four cell lines. Cisplatin in 
water caused negligible toxicity at the shown dosages. Compared to cisplatin in 0.9% NaCl 
(cispt), cisplatin prodrug crosslinked TPGS-PLL nanogel (GelPtcros) formulation reduced the 
IC50 of cisplatin by 97.4%, 96.6%, 98.9%, and 95.9% for NIH3T3, SK-BR-3, MDA-MB-231, 
and HCC38 cells, respectively. Compared to GelPtcros, siPLK1 loaded cisplatin prodrug 
crosslinked TPGS-PLL nanogel (GelSiPtcros) further reduced the IC50 by 86.5%, 79.1%, 
67.6%, and 76.4% for NIH3T3, SK-BR-3, MDA-MB-231, and HCC38 cells, respectively.  
Formulation cisplatin in nanogel increase the cytotoxicity because nanocarrier can deliver 
therapeutic agents in a bulky way (as a reservoir) by a mechanism called endocytosis. In this 
process, the nanocarrier sacrifices their surface energy to bend and detach a small piece of the 
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cell membrane which envelop the nanocarrier and transport it into the cell. The delivery 
efficiency is much higher than when single molecule cross the cell membrane by mechanisms 
such as facilitated diffusional transport, active transport and receptor-mediated transport. Also, 
the therapeutic agents can be released in a sustained manner to facilitate prolonged therapeutic 
effects. Cisplatin monotherapy is not a standard regimen for the treatment of breast cancer. 
Only subsets of triple negative breast cancer such as those with BRCA1/2 mutations, ΔNp63α 
and Tap73 expressiones were shown to have cisplatin sensitivity [291]. Cisplatin resistance is 
shown to be related to P53 mutation, a common gene mutation in breast cancer [292]. All the 
three cell lines in this study have P53 mutation. In the case of dysfunctional p53, DNA damage 
induced G1 arrest diminishes, the cells display a higher reliability on DNA damage induced G2 
arrest [293]. The inhibition of Plk1, the important mitotic regulator, can strengthen the G2 
arrest and prevent mitotic slippage. Inhibition of Plk1 by siPLK1 makes the nanogel of cisplatin 





Fig. 6.10. Cell viability study of NIH3T3 (A), SK-BR-3 (B), MDA-MB-231 (C), and HCC38 
(D) cells incubated with cispt crosslinked siPLK1 loaded PLL-TPGS nanogel (GelSiPtcros), 
cispt crosslinked PLL-TPGS nanogel (GelPtcros), and cisplatin in 0.9% NaCl (cispt) for 48 h. 
The siPLk1 concentration for NIH3T3, SK-BR-2 and HCC38 is 10 nM; and the siPLK1 
concentration for MDA-MB-231 is 5 nM. Data represent mean + SD, n=6. 
 
Table 6.2. IC50 (µg/mL) of cisplatin formulated GelSiPtcros, GelPtcros, and cisplatin in water 
(Cispt); and IC50 (µg/mL) of siPLK1 formulated in GelSi after 48 h incubation with NIH3T3, 





GelPt (μg/mL) Cispt (μg/mL) GelSi (nM) 
NIH3T3 0.0126 0.093 3.60 29.53 
SK-BR-3 0.0159 0.076 2.21 25.87 
MDA-MB-231 0.0107 0.033 2.94 11.87 
HCC38 0.0103 0.044 1.06 32.20 
a 
siPLK1 concentration for NIH3T3, SK-BR-3, and HCC38 is 10 nM; siPLK1 concentration for 





6.3.8. Cell cycle 
The cell cycles of SK-BR-3 cells after 24 h treatment of free cisplatin (e.g. cisplatin in water) 
and different nanogel formulations at cisplatin concentration of 0.075 μg/mL and siPLK1 
concentration of 10 nM were examined by PI staining and flow cytometer analysis. It can be 
seen from the flow cytometer histograms that low concentration of free cisplatin caused around 
18.7% increase in cells in G2 phase. However, cisplatin at this dosage was not able to cause 
significant cells death. It has been shown in literature that gene repair machinery can 
successfully repair the defect caused by cisplatin at low cisplatin dosage without causing cell 
death. Hence, it is possible that cisplatin at low dosage can cause a cell cycle arrest at G2, but 
the arrest was eventually overcome; result in a resume in mitosis. GelPtcros increased the cells 
in G2 by 23.6% compared to free cisplatin, indicating a higher extend of G2 arrest. This may 
due to enhanced cisplatin cell internalization, leading to a higher intracellular cisplatin 
concentration. It has been shown that the percentage of cells which are arrested in G2 is 
correlated with cisplatin dosage. Furthermore, the co-delivery of 10 nM siPLK1 together with 
cisplatin in cisplatin prodrug crosslinked PLL-TPGS nanogels (GelSiPtcros) lead to a further 
increase in G2 arrest by 11.5% compared with GelPtcros. This result demonstrated the effect of 
PLK1 inhibition in promoting DNA-damage induced G2 arrest. This may be one reason that 




Fig. 6.11. Representative flow cytometry histograms of SK-BR-3 cells without treatment (A), 
being treated with cisplatin in water (B), cispt crosslinked PLL-TPGS nanogel (GelPtcros) (B), 
and cispt crosslinked siPLK1 loaded PLL-TPGS nanogel (GelSiPtcros) (D). Cisplatin 
concentration for all formulations is 0.075 μg/mL, and siPLK1 concentration for GelSiPtcross 
is 10 nM; incubation time is 24 h.  
 
6.4. Conclusion 
In this study, we formulated hydrophilic small molecule drug cisplatin and hydrophilic 
macromolecule siPLK1 into PLL-TPGS nanogels by water-in-oil emulsion method. In this 
system, cisplatin was the anticancer drug of interest, and also the crosslinker which functioned 
to chemically crosslink and stabilize the nanogels. In addition, the cisplatin prodrug crosslinked 
nanogel facilitated a sustained release of cisplatin, which otherwise will be released very fast 
due to the water permeable and interconnected pores of the nanogel. The modification of PLL 
with TPGS shielded the highly positive surface charge of PLL, resulted in a reduction in 
unspecific cell internalization. The use of nanocarrier and rational combination of siPLK1 and 
cisplatin greatly improved the in vitro efficacy and reduced the drug resistance of cisplatin, 
revealing the potential of cisplatin for the treatment of breast cancer. 
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Chapter 7. Conclusions and recommendations 
7.1. Conclusions 
The scope of the projects covers the design, fabrication, and in vitro evaluation of the ligand 
and siRNA mediated nanomedicine for the treatment of cancer. The main conclusions drawn 
from the experimental results are listed as follows. 
 The Herceptin density on Herceptin conjugated PLA-TPGS/TPGS-COOH nanoparticles 
(NPH) can be coarsely adjusted by changing the surface functional group density when 
using excess amount of Herceptin; and finely adjusted by changing the feeding 
concentration of Herceptin for the conjugation reaction.  
 
 Variation in surface Herceptin density led to a change in the cellular uptake and 
cytotoxicity of the Herceptin modified nanoparticles. In the tested range, surface 
Herceptin density had a positive correlation with the cellular uptake and cytotoxicity. 
 
 The tethering chain (the PEG portion of the TPGS-COOH) was shown to have influence 
on the cellular uptake and cytotoxicity when all other parameters were kept constant. For 
the NPH, TPGS1000 was shown to have the highest cellular uptake and cytotoxicity on 
breast cancer cell lines, compared to TPGS2000, TPGS3350, and TPGS5000.  
 
 Herceptin and siPLK1 conjugated and docetaxel encapsulated TPGS micelle (micSDH) 
was shown to be an efficient platform for the co-delivery of siPLK1 and docetaxel at 
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adjustable loading ratios and sustained release of both siPLK1 and docetaxel. The 
micSDH was shown to have the lowest IC50 compared to micSD, micD, and taxotere®; the 
possible reason is the lengthening of G2/M arrest and an increase in apoptosis. 
 
 SiPLK1 loaded cisplatin prodrug crosslinked PLL-TPGS nanogel (GelSiPtcros) was 
shown to efficiently co-deliver cisplatin and siPLK1 at adjustable ratios. The chemical 
crosslinking of PLL-TPGS nanogel by cisplatin prodrug increased the stability and 
reduced the burst release rate of cisplatin and siPLK1. The GelSiPtcros was demonstrated 
to have the lowest IC50 compared to GelPtcros and the free drug cisplatin; the possible 
reason is the enhancement of G2/M arrest and apoptosis.  
7.2. Recommendations  
Hyperthermia therapies hold great promise because they usually cause tolerable toxicity; 
especially local hyperthermia which seems only causes temporary side effects such as burns, 
blisters, discomfort, pain, swelling, and bleeding [294]. Supraparamagnetic iron oxides (IOs, 
Fe3O4) can generate sufficient heat for hyperthermia therapy when they are exposed to an 
alternating magnetic field at specific frequency due to the high specific absorption rate. In 
addition, IOs can function as MRI contrast agent for tumor imaging. Hence, IOs enable image 
guided therapy (i.e. theranostics). Encapsulation of IOs in polymeric nanoparticles has been 
shown to enhance the cellular uptake and efficacy of hyperthermia therapy. However, cancer 
cells may present thermoresistance due to the overexpression of heat-shock proteins (HSPs) 
[295]. Inhibition of heat shock factor 1 (HSF1) which is the upstream of HSPs was shown to 
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enhance the efficacy of traditional hyperthermia. In addition, among all HSPs, HSP70 is found 
to be significantly unregulated during hyperthermia. Hence, modification of IOs or IO loaded 
nanocarriers with siRNA which target the thermoresistance may reduce the therapy barrier and 
enhance the efficacy of magnetic hyperthermia.  
 
Fig. 7.1. Illustration of hyperthermia therapy [294].  
Investigations on the immunotherapy for the treatment of cancer have a long history. Antibody 
targeting tumor associated proteins (Her/neu, EGFR, VEGF, CD20, CD52, and CD33), bone 
marrow transplantation, cytokine IL-2, and IFN-α have gained FDA approval for the treatment 
of cancer [33]. Two issues that hindered the application of many immunotherapies are the slow 
response and low efficacy; and large variation in patient response. Recently, immunotherapy 
agent Yervoy (ipilimumab) which blocks the immune checkpoint CTLA4 was shown to be the 
first drug that can prolong the lives of people with melanoma; and has been approved by FDA. 
However, around 12.9% of patients treated with Yervoy suffered severe or fatal autoimmune 
reactions. Co-formulaiton of tumor antigen (e.g. peptides), immunostimulatory cytokines (e.g. 
IL-2), and antagonist (e.g. siRNA) to immunesuppresion mechanism (e.g. CTLA4, PD-L1) in 
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ligand modified PEGylated liposome has potential to achieve synergistic effect and lower the 
dosage needed for each component.   
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